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SUMMARY
Oral tolerance is the specific immunological unresponsiveness normally induced by 
feeding a soluble antigen. Though it is an obstacle to oral vaccination, it is probably the 
mechanism that prevents intestinal hypersensitivity reactions to food antigens and there is 
currently a great deal of interest in the manipulation of the phenomenon to provide a novel 
strategy for immunotherapy of autoimmune and inflammatory disorders. However, the 
mechanisms of oral tolerance and the major factors that influence them remain controversial 
and require to be clarified before practical application. The principal aim of my project was 
to assess the role for a number of the mechanisms that had been proposed to regulate 
peripheral immune responses to orally administered antigen.
At the time I began my study, the effects of oral tolerance were known to be 
influenced by the dose of antigen and the dogma was that low feeding doses could invoke 
active regulatory mechanisms, while high doses could inactivate T cells directly. However, 
this theory was based on reports from different model systems where the findings were not 
consistent in every aspect and in general were restricted to comparisons of only a few 
antigen doses. As active regulation and direct T cell inactivation have different implications 
for the clinical application of oral tolerance, I attempted to clarify this issue by using the 
dietary antigen ovalbumin (OVA) to examine the systemic effects of feeding mice a wide 
range of doses (100/rfg-25mg).
A single dose of 10-25mg fed OVA reduced every antigen-specific effector function 
examined after parenteral immunisation with OVA/CFA, including DTH, IgG, IgGl and 
IgG2a responses in vivo and PLN cell proliferation and production of IL3, IL5, IL10 and 
IFNy in vitro. That the activity associated with both Thl and Th2 cells was reduced 
suggests that neither T cell subset could have been involved in modulating the other thereby 
ruling out this mechanism of active regulation in high dose oral tolerance.
Feeding OVA at doses below lOmg had different effects on individual effector 
functions, and although all responses were progressively reduced by increasing antigen 
doses, this appeared to follow a pattern generally consistent with individual T helper cell
subsets. Thl-despendent DTH, IgG2a and IFNy responses were the most susceptible to 
inhibition and were reduced by feeding as little as 100/<g OVA, while PLN cell proliferative 
responses became inhibited at doses ^  2mg fed OVA. The regulation of Th2-dependent 
responses was less clear cut. IL5 production was tolerised by as little as 100/4g fed OVA, 
whereas IgGl and IL10 responses resisted the effects of tolerance induced by feeding 
lOOpig, lmg, 2mg and 5mg OVA, only becoming significantly inhibited at doses of ^10mg 
fed OVA. These findings indicate that although the regulatory factors mediating IL5 
production may differ from those controlling the other Th2-dependent responses, it is 
possible that low dose oral tolerance may be mediated by regulatory Th2 cells, particularly
since IgGl and IL10 responses were preferentially activated by 100^g-lmg fed OVA.
However, I was unable to detect evidence for the non-specific bystander suppression
that is reported to accompany Th2-dependent crossregulation of Thl cells. Bystander 
suppression is induced in an antigen-specific manner but inhibits subsequent responses to 
unrelated antigen present in the same microenvironment as the original antigen. To examine 
for the presence of this phenomenon, I assessed the responses of cells restimulated with the 
antigen PPD, which had been present in the CFA used for parenteral immunisation with 
OVA. Under these circumstances, proliferation and cytokine production by orally tolerised 
cells was comparable with control responses and as this finding was irrespective of the dose 
of fed OVA, it suggests that bystander suppression may not have been operating in either 
low or high dose oral tolerance.
Feeding very low doses of antigen is known to prime systemic immune responses. 
As this would be useful for the development of oral vaccines but potentially hazardous for 
the clinical application of fed antigens as immunotherapy, I also assessed this feature in my 
dose response study. My results showed that OVA-specific DTH, proliferation and IFNy 
responses were enhanced by 10-50/*g fed OVA, while upregulation of IgGl, IL3 and IL5 
responses required feeding 50pig OVA and IgG2a antibody production was not augmented 
by either feeding dose. These findings suggest that individual effector responses vary in 
their susceptibility to upregulation by fed OVA. However, these findings were observed
only in mice challenged with a suboptimal dose of OVA/CFA after feeding, indicating that 
the extent of oral priming may have been weak.
The capacity of certain Th2-dependent functions to remain resistant to inhibition by 
low doses of fed antigen indicated that oral tolerance may be the result of different 
mechanisms depending on the dose fed antigen administered. I therefore examined directly 
the role of Th2 cells in oral tolerance by examining IL4_/_ mice, which lack functional Th2 
cells. Although no OVA-specific Th2-dependent responses were detected in these animals, 
all other effector responses examined were reduced by feeding OVA prior to challenge. This 
included DTH, IgG and IgG2a responses in vivo and PLN cell proliferation and production 
of IL3 and IFNy in vitro. Moreover, as my findings were similar for mice fed either 2 or 
25mg OVA, a critical role for Th2 cell activity in either form of oral tolerance seems 
unlikely.
I also assessed the role for other T cell subsets and cytokines in mediating 
suppression. As the cytostatic properties of IFNy and TGFp have been known for some 
time, it seemed possible that either of these cytokines might be required for suppression. 
However, no role was found for endogenous IFNy in either the induction or maintenance of 
oral tolerance, as normal suppression of effector responses occurred in animals depleted of 
IFNy at the time of feeding as well as in IFNyR"/_ mice. Mice given neutralising anti-TGFp 
antibody also developed specific tolerance of DTH responses in vivo and IL5, IL10 and 
IFNy responses in vitro after feeding 2 or 25mg OVA. Furthermore, neutralisation of TGFp 
in vitro did not reverse the inhibition of proliferation and secretion of IL3, IL5 or IL10 seen 
in cells from orally tolerised animals. However, some exceptions to these findings 
occurred, with apparently no tolerance of IgG or proliferation in anti-TGFp treated mice and 
with variable effects on the in vivo and in vitro inhibition of IFNy. Therefore, TGFp 
remains a potential mediator of some aspects of oral tolerance.
Although my findings could not support a critical role for any one particular cytokine 
in the modulation of all aspects of oral tolerance, it remained possible that another form of 
active regulation might be involved. Early reports had implicated a suppressive role for 
CD8+ T cells in oral tolerance and I examined whether this might reflect their cytotoxic
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potential. However, I found that the peripheral immune responses suppressed by feeding 
either a high or low dose of OVA included CD8f CTL responses. These CTL were 
generated by parenteral immunisation with OVA ISCOMS and recognised the 
immunodominant OVA258-276 epitope presented in the context of H-2Kb class I MHC 
molecules. In addition, the cytotoxic response depended on the presence of CD4+ T cells 
and CTL generated in a CD4-independent manner by challenge with OVA/CFA were not 
altered by fed OVA. As these findings indicated that a subset of CD8+ T cells remain 
resistant to inhibition in orally tolerised mice, I assessed whether their presence was required 
for the induction of unresponsiveness. However, tolerance developed normally in mice 
depleted of C D ^  cells at the time of feeding OVA. In contrast, the presence of CD4+ T 
cells was compulsory for oral tolerance induction, suggesting that this T cell subset is the 
principal target of oral tolerance.
As my findings were inconsistent with a role for active regulatory mechanisms in oral 
tolerance, I went on to investigate whether direct T cell inactivation might be involved. I 
firstly showed that PLN cells removed from orally tolerised mice after parenteral 
immunisation exhibited compromised viability when cultured in the absence of antigen in 
vitro. This was comparable with naive cell death, occurred in mice fed either 2 or 25mg 
doses of OVA and affected both CD4+ and CD8+ T cells. Dying lymphocytes from 
unstimulated cultures of tolerised cells developed morphological features indicative of 
apoptosis, including nuclear fragmentation and membrane blebbing, and these changes were 
accompanied by an increased proportion of cells with hypodiploid DNA content. The cell 
death was probably more extensive than could be reasonably accounted for by deletion of 
specific clones alone, but the addition of OVA to the tolerant cultures reduced levels of 
apoptosis, indicating that the cell death was influenced by antigen and suggesting that some 
OVA-specific T cells remained present when lymph node cells were removed from tolerant 
animals. These cells may have been anergic as their unresponsiveness was found to be 
reversed, at least in part, by exposure to rIL2 before restimulation with OVA in vitro.
Although these results are compatible with direct inactivation of T cells in oral 
tolerance, this did not involve fas-dependent apoptosis either in vivo or in vitro. Entirely
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normal oral tolerance of all immune functions was observed in fas-deficient MRL lpr mice 
and the functional defects associated with oral tolerance were not reversed by a fas-Fc fusion 
protein, which blocks fas-dependent apoptosis in other systems.
I also found that induction of a tolerant phenotype was preceded by transient T cell 
activation after feeding OVA. This was evidenced by the capacity of spleen cells from OVA 
fed mice to proliferate, enter into cell cycle and secrete IFNy and IL3 when restimulated with 
OVA during the first 3 days after feeding, but not thereafter. As these mice were tolerant to 
challenge during this time, my findings support the possibility that a transient priming of 
specific T lymphocytes by fed antigen leads to functional inactivation and this may increase 
their susceptibility to apoptosis in the absence of antigen in vitro.
My findings thus far illustrate that the peripheral tolerance induced by feeding OVA is 
profound, can inhibit effector responses of both Thl and Th2 cell subsets and may reflect T 
cell anergy and/or deletion. In the final part of my study, I examined the long term-effects of 
feeding antigen on a wide range of effector responses as this aspect has never been examined 
in any great detail and will be relevant for clinical practice. I found that animals fed 25mg 
OVA showed some degree of tolerance for virtually their entire life-span, with significantly 
reduced DTH responses in vivo and inhibited OVA-specific IL3, IL5 and IL10 production in 
vitro when challenged for up to 18 months after feeding. However, other effector responses 
recovered more quickly. The tolerance of OVA-specific serum IgGl antibody production 
and antigen-specific proliferation did not last beyond 3 months after feeding, while OVA- 
specific IgG and IgG2a antibodies were only tolerant when animals had been challenged 10 
days after feeding. The effects of tolerance were generally less persistent in mice fed 2mg 
OVA, where DTH responses were not tolerised beyond 9 months after feeding and the 
tolerance of OVA-specific PLN cell proliferative and cytokine responses wained after 3 
months. More strikingly, the inhibition of OVA-specific IgG, IgGl and IgG2a responses 
was not observed beyond 10 days after feeding.
Some evidence was provided that the persistence of tolerance may be accompanied 
by upregulation of certain responses. Thus, the long-lasting tolerance induced by feeding 
25mg OVA was associated with a switch to enhanced IFNy production upon immunisation 6
months later. Although transient, it is possible that this effect might have been necessary for 
the maintenance of unresponsiveness preferentially associated with high dose oral tolerance. 
An opposite effect was seen in low dose oral tolerance, since the decline of tolerance in 
animals fed 2mg OVA was concomitant with increased OVA-specific IL10 production, 
which was observed at both 6 and 9 months after feeding and was accompanied by enhanced 
IL5 responses at 9 months. This suggests that the loss of oral tolerance in these mice was 
followed by a skewing of immune responses in favour of the production of Th2-dependent 
cytokines and thereby provides further evidence against a suppressive role for Th2 cells in 
low dose oral tolerance.
In summary, these results highlight that oral tolerance can be manipulated, by altering 
the feeding dose, to be a long-lasting and dynamic phenomenon. However, its long-term 
effects on individual responses differ and therefore its use as a therapy for immunopathology 
will require that individual responses be assessed directly.
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Chapter 1: Introduction
Preface
Dietary proteins form part of the enormous load of foreign antigen to which the 
gastrointestinal (GI) tract is continuously exposed. Although the gut-associated lymphoid 
tissues (GALT) represent a considerable arsenal of effector mechanisms to counter the threat 
of potential pathogens, this armoury is normally not directed against food antigens, partly 
because it would limit their uptake and metabolic usefulness but more importantly, because it 
might incur hypersensitivity to foods. This is illustrated by coeliac disease, in which a T-cell 
mediated reaction to wheat gluten causes severe enteropathy [1,2]. The inflammatory bowel 
diseases, Crohn's disease and ulcerative colitis are now also thought to reflect inappropriate 
hypersensitivity to harmless intestinal antigens from the gut flora [3, 4]. However, these 
conditions are rare because the GALT somehow descriminates between non-harmful 
antigens and those of pathogenic importance. Whereas mucosal pathogens elicit an active 
primary immune response followed by memory to subsequent exposure [5], commensal gut 
flora reside in the intestine without invoking pathological responses [6] and oral 
administration of soluble antigens usually induces a suppressed response to subsequent 
enounter with the antigen, irrespective of the route of administration [7]. This phenomenon 
is termed oral tolerance. In addition to preventing food hypersensitivities, oral tolerance may 
provide a potent therapy for a variety of autoimmune and inflammatory disorders [8]. 
However, as well as being of profound physiological importance, orally induced tolerance 
respresents a major barrier to the development of oral vaccines utilising defined protein 
antigens.
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1. The GI Tract
(A) Structure and function
The GI tract includes the mouth, pharynx, eosophagus, stomach, duodenum, 
jejunum, ileum, colon and rectum. Throughout its length, the wall of the mucosa has the 
general structural organization shown in Fig 1.1. From the stomach onwards, this surface is 
covered by a single layer of epithelium that is composed of columnar epithelial cells, mucus- 
secreting goblet cells, undifferentiated crypt epithelial cells, Paneth cells, enteroendocrine 
cells and intraepithelial lymphocytes. Just below the epithelium is a layer of connective 
tissue, the lamina propria, which is separated from the underlying tissues by a thin layer of 
smooth muscle, the muscularis mucosa. The submucosa lies beneath the mucosa and on top 
of another layer of smooth muscle, the muscularis externa, contractions of which provide the 
forces for moving the gastrointestinal contents. Finally, a layer of connective tissue 
surrounds the outer surface of the GI tract and this serosa is connected to the abdominal wall 
at various points by mesenteries.
The mucosa is highly folded and the surface of these folds is further convoluted by 
fingerlike projections known as villi, which are each covered with a single layer of 
epithelium with microvillous protrusions on the apical surface. In this way the surface area 
is greatly increased to facilitate absorption of nutrients. Yet the GI tract also must function 
as a barrier against a wide range of harmful antigens and infectious pathogens. Protecting 
against such agents are many nonimmunological factors including gastric acid, pancreatic 
juice, bile, motility, mucus, the surface glycocalyx and epithelial cell turnover. In addition 
to these physiological barriers, an immunological barrier is created and maintained by the 
specific immune system.
(B) The Gut Associated Lymphoid Tissues (GALT)
The GALT forms the major part of the mucosa-associated lymphoid tissue (MALT), 
which also comprises the bronchial-associated lymphoid tissue (BALT), nasopharyngeal- 
associated lymphoid tissue (NALT), the mammary, lacrimal and salivary glands and the 
lymphoid tissues of the urogenital tract and inner ear. In man, the total surface area of the
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MALT is over 400 square metres, which is more than 200 fold greater than the surface area 
of the skin [6], highlighting the importance of this defense system in combating infection. 
Luminal antigens, including dietary proteins, are recognised by the GALT, which consists 
of both organised lymphoid aggregates, represented by the Peyer's patches, appendix, 
mesenteric lymph node (MLN) and lymphoid nodules. In addition, the gut villi contain 
intraepithelial lymphocytes (IEL), while many lymphocytes, macrophages and mucosal mast 
cells are scattered throughout the lamina propria of the intestine itself [9]. In addition, there 
may be a primary source of lymphoid cells present in cryptopatches within the lamina 
propria [10].
(C) Induction of Local Immune Responses in the Intestine
The Peyer's patches are the major inductive sites for intestinal immunity and are 
found on the wall of the small intestine, from the ileum to the colon, extending throughout 
the lamina propria and submucosa. They appear as mounds protruding between the 
intestinal villi and are covered by a single layer of columnar epithelial cells.
The Peyer's patch has a typical secondary lymphoid organ structure with T cell areas 
and B cell follicles containing germinal centres (Fig 1.2). The germinal centres are the major 
source of IgA+ B cell precursors [11] and also contain a few T cells. However, the majority 
of T lymphocytes reside in the parafollicular region and, to a lesser extent, in the dome 
region immediately beneath the epithelium. The parafollicular region is also the site where 
lymphocytes enter the patch via high endothelial venules (HEV). Parafollicular T cells are 
virtually all mature ap  T cells of both CD4+ and CD8+ phenotype, whereas those T cells 
present in the dome are predominantly CD4+ cells of both Thl and Th2 phenotype [9]. The 
Peyer's patch also contains many antigen-presenting cells (APC), including dendritic cells 
and macrophages, which are found throughout the patch in both T and B cell areas. Thus, 
the Peyer's patch contains all the components required for the initiation of immune responses 
to antigens encountered in the lumen of the small intestine. Furthermore, Peyer's patches 
have been shown to be sites where regulatory cells are generated [12-14] and this will be 
discussed in more detail later.
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Although Peyer's patches have a typical secondary lymphoid structure, they differ 
from other secondary lymphoid organs because they lack afferent lymphatics. Instead, 
antigen is sampled directly from the intestinal lumen by overlying specialised epithelial cells, 
known as M cells because of the characterisitic irregular microfolds present on their luminal 
surface [15-17] (Fig 1.3). M cells do not express class IIMHC antigens and thus primarily 
perform a transport function, allowing materials from the intestinal lumen to reach 
lymphocytes and macrophages enfolded in pockets formed by the basolateral membranes of 
the M cells [18, 19]. Antigens transported by M cells may also pass down through the basal 
lamina into the lymphoid follicles before being carried into the MLN via draining lymphatics. 
This route provides one way in which an antigen from the intestinal lumen can gain access to 
the systemic circulation.
A possible alternative route of access for soluble antigens is to be endocytosed across 
the absorptive gut epithelium [20, 21]. In this way, they may reach the systemic circulation 
or may be processed and presented in the underlying lamina propria where class II MHC+ 
cells, such as macrophages, B cells or dendritic cells are abundant. MHC class II 
determinants present on the basolateral membrane of intestinal epithelial cells [22] may also 
allow these cells to process and present antigen to T cells of the lamina propria. Epithelial 
cells generally lack expression of costimulatory molecules and reports suggest that they can 
present antigen in a tolerogenic manner [23]. This function has recently been shown in oral 
tolerance to haptens [24] and therefore it represents a possible mechanism to downregulate 
local immune responses.
(D) Local Effector Sites
The lamina propria of the gut contains B cells, T cells, macrophages and dendritic 
cells, thereby constituting one of the main effector sites for mucosal immune responses. In 
addition, inflammatory cells such as eosinophils and mast cells are also present. B cells 
represent 15-45% of lamina propria cells [25], and there are many plasma cells, of which 
-80% are plasma cells producing secretory IgA, while -18% secrete IgM and only -3% 
secrete IgG [26-29]. The same relative proportions are also seen in the ileum and colon. T
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cells constitute -50% of lymphocytes within the lamina propria and 40-60% of these are 
CD4+CD8- [27, 30] with the remainder being CD4_CD8+. Several studies show that a 
significant proportion of CD4+ T cells in the lamina propria have a memory/activated 
phenotype and are capable of providing helper signals to enhance IgA responses [31, 32]. 
This is consistent with reports that Th2 cells predominate in the lamina propria [33], 
although Thl cells are also present [34], In addition, as yet unidentified APC in the lamina 
propria can present antigen in a tolerogenic manner [35, 36] and therefore may play an 
important role in the induction of oral tolerance.
(E) IEL
The mucosal immune system also contains a unique population of T lymphocytes, 
known as IEL, which are interspersed between the columnar epithelial cells of the villi in the 
small and large intestine [37]. These cells can be subdivided into two classes based on their 
expression of either ap  or y8 TcR. Mouse IEL populations contain 20-80% y8 T cells and 
this population ranges from 13-87% in human large intestinal IEL isolates. However, 
human small intestinal IEL contain only -10% y8 T cells. [38]. A characterisitic of IEL is 
their predominant expression of CD8. In mouse, >90% IEL are CD8+ [39, 40], with -10% 
of ap  IEL also expressing CD4 (double positives, DP) [41]. Human TcR a p  IEL are 
primarily CD8+, although CD4+CD8" and CD4CD8- subsets can be detected, and 50-80% 
human y8 IEL are CD8+ [38,42,43]. IEL can be further subdivided depending on the form 
of CD8 expressed. Although the CD8 coreceptor usually exist as a dimer of aP chains [44], 
the absence of CD8P on subsets of IEL has been known for some time [39] and may be 
associated with their extrathymic origin [45-51]. Thus, all y8 IEL and -50% ap  IEL in mice 
are CD8p_ [41]. Human CD8 y8 IEL are also predominantly CD8p_ [38].
The function of IEL is not known, but one suggestion is that they constitute a 
primitive population specialised for immune surveillance of epithelial surfaces [37]. In 
support of this hypothesis, IEL exhibit constitutive cytotoxic activity in vitro [40], but as 
their proliferative responses are poor [52-54] and can be reconstituted in the presence of IL2 
[55], these cells may be anergic in situ. This idea is futher supported by studies of antigen-
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specific TcR transgenic mice where IEL were rendered functionally unresponsive after 
recognition of antigen presented by gut epithelium [56, 57]. Another possibility is that IEL 
may play a role in local immunoregulation via their production of a variety of cytokines, 
including 1L2, IFNy, IL5 and TGFp [58, 59] and the relevance of this for oral tolerance will 
be discussed later.
(F) IgA
Secretory IgA is a dimeric molecule held together by a J (joining) chain, which forms 
disulphide bonds with the IgA monomers [60]. This polymeric molecule is secreted intact 
by mucosal plasma cells and transported across the epithelia into the external environment of 
the gut lumen. Although the overall function of secretory IgA remains unclear, it is capable 
of neutralising viruses [61] and toxins [62, 63]. In addition, IgA helps prevent bacterial 
colonisation of the mucosa by binding to the mucus layer overlying the epithelia and 
inhibiting the adherence of microorganisms [64] or promoting their entrapment in the mucus 
[65, 66] and subsequent agglutination [67]. This function is known as immune exclusion 
and a similar mechanism may also reduce the absorption of dietary and respiratory antigens 
[68], possibly accounting for the finding that patients with selective IgA deficiency show 
increased absorption of food antigens [69], as well as an increased susceptibility to food 
hypersensitivity [70]. However, most patients with this common immune deficiency have 
no clinical symptoms and there is no correlation between the presence of immune exclusion 
and oral tolerance [71]. Moreover, the absence of IgA antibodies against food antigens in 
normal individuals indicates that local IgA production does not correlate with systemic 
unresponsiveness induced by a fed antigen.
(G) Lymphocyte Recirculation
Upon encountering the appropriate antigen in the Peyer's patch or lamina propria, 
responding lymphocytes exit via the lymphatic network in the mucosal wall and drain into 
the afferent lymphatics of the MLN and thence via the efferent lymphatics and thoracic duct 
to the bloodstream before recirculating back to the effector sites of mucosal tissues [72, 73].
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This recirculation pathway differs from the route taken by lymphocytes stimulated by antigen 
in a peripheral tissue (Fig 1.4) and as a result T cells primed or tolerised by mucosal antigen 
may not disseminate throughout the systemic immune system. This distribution of T cells is 
regulated by lymphocyte-specific homing antigens and by adhesion receptors expressed on 
the surface of endothelial cells in effector sites, with both sets of molecules being distinct for 
the mucosal and peripheral recirculation pathways. The adhesion receptor, mucosal 
addressin cell adhesion molecule 1 (MAdCAM-1) is preferentially expressed by mucosal 
endothelia and binds to the a4(37 integrin molecule (LPAM-1) expressed on the surface of 
lymphocytes activated in mucosal tissues. This interaction is thought to play a key role in 
the homing of effector lymphocytes to mucosal tissues [74, 75].
2. Regulation of Immune Responses to Dietary Antigens in Oral Tolerance
(A) History
The observation that fed antigens could suppress systemic immune responses was 
recognized long before the era of modem immunology and was first reported in 1829 by 
Dakin, who described how South American Indians ate poison ivy in an attempt to prevent 
what we now understand to be contact hypersensitivity to the plant [76]. The first 
experimental evidence for oral tolerance was obtained by Wells (1911), who described a 
state in which anaphylaxis in guinea pigs was prevented by previous feeding of hen's egg 
proteins [77]. However, the immunological nature of the phenomenon was only established 
by the later experiments of Chase (1946), who demonstrated the antigen specificity of oral 
tolerance using the hapten DNFB to suppress contact hypersensitivity in guinea pigs [78]. 
Since then oral tolerance has been investigated widely, initially by mucosal immunologists, 
but now also by those interested in exploiting the phenomenon as a model of 
immunoregulation or as a therapy for immunopathology.
(B) Scope & Longevity of Oral Tolerance
The induction of oral tolerance has been described in many species, including 
humans [79-81], pigs [82, 83], dogs [84], guinea pigs [85, 86] and rabbits [87]. Species
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differences do occur and oral tolerance may not be induced at all in adult ruminants [88]. 
However, the phenomenon has been best described in laboratory rodents, where systemic 
immune unresponsiveness was demonstrated with a wide range of nonreplicating antigens, 
including numerous proteins, contact sensitizing agents [89-93], peptides [94-96], sheep red 
blood cells (SRBC) [12, 97-99], allogeneic leukocytes [100] and inactivated viruses or 
bacteria [101-103]. In addition, more recent work has used proteins of immunopathological 
importance, such as myelin basic protein (MBP), uveal S antigen, insulin and collagen [94, 
104-106].
Virtually all aspects of the immune response can be rendered tolerant by feeding 
antigen. Fed protein antigen will inhibit subsequent systemic IgM, IgG and IgE antibody 
responses [102, 107-113], as well as cell mediated immune (CMI) responses measured by 
delayed-type hypersensitivity (DTH) or contact sensitivity in vivo [90-93, 111, 112, 114-
116] and lymphocyte proliferation [94, 102, 111, 117] and cytokine production in vitro
[118]. However, CMI responses are generally easier to tolerize than are humoral responses, 
requiring less antigen and persisting longer [86, 112, 115, 116, 119, 120]. The one 
exception is that IgE production is relatively resistant to oral tolerance [109, 121, 122]. IgE 
and DTH responses are associated with pathological food hypersensitivity and therefore it 
would be logical that prevention of food-specific IgE and DTH responses were the most 
important biological role of oral tolerance.
The effect of oral tolerance on mucosal immune responses is less clear and levels of 
secretory IgA have been reported to be primed [102, 110], tolerised [12, 99] or unaltered 
[123] by different feeding regimes. In addition, fed antigen has been reported to prime 
Peyer's patch T cells that suppressed IgG production but aided the synthesis of IgA 
antibodies [124].
(C) Factors Influencing Immune Responses to Fed Antigen
(i) Nature of Antigen
Although a wide range of antigens is capable of inducing oral tolerance, certain types 
of antigen are more likely to provoke active immunity rather than tolerance when
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administered via the oral route. Thus oral tolerance requires that the antigen is non-viable 
[103], thymus-dependent [101, 111] and generally soluble in form [125]. This may explain 
the ability of the intestinal immune system to discriminate between dietary and pathogenic 
material, since potential pathogens, such as bacteria, will present a large amount of thymus- 
independent antigen in a particulate and viable form. In addition, particulate antigens may 
target M cells in Peyer's patches [17, 126] and therefore be processed by the intestine more 
efficiently than soluble antigens, which may passively diffuse across the villus epithelium to 
be presented by epithelial cells in a tolerogenic manner, as described previously. Tolerance 
can also be induced by nasal administration of similar forms of antigen [96, 127-130], 
suggesting the possibility of a common mucosal phenomenon.
(ii) Frequency and Dose of Fed Antigen
The influence of antigen dose on the induction of oral tolerance has been investigated 
using a number of protein antigens, including OVA [131], HEL [132] and MBP [132]. 
Although a wide dose range of fed antigen induces oral tolerance in experimental animals [8, 
131, 133] and a single feed of as little as a few milligrams of antigen can tolerise mice [134, 
135], the exact dose required for optimal effect depends on the protein under study. 
Moreover, individual systemic responses display dose-dependent differences in their 
susceptibility to tolerance induction. CMI responses have been shown to be particularly 
easy to tolerise, with 100|Hg or more of fed OVA being sufficient to suppress DTH 
responses in mice [131, 136]. Under the same circumstances, humoral immunity is more 
resistant to the effects of oral tolerance, requiring at least 5-10mg of fed OVA to become 
inhibited [131, 136]. These differences may reflect the induction of distinct regulatory 
mechanisms (see below) and have important implications for the practical application of oral 
tolerance.
Antigen doses below those that induce oral tolerance, can prime systemic immune 
responses. In mice, systemic priming occurs after feeding l-50|ig protein and affects CMI 
responses more than humoral immunity [131]. This has also been reported in piglets, where 
large amounts of weaning diet produced tolerance if fed before weaning, whereas low
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amounts of this diet primed the animals to develop food hypersensitivity [82]. Moreover, it 
has been proposed that initial exposure to low amounts of food antigens predisposes to 
eczema in children [137].
In addition to dose, the frequency of antigen administration can also regulate oral 
tolerance since multiple or continuous feeding inhibits IgG antibody production more 
effectively than a single feed of the same total antigen dose [138, 139].
(iii) Genetic Background
Coeliac disease is closely linked to the HLA-DQw2 locus of the human MHC [140], 
indicating that genetic factors may influence the regulation of immune responses to fed 
antigens. Consistent with this theory, early studies in mice fed OVA noted strain differences 
in the susceptibility to oral tolerance induced either in normal animals [71, 141, 142] or 
those already primed to OVA [141]. Further work showed that congenic mice carrying the 
H-2d MHC haplotype were particularly susceptible to the induction of oral tolerance, 
whereas the H-2b haplotype was associated with a less profound tolerance [143, 144]. 
However, the immunological basis of this MHC-linked effect remains to be established.
Other non-MHC-linked genes have also been implicated in oral tolerance [142] and 
appear to operate through the rapid clearance of absorbed antigen from the circulation [71]. 
Thus oral tolerance induction may be under the control of several genes that influence both 
specific immune responsiveness and nonspecific factors such as protein clearance and 
catabolism.
(iv) Host Age
Food hypersensitivities are most common in infants, particularly at or near the time 
of weaning, suggesting that oral tolerance is defective during these periods. Neonatal and 
weaning mice also exhibit defective induction of tolerance to fed protein antigens [145-147]. 
The ability to sensitise calves or piglets by feeding antigen during the preweaning period 
further supports an age-related defect in oral tolerance at this time [82, 83, 88, 148]. It has 
been suggested that the defect in oral tolerance during infancy may reflect an inability of the
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immature immune system to respond appropriately to intestinally derived tolerogen [7]. This 
proposal is consistent with the finding that oral tolerance can be induced normally when 
infant mice are transferred with mature lymphocytes [138, 145]. In contrast, the disruption 
of oral tolerance associated with weaning occurs after the animal has developed an adult 
pattern of susceptibility to tolerance. Therefore, this phenomenon has been proposed to 
reflect alterations in either the intestinal microenvironment or the systemic hormone levels 
associated with weaning [7].
Ageing may also affect oral tolerance, as many immune functions generally decline 
with age [149]. However, the onset and rate of immunosenescence in GALT has been 
reported to occur much later and more slowly than changes in the systemic immune system 
[150] and this might explain why, even at 20 months of age, oral tolerance can still be 
induced in mice [151]. However, the duration of systemic unresponsiveness was brief in 
these aged mice, suggesting that the factors regulating maintenance of unresponsiveness had 
become defective with age. These studies assessed only humoral immunity and are similar 
to observations made in orally tolerised young adult mice, where suppression of humoral, 
but not CMI, waned within a few months after feeding [120].
(v) Intestinal Flora
As noted above, changes in the gut flora at the time of weaning may account for the 
defective oral tolerance associated with this period and there is ample evidence that the 
intestinal flora can influence local and systemic immune responsiveness. This idea is 
consistent with observations that germ-free mice have defective systemic immune 
competence [152, 153] and that the duration of oral tolerance is reduced in these animals 
[154]. However, the bacterial products responsible for this immunoregulation have yet to be 
determined.
(vi) Intestinal Absorption and Antigen Uptake
Oral tolerance to protein antigens may reflect the manner in which the protein is 
processed in the intestine. Serum removed from mice 1 hour after feeding OVA induces
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systemic tolerance when transferred intraperitoneally to naive recipients [155-157] and 
similar observations have been made for other protein antigens [116]. The processing event 
required to generate the serum tolerogen appears to occur in the intestine, since the ability to 
transfer tolerance cannot be reproduced using serum from mice given equivalent doses of 
antigen via other parenteral routes [156]. This passage across the mucosal epithelium 
appears to be a critical factor, an idea supported by the fact that coupling antigen to the non­
toxic, epithelial-binding cholera toxin (CT) B subunit dramatically enhances its tolerogenic 
capacity [158]. However, an intact lymphoid system is also required for generation of 
serum tolerogen, as this material is not found in OVA-fed SCID mice [159] or irradiated 
mice [160] unless these animals are reconstituted with lymphoid cells [159, 160].
The precise nature of the serum tolerogen remains unclear, but recent studies suggest 
that it consists of low molecular weight fragments (21 & 24kD) of intact OVA (43kD) [157]. 
Digestion by gut enzymes does not appear to generate these fragments, as they are present at 
a time when complete cleavage would not have occured in vivo and rectal administration of 
antigen can also induce tolerance [161, 162]. These findings suggest that the small intestine 
may filter soluble antigens from the lumen to produce deaggregated monomers of protein 
that are known to be tolerogenic in other systems [163].
(vii) Antigen Presentation
The fact that stimulation of the reticuloendothelial system (RES) can prevent the 
induction of oral tolerance [164-166] indicates that antigen presentation may be important in 
regulating the response to a fed antigen. However, both the site of antigen presentation and 
the APC involved remain to be elucidated.
If oral tolerance was induced at local sites, this may implicate MHC class II+ 
epithelial cells or non-professional APC within either the Peyer's patches or lamina propria, 
as antigen presentation in both of these mucosal tissues has been associated with tolerance 
induction [35, 124, 167]. However, as T cells tolerised via the intestine should recirculate 
preferentially back to mucosal sites [72, 73], it would be difficult to explain systemic 
immune unresponsiveness in this way and thus antigen presentation in the periphery may be
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required. This could be achieved if APC acquired antigen in the gut and then dispersed to 
the periphery to present antigen in a tolerogenic manner. Although dendritic cells (DC) are 
normally associated with T cell activation [168], they are the most potent presenters of 
soluble proteins [169], and recent work suggests that DC can present antigen in a 
tolerogenic fashion [170]. Numerous antigen-laden DC have been shown to migrate to the 
MLN from the gut after intra-luminal or intra-gastric challenge [171, 172] and, although 
these cells prime T cells when transferred into naive recipients [172], the possibility remains 
that the cells were activated during the isolation procedure. An alternative is that fed antigen 
might associate with non-professional APC, such as resting B cells or unactivated 
macrophages, either locally or peripherally, to be presented to T cells in the absence of 
costimulation or in low affinity interactions, thereby inducing anergy and/or preferential 
activation of Th2 cells [173-175]. Epithelial cells could also do this [23].
(viii) Immunological Status of Host
The ability to tolerise an animal that has already been primed to that antigen will be 
critical if oral tolerance is to be used to inhibit established autoimmune disorders. Although 
the induction of systemic tolerance to an antigen is more difficult if the T cells are 
experienced [176], several investigators have shown that oral tolerance can be induced in 
parenterally primed mice [141, 177, 178] and other recent studies have shown that feeding 
specific antigens can cure animals with ongoing EAE or collagen-induced arthritis [94, 113,
117]. Primed T cells appear to be suppressed far more easily than B cells, but compared 
with oral tolerance in naive animals, suppression of primed responses requires larger doses 
of fed antigen and more frequent feeds, which have to be administered within a short time 
window after systemic priming. Therefore the immunoregulatory mechanisms governing 
tolerance in primed mice may differ from those induced in naive animals. This may reflect 
differences in the costimulatory requirements of primed and naive cells, as will be discussed 
in more detail later.
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3. Clinical and Practical Relevance of Oral Tolerance
(A) Physiological Prevention of Intestinal Hypersensitivity
Hypersensitivity to foods is probably due to a breakdown of oral tolerance [121,
179]. This idea is consistent with the findings that mucosal pathology can be induced by 
feeding antigen when oral tolerance is prevented experimentally by administering 
cyclophosphamide, by activating the reticuloendothelial system, by feeding very low doses 
of antigen or by using animals during the neonatal or weaning period [83, 119, 164, 166,
180]. The features of this pathology are similar to those found in the early stages of 
naturally occurring food sensitive enteropathies (FSE), such as coeliac disease [181, 182]. 
More recently, studies of transgenic and knockout rodents suggest that this IBD may also 
reflect a similar defect in local immunoregulation. Colitis has been found in several models, 
including HLA-B27/p2 microglobulin transgenic rats [183], mice transgenic for the CD3e 
chain when reconstituted with bone marrow [184, 185] and mice genetically deficient in IL2 
[186], IL10 [187], either a  or p chains of the TcR [188], MHC class I [189], TCR5 [189, 
190] or Gi2a [191], an inhibitor of G proteins. In each case, development of IBD requires 
gut flora and there may normally be a stable immune suppression against luminal bacteria 
which is required for maintaining mucosal homeostasis and preventing enteropathy. This 
remains to be proven for IBD, but highlights the need to understand the basis of oral 
tolerance.
(B) Immunotherapy
The oral route offers a convenient and highly acceptable means of administering 
therapeutic agents and there are now numerous examples in which feeding antigen can 
prevent experimental models of antigen-specific immunopathology [94, 100, 192, 193] 
(Table 1.1). This work has stimulated trials of oral tolerance as an immunotherapy for 
human disease. Multiple sclerosis was the first condition to be treated in this way and the 
results of a phase II double blind trial showed that 12 out of 15 multiple sclerosis patients 
improved when fed daily with 300mg bovine myelin [194]. A large multi-centre trial is now 
underway which should provide more information. The other clinical disease for which
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published information is available is rheumatoid arthritis. Phase I and II trials of feeding 
relatively small amounts of chicken collagen (100-500jig daily) suggested that a small 
proportion of patients improved when treated for 90 days and up to 15% had complete 
remission [195]. However, a recent report from an analogous study of rheumatoid arthritis 
patients fed bovine collagen for 12 weeks showed rather more ambivalent results [196]. 
Nevertheless, a multi-centre trial of around 300 patients is now in progress in the U.S.A.. 
There are also clinical trials proceeding in patients with insulin-dependent diabetes mellitus, 
myaesthenia gravis and uveitis, but no published data are available yet. Although 
encouraging, clearly more needs to be understood of the regulatory mechanisms involved in 
oral tolerance if widely applicable effective regimes are to be developed utilising this 
approach.
(C) Development of Oral Vaccines
Traditional vaccine research has focussed on the induction of systemic immunity by 
parenteral immunistion. While this approach may be approriate against pathogens which 
gain access to the body through damaged or punctured skin, the majority of pathogens infect 
hosts via mucosal surfaces. Parenterally administered vaccines generally do not induce the 
mucosal immune responses required to prevent infection with pathogens encountered at 
mucosal sites [197]. Orally administered vaccines, such as polio, are also favoured because, 
in addition to inducing local immunity in the intestine, they may also stimulate immune 
responses at distal mucosal surfaces, such as the breast [198], and can induce widespread 
systemic immunity [199-201]. Furthermore, oral vaccines have several economic and 
practical advantages, including ease of administration, reduced side-effects and the potential 
for almost unlimited boosting. For these reasons, a major goal of current vaccine research is 
the construction of orally active vaccines that contain protective recombinant proteins or 
peptides as the immunogen. Such vaccines will be unsuccessful unless the induction of oral 
tolerance can be overcome. Therefore an understanding of the principles involved in this 
phenomenon will assist the design of appropriate oral vaccines.
15
4. Mechanisms of Tolerance
Clearly a fuller understanding of oral tolerance will have important implications not 
only for the development of oral vaccines, but also for the prevention of FSE and for the 
manipulation of autoimmune/inflammatory disorders.
(A) Current Ideas on the Mechanisms of Peripheral Tolerance
Oral tolerance is a form of peripheral tolerance and therefore the mechanisms by 
which peripheral tolerance can be induced by parenterally administered antigens may clearly 
be relevant to oral tolerance.
Antigen Ignorance
When a naive lymphocyte meets its antigen, it can respond in one of three ways: 
ignore it, become activated or become unresponsive. There is evidence from transgenic 
models that peptides may be presented in the context of class I MHC on cells which are 
unable to trigger any response from T cells with the appropriate TcR because they lach 
expression of the costimulatory or accessory molecules required to enhance T cell avidity 
[202-204]. In many cases extrathymic antigens also appear to be ignored by CD4+ T cells 
and this may be because parenchymal tissues normally express relatively few class II MHC 
molecules and therefore may not be surveyed efficiently by naive T cells [205, 206]. The T 
cells apparently ignore the presentation of antigen by these non-professional APC, as they 
show no evidence of activation and respond normally if the appropriate antigen is later 
presented by a professional APC or in the context of inflammation [206-209].
Active Regulation
In active suppression, tolerance is mediated by the regulation of one lymphocyte 
population by another. Evidence for this effect was initially demonstrated in adoptive 
transfer studies, where spleen cells from mice tolerant to SRBC could transfer 
unresponsiveness to naive recipients [210]. Suppression has now been described in various
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forms of extrathymic tolerance [211] and is also believed to play an important role in the 
regulation of normal immune responses [212].
Although induced in an antigen-specific manner [213, 214], active suppression of 
this kind may exert its effects through a variety of antigen non-specific soluble factors, 
including glucocorticoids [215] and lymphokines, such as IL6 [216], IL10 [217], IFNy 
[218] and TGFp [219], Although originally considered to be mediated by CD8+ T cells, the 
suppressor phenomenon has recently been applied to the current paradigm of CD4+ T cell 
regulation, in which Thl cells are associated primarily with IL2 and IFNy production, while 
Th2 cells secrete IL4, IL5, IL6 and ELIO. Thl cells are involved in DTH and inflammatory 
responses and support B cell production of IgM and IgG2a, while Th2 cells predominate in 
allergies and parasitic infections and are classical helper cells for antibody production, 
particularly IgE and IgGl [220]. In addition, the Thl and Th2 type cells mutually regulate 
each other. Thus Thl-dependent IFNy downregulates production of lymphokines by Th2 
cells, which in turn can inhibit Thl cell activity via IL4 and IL10 production [220, 221]. 
This original model may now encompass CD8+ T cells, as this population can also be 
divided into subsets which appear similar to Th 1 and Th2 CD4+ T cells in their production 
of distinct lymphokines [222, 223]. Type 1 cells suppress B cells and display cytolytic 
activity, while type 2 cells provide B cell help and suppress DTH responses [222, 223]. 
Therefore lymphokine regulation of tolerance could underly the suppressor activity reported 
of both CD4+ and CD8+ T cells [224-226].
Direct Inactivation
Direct T cell inactivation can occur in two different ways, either by clonal deletion via 
apoptosis or by functional anergy.
Clonal Deletion
Clonal deletion of T lymphocytes and possibly B cells is required for central 
tolerance to self antigens [227] and also occurs extrathymically when peripheral tolerance is 
induced by exogenous superantigens [228] or after parenteral administration of conventional
17
antigens to TcR transgenic animals [229]. Clonal deletion occurs via apoptosis, which 
begins with condensation of the cell nucleus and cytoplasm leading to membrane blebbing 
and a final stage of cell fragmentation into membrane-bounded bodies [230, 231]. This 
process reflects the action of endonucleases, which become activated in apoptosis to degrade 
nuclear DNA into oligosomal fragments [232, 233]. Death of mature lymphocytes by 
apoptosis frequently involves signalling via fas/Apo-l/CD95 [234, 235], a surface receptor 
belonging to the tumor necrosis factor (TNF) receptor family and constitutively expressed on 
T lymphocytes. Both fas and the 55kDa TNF receptor 1 (TNF-R1) share a distinctive 
cytoplasmic region (the "death box") essential for signalling apoptosis upon interaction with 
ligand. The ligand for fas (fasL) is expressed on the surface of T cells after activation and 
may interact with fas to trigger cell death on the same cell [236] or on different cells [237]. 
This proccess has been proposed as an important homeostatic mechanism for controlling the 
size and persistence of antigen-specific effector responses [238]. fas-fasL interactions 
account for the proportion of CTL-mediated cytotoxicity which is not mediated by perforin 
[239-242] and operates when CTL recognise self peptides either on themselves, to induce 
suicide [236, 243], or on other T cells, to induce fratricide [237]. Clearly this could be 
implicated in oral tolerance and a similar fas-dependent phenomenon has also been reported 
for CD4+ T lymphocytes, particularly those of the Thl cell subset, which preferentially 
express fas L [241, 244]. Further support that fas-fas L interactions play an important role 
in extrathymic tolerance comes from studies of MRL lpr/lpr and gld/gld mice, which have a 
genetic absence of functional fas or fas L respectively and display profound 
lymphoproliferation [245] and increased susceptibility to autoimmune disorders [246]. Less 
is known of TNF-R1-transduced death, but this has been shown to be involved in some 
cytolytic functions of T cells [247].
Anergy
CD4+ T cells require TcR engagement by an immunogenic peptide bound to a class 
II MHC molecules, as well as a costimulus provided by the APC, for successful activation 
leading to clonal expansion [248, 249]. Although the nature of the costimulus has not been
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completely elucidated, substantial evidence implicates a role for B7-CD28 interactions in Thl 
cell activation [250], whereas IL1 has been shown to costimulate Th2 cells [251, 252]. It 
has been clearly shown that TcR engagement without costimulation does not provide 
adequate signalling to induce proliferation [253-255] but rather leads to profound T cell 
unresponsiveness upon restimulation [254-258]. This phenotype is known as T cell anergy 
and was first demonstrated directly when T cell clones that had been exposed to antigen on 
other T cells in culture were subsequently unable to respond to the same antigen presented 
on normal APC [253]. It is now known that anergy can be induced by costimulator- 
incompetent "non-professional" APC [259] or by using altered peptide ligands [260, 261]. 
Furthermore, anergic T cells can be characterised by their inability to proliferate or produce 
EL2 [262] and by their capacity to regain normal activity when provided with exogenous IL2 
[263] or "parked" in the absence of antigen [264]. Although the intracellular events leading 
to anergy are currently under investigation, it is known that partial TcR signalling results in 
altered TcR£ chain phosphorylation and a subsequent lack of its association with zap 70 
protein-tyrosine kinase [261].
Anergic T cells may be compromised in many ways, but they can still produce 
readily detectable, although reduced levels of certain cytokines, including IFNy, IL3 and 
granulocyte macrophage-colony stimulating factor (GM-CSF) upon restimulation [256, 261, 
265]. The regulatory activity associated with some of these cytokines might explain why 
anergic cells from orally tolerised mice can act as Ts when adoptively transferred into 
athymic and SCID mice [266]. Alternatively, this may be due to their ability to compete with 
naive cells for available IL2 or antigen-MHC complexes on APC [267].
(B) Mechanisms of Oral Tolerance
(i) Introduction
As with peripheral tolerance, the mechanisms of oral tolerance may also involve 
either active modulation or direct inactivation of responding lymphocytes. The distinct 
immunological properties of each of these mechanisms may have important clinical 
implications. Thus, a unique feature of active suppression is the phenomenon of "bystander
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suppression," in which immune responses to an unrelated antigen may also be inhibited if 
both antigens are present simultaneously at the time of challenge. This could only occur if 
the active regulatory mechanism was mediated by antigen non-specific factors such as 
cytokines. In contrast, the functional effects of deletion or anergy should be restricted to 
antigen-specific lymphocytes and to be of practical use in therapy of autoimmune and 
inflammatory disorders, tolerance caused by direct T cell inactivation would require that the 
disease-inducing antigen was known. Conversely, bystander suppression would allow use 
of an unrelated but anatomically linked antigen. However, antigen-induced inactivation of 
lymphocytes might have the theoretical advantage of being stable and long-lasting, as it 
would be less susceptible to modification by other immune responses. Both mechanisms 
have been implicated in oral tolerance and it has been suggested that their induction may be 
dependent on the dose of antigen used to induce tolerance.
(ii) Evidence for Active Modulation
Many early studies demonstrated active suppression in vivo following oral 
administration of antigen by showing that tolerance could be transferred to naive recipients 
with T cells [268, 269]. Furthermore, lymphocytes from tolerised animals can actively 
suppress T cell proliferation and cytokine production by primed cells in co-culture in vitro 
[270, 271]. A number of mechanisms have been implicated in this phenomenon.
CD8+ T Cells
Most of the initial mechanistic studies in oral tolerance proposed a role for CD8+ 
suppressor T cells. Oral tolerance could be transferred by CD8+ cells, reviewed in: [7, 8, 
133] and the tolerance in vivo could be prevented by treatment with agents that were believed 
to be specifically toxic for Ts cells, such as cyclophosphamide [272] and 2'-deoxyguanosine
[119]. Upon further investigation, the Ts cells were thought to be restricted by the product 
of "I-J" genes encoded by the class II region of the MHC which had been implicated in other 
Ts-mediated models of peripheral tolerance [273]. However, CD8+ Ts cells and the I-J
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molecule were never characterised at the molecular level and most immunologists now 
consider their existence unlikely.
However, a number of recent studies appear to confirm that CD8+ T cells can 
transfer suppression to naive recipients [96, 274]. In addition, the regulatory CD8+ T cells 
induced in this way have been shown to mediate "bystander suppression" via the release of 
inhibitory cytokines such as TGFp [274]. Clearly this is an area that needs to be 
reexamined. In addition, the possibility that CD8+ T cells may mediate suppression by 
conventional MHC class I-restricted lysis either of antigen-bearing APC [275] or idiotype+ T 
cells needs to be explored.
y8 TcR+ Cells
One further possible population of CD8+ regulatory T cells may be the subset which 
express the yS form of the TcR. In both murine and rat models of intranasal tolerance, 
transfer of as few as 500 antigen-specific CD8+ y8 TcR+ cells suppressed CD4+ T cell 
responses and IgE production in naive recipients [129, 276]. Similarly, yS TcR+ cells from 
orally tolerised rats have been found to transfer suppression of uveitis in an antigen-specific 
manner [277], while the depletion of y8 TcR+ cells either with monoclonal antibodies [278] 
or by genetic manipulation [279], has shown that these cells may be essential for the 
development of peripheral tolerance induced by fed antigen. Interestingly, the y8 TcR+ cells 
identified in all of these studies were of splenic origin and, despite the relative abundance of 
y8 TcR+ cells in the gut, attempts to transfer tolerance with IEL have been unsuccessful 
[280]. However, the functions of y8 TcR+ cells in the immune system are still unknown 
and their role in oral tolerance must remain controversial.
CD4+ T Cells
A possible role for CD4+ T cell crossregulation in oral tolerance is suggested by the 
fact that CD4+ T cells can transfer oral tolerance in some systems [266, 281] and by the fact 
that it is easier to induce and maintain oral tolerance of CMI responses in comparison with 
humoral responses [131, 136]. Th2 cells are said to be predominant in the mucosa and
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enhancement of IL4 production and preferential outgrowth of IL4/IL10-producing T cell 
clones in vitro from the MLN of animals tolerised by feeding OVA or MBP has been 
described [282-284]. The prevention of EAE by feeding rats MBP has also been associated 
with preferential upregulation of IL4 in the brain, together with decreased IFNy expression 
[285]. Although this supports a role for classical Th2 cells, it has also been suggested that 
there may be a unique CD4+ T cell population which produces TGF(3 in addition to DL4 and 
IL10, and referred to as Th3 cells [282]. However, it should be noted that these findings 
have been confined to one or two models of oral tolerance and may be very dose dependent 
[7, 282-284]. Moreover, IFNy has also been implicated in mediating mucosal tolerance, 
although this was based on results from a very limited panel of effector responses [129]. 
Therefore the regulatory activity of Thl and Th2 cell subsets in oral tolerance remains an 
open issue.
Cytokines
An alternative to the idea that a discrete subpopulation of lymphocytes is responsible 
for oral tolerance is that individual inhibitory cytokines may be produced preferentially in 
response to fed protein. Those which have received most interest are IL4, IL10, IFNy and 
TGF(3.
IL4
Development of Th2 cells and their ability to inhibit Thl cells is dependent on IL4 
[286-288]. In several models of peripheral tolerance, IL4 is enhanced and depletion of IL4 
prevents the induction of tolerance [289]. In addition, as noted above, preferential 
upregulation of IL4 production has been described in oral tolerance [282-284].
IL10
IL10 is a further Th2-dependent cytokine [290] which is an attractive candidate 
mediator of oral tolerance as it suppresses Thl cell activity via downregulation of 
macrophage IL12 production [221, 291]. In addition, its absence in IL10_/" mice allows the
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development of intestinal pathology due to hyperreactivity to components of the normal gut 
flora [187]. However, the role of IL10 in oral tolerance is controversial, as although initial 
reports showed that ILlO-producing T cell clones could be isolated from animals tolerised by 
feeding MBP [282], normal oral tolerance occurs in mice depleted of IL10 using antibody
[292].
IFNy
As described above, immune regulation by EFNy has been reported in some models 
of mucosal tolerance, including the CD8+ y8 TcR+ cells which transfer nasal tolerance to 
soluble OVA [128, 129]. These results are consistent with the cytostatic properties of IFNy
[293], together with the preservation of IFNy production in mice tolerised by parenteral 
injection of SEB [228]. Furthermore, IFNy plays a central role in some models of T cell 
anergy and cell death in vitro [294, 295]. However, as most workers find that IFNy and its 
effects are highly susceptible to the suppressive effects of feeding antigen, once again its 
exact role in oral tolerance remains uncertain.
TGFp
Abundant in the normal intestine [296-298], TGFP is produced by cells of both 
haematopoietic and epithelial origin and is important in regulating epithelial homeostasis and 
IgA switching [299]. TGFp also has well-documented suppressive effects on many aspects 
of the immune response [299] and is the cytokine mediator receiving the most attention in 
current studies of oral tolerance. The prevention of EAE by oral administration of MBP is 
associated with upregulation of TGFp in the brain [285] and TGFp-secreting T cell clones 
can be isolated preferentially from animals tolerised in this way [282]. Furthermore, 
protection from EAE can be transferred with CD8+ T cells or clones that produce TGFp, and 
the bystander suppressor effects exerted by these cells in vitro can be prevented with anti- 
TGFp [282-285]. Consistent with an important role for TGFp in oral tolerance, it has also 
been recently demonstrated that antigen-specific TGFp production is preserved in orally
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tolerised TcR transgenic animals [300] and that depletion of this cytokine in vivo can 
prevent the orally induced suppression of EAE [301].
(iii) Direct Inactivation of Antigen Specific Lymphocytes
Even in some early studies, oral tolerance was found to be non-transferrable [302] 
and partly insensitive to the effects of cyclophosphamide [112]. These results would be 
compatible with what we now understand of the mechanisms involved in direct T cell 
inactivation.
Clonal Deletion
Evidence for deletion of antigen-reactive cells in oral tolerance has been provided in 
OVA-specific TcR transgenic mice, where both local and systemic clonal deletion by 
apoptosis was apparent within a few days after feeding OVA [300]. However, in this study, 
very large doses of antigen were required to demonstrate deletion and the molecular 
mechanism of apoptosis was not addressed. Similar effects have yet to be documented in 
normal mice fed more physiologically relevant doses of antigen.
Clonal Anergy
The induction of clonal anergy has recently been proposed as a possible mechanism 
of oral tolerance. Studies of oral tolerance to MBP or OVA showed that T cells removed 
from antigen-fed mice failed to produce IL2 but did express IL2R upon restimulation with 
antigen in vitro and limiting dilution analysis indicated that this may be due to a decrease in 
the frequency of proliferating or IL2-producing antigen-specific cells rather than active 
suppression [118, 303-305]. Although similar results would also be obtained if clonal 
deletion occurred in oral tolerance, more direct evidence for anergy is that the impaired 
antigen-specific proliferation of the orally tolerised cells was restored by culture in vitro with 
exogenous IL2, indicating the continued presence of antigen-reactive T cells [304]. 
However, anergy in oral tolerance has yet to be shown directly using transgenic systems, as 
has been done in other models of peripheral tolerance.
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iv) Influence of Antigen Dose on the Mechanisms of Oral Tolerance
One explanation for the apparently contradictory evidence for both active regulation 
and direct T cell inactivation in oral tolerance is that these mechanisms may be involved in 
tolerance induced by different doses of fed antigen [132]. The balance of evidence suggests 
that feeding high doses of antigen may induce clonal deletion or anergy, while lower doses 
may elicit active suppression by inhibitory cytokines or by Th2/CD8+ T cells [131-133, 136, 
284]. However, the majority of this work examined only two comparative doses of fed 
antigen [132, 284] and the few groups which assessed a more complete antigen dose range 
concentrated mainly on describing in vivo effector responses and did not determine the 
underlying mechanisms [131, 133, 136]. Therefore, it is possible that active regulation and 
direct T cell inactivation may not be mutually exclusive in oral tolerance and this requires 
fuller investigation, particularly since this would have important implications for the 
manipulation of oral tolerance as a therapeutic strategy.
5. Aims of this Study
The principal aim of this study was to examine the regulation of peripheral immune 
responses to a fed protein under closely defined experimental conditions. The antigen OVA 
was used for this purpose for the following reasons. Firstly, OVA is an immunologically 
well characterised protein antigen which is inexpensive and readily available from 
commercial sources. Secondly, it had been extensively utilised in this laboratory as an oral 
antigen and the techniques for inducing oral tolerance and for assessing various aspects of 
systemic immunity to OVA were well established.
A variety of different consequences have been reported for systemic immune 
responses after feeding antigen. As these are suggested to reflect the distinct doses of fed 
antigen administered, I thought it important to begin my study by establishing the regulatory 
effects of a wide dose range of fed OVA. I examined both Thl- and Th2-dependent 
responses to determine if their regulation was independent of each other at any particular 
antigen dose. The results of this work, which are detailed in Chapter 3, allowed me to
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choose a high and low dose of antigen for the comparative studies detailed in the subsequent 
chapters examining the role of Th2 and CD8+ regulatory cells.
Although high doses of fed antigen have become associated with direct T cell 
inactivation, most evidence for this idea was provided by studies of oral tolerance in antigen- 
specific TcR transgenic models or in animals fed superantigens and few studies have 
explored the mechanism in normal mice fed conventional antigen. Therefore, in Chapter 6 ,1 
attempted to provide evidence for cellular deletion and anergy in mice fed OVA.
Finally, since oral tolerance is currently under evaluation as a potential 
immunotherapy it would be important to understand the longevity of its effects. This has 
been addressed by few previous studies and I therefore attempted to extend their findings in 
Chapter 7 by comparing two doses of fed OVA and describing the persistence of tolerance 
for a wider range of effector responses.
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Table 1.1: Use of Oral Tolerance to Prevent Immunopathologya
Immunopathology Antigen
Encephalomyelitis Myelin basic protein
Arthritis Collagen
Diabetes Insulin
Uveoretinitis Uveal S antigen
Glomerulonephritis Various proteins
Allograft rejection Allogeneic leukocytes/Allopeptides
aFeeding a range of antigens of pathological significance has been found to prevent 
the induction of associated immunopathological disease. See text for references.
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Chapter 2: Materials and Methods
Animals
Specified pathogen-free (SPF), female BALB/c (H-2^), C57B1/6 (H-2^), athymic 
outbred nude (H-2^X(i), MRL lpr/lpr-/L (H-2 ) and lpr/lpr+/+ (H -2 ) mice were purchased 
from Harlan Olac (Bicester, Oxon, U.K.) or were bred in house (Central Research Facility, 
CRF, University of Glasgow) and maintained in the CRF.
Female IL4"/- (129Sv x C57B1/6)F2 (H-2^) mice [306] were kindly provided by Drs 
J. Alexander (University of Strathclyde, Glasgow) and H. Bluethmann (F. Hoffman-La 
Roche AG, Basel, Switzerland). These mice were maintained initially in the Department of 
Immunology, University of Strathclyde and then in the CRF. Whenever possible, controls 
in these experiments were sex-matched wild-type (IL4+/+)F2 mice of the same strain 
combination, but in some cases, normal C57B1/6 mice were used as controls. Female 
IFNyR-/- (129Sv, H-2^) mice [307] were also obtained from Dr. H. Bluethmann and 
maintained in CRF.
Unless specified, all animals were housed under standard conditions with free access 
to both water and standard rodent pellets, containing no ovalbumin, and were first used at 6- 
8 weeks of age. Nude mice were housed in isolators.
Antigens and Mitogens
Ovalbumin (OVA, Fraction V), human serum albumin (HSA), Staphylococcal 
enterotoxin B (SEB) and concanavalin A (Con A) were obtained from Sigma (Sigma-Aldrich 
Company, Poole, U.K.), while purified protein derivative (PPD) from M. tuberculosis was 
obtained from Central Veterinary Laboratory, (C.V.L., New Haw, Addlestone, Surrey, 
U.K.) and prepared according to manufacturer's instructions.
Heat-aggregated OVA (HAO) was prepared by heating a 2% (w/v) solution of OVA 
in saline (Baxter Healthcare Ltd. Norfolk, U.K.) at 70°C for 60 minutes in a water bath
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(Grant Instruments Ltd., Barrington, Cambridge, U.K.). The resulting suspension was 
centrifuged at 450g for 5 minutes and the precipitated OVA washed further by resuspending 
in ice cold saline and centrifuging at 450g for 10 minutes. After discarding the supernatant, 
the HAO was resuspended at 20mg/ml in saline and stored at -20°C until required. Before 
use, the HAO was diluted to 2mg/ml in saline and sonicated for 20 minutes to produce a 
colloidal suspension [111, 112].
Maintenance of Cell Lines and Hybridomas in vitro
EL4 cells (a thymoma of C57B1/6 origin from American Type Culture Collection, 
ATCC, Rockville, MD. U.S.A.) were maintained in tissue culture flasks (Costar, 
Nucleopore, High Wycombe, U.K.) in RPMI 1640 containing 10% (FCS), lOOU/ml 
penicillin/ 100p,g/ml streptomycin, 1.25flg/ml amphotericin B (Fungizone), 2mM glutamine 
(all Gibco Life Technologies, Paisley, U.K.) and 0.05M 2-mercaptoethanol (2-ME; Sigma) 
(complete medium). EG7 OVA cells (H-2^) were obtained originally from Dr M. Bevan 
(University of Washington, Seattle, U.S.A.). These cells were derived from EL4 cells 
transfected with a neomycin resistance gene and a single copy of a plasmid containing a 
cDNA copy of the chicken OVA mRNA (Moore et. al.) and were maintained in complete 
medium supplemented with 400|ig/ml Geneticin (Gibco). Both cell lines were subcultured 
every 2-3 days by adding l-2ml of cell suspension, containing approximately 2-5x10^ cells, 
to 10ml of fresh medium and were subcultured 2 days before being used in vitro to ensure 
that the majority of cells would be in the log phase of growth.
YTS 191.1.2. (a rat anti-murine L3T4 (CD4) hybridoma) and YTS 169.4.2.1 (a rat 
anti-murine Lyt-2 (CD8a) hybridoma) [308] were both obtained from European Collection 
of Animal Cell Cultures (ECACC), Centre for Applied Microbiology and Research, Porton 
Down, Salisbury, U.K and were maintained at 3-9x10^ cells/ml in either RPMI 1640 
containing 20%FCS, lOOU/ml penicillin/ 100p,g/ml streptomycin, 1.25p.g/ml Fungizone, 
2mM glutamine and 5xl0~^M 2-ME or in complete medium, respectively.
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Oral Administration of OVA
Mice were fasted for 18 hours prior to being fed single doses of OVA, which were 
dissolved in 0.2ml saline and administered via a stainless steel gavage needle (1.5 by 20 
gauge, International Market Supply, Dane Mill, Broadhurst Lane, Chesire, U.K.) without 
anaesthetic. Control animals were fed 0.2ml saline alone.
Systemic Immunisation Procedures
In all experiments, subcutaneous (s.c.) immunisations were performed by injection 
of a total volume of 50jil into one rear footpad under light anaesthetic using 5% halothane 
(Zeneca Ltd. Macclesfield Cheshire, U.K.), while intraperitoneal (i.p.) immunisations were 
performed by injection of a total volume of 0.2ml without anaesthetic.
Systemic IgG, delayed type hypersensitivity and proliferative responses were 
induced by immunising mice s.c. with an emulsion of lOOpg OVA in saline prepared at a 
ratio of 1:1 with complete Freund's adjuvant (CFA; Sigma).
Systemic CTL responses were induced in C57B1/6 mice either by i.p. immunisation 
with 3jig OVA/ISCOMS (kindly provided by A. Donachie, Department of Immunology, 
University of Glasgow) prepared in saline and containing OVA and Quil A at a ratio of 10:1, 
as described elsewhere (Reid and Mowat), or by s.c. immunisation with lOOpg OVA/CFA.
Induction of Hyperimmune Anti-OVA Antibodies
Serum IgG was induced in B ALB/c mice by s.c. injection into one rear footpad with 
100pg OVA/CFA and boosted with lOOpg OVA in incomplete Freund's adjuvant (IFA; 
Sigma) one month later. Serum was collected after a further month.
Collection of Serum for Antibody Measurements
Mice under halothane anaesthesia were bled from the retro-orbital plexus using 
heparinised capillary tubes (Hawksley & Sons Ltd. Lancing, Sussex, U.K.). A maximum 
of 200|il was collected and serum was separated by centrifugation for 15 minutes at 450g 
and stored at -20°C until use. Alternatively, blood samples were collected from the major
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blood vessels within the chest cavity of mice immediately after sacrifice, and serum 
separated as described above.
Preparation of Monoclonal Antibodies (Mabs) from Ascites Fluid in Athymic 
Mice
Nude mice were injected i.p. with 0.5ml pristane (2,6,10,14-teramethylpentadecane; 
Sigma) 14 and 7 days prior to i.p. inoculation with either 1x10^ YTS 169.4. 2.1 or 1.5x10^ 
YTS 191.1.2. hybridoma cells in 1ml RPMI-1640. After a further 1-2 weeks, Mab rich- 
ascites fluid was harvested from the peritoneal cavity using a needle and syringe when 
peritoneal tumour and swelling had developed. The fluid was centrifuged at 1500g for 10 
minutes at room temperature and supernatant collected for further purification of IgG.
Ammonium Sulphate Precipitation of IgG from Hyperimmune Serum or 
Ascites Fluid
IgG was purified from hyperimmune serum or ascites by dropwise addition of 
saturated ammonium sulphate solution (pH 6.5) to a final concentration of 45% w/v and the 
mixture left overnight at 4°C to ensure complete precipitation of IgG. Following 
centrifugation at 200g for 1 hour at 4°C, the supernatant was discarded and the precipitate, 
dissolved in 10ml PBS (Appendix 1), was placed in dialysis tubing (Medicell, Inemational 
Ltd. London, U.K.) and dialysed against 11 PBS for 48 hours at 4°C to remove the 
ammonium sulphate. The PBS was changed 6 times over this period and afterwards the 
dialysis tubing was removed and placed in polyethylene glycol (PEG) 2000 (Sigma) until its 
contents were concentrated to approximately 5ml. The solution was then removed, 
centrifuged at 50g for 30 minutes to clarify the supernatant and an aliquot assessed for IgG 
content by measuring the OD at 280nm using an Ultospec 2000 spectrophotometer 
(Pharmacia Biotech, Herts, U.K.). The concentration of IgG was calculated to be
1.85mg/ml on the basis that an OD280 of 1.43=lmg/ml IgG.
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Depletion of T Cell Subsets in vivo
To deplete CD4+ and CD8+ T cells in vivo, mice were injected i.p. with 0.5mg of 
anti-CD4 mAb (YTS 191.1.2) or anti-CD8 mAb (YTS. 169.4.2.1) dissolved in 0.5ml saline 
on days -2 and 0 before first administration of antigen. Control animals received either 
0.5mg rat IgG (Sigma) or 0.5ml saline.
Depletion of Cytokines in vivo
To deplete IFNy in vivo, mice were injected i.p. with 0.5mg hamster-anti murine 
IFNy (IgG; Cell Tech Ltd. Berkshire, U.K.) in 0.2ml saline 1 day before and 1 hour prior to 
the first administration of antigen. Control animals received 0.2ml hamster serum diluted 
1:4 to produce an approximate IgG concentration of 0.5mg (kindly provided by the Anatomy 
Animal Facility, University of Glasgow).
Assessment of Antigen-specific Delayed Type Hypersensitivity (DTH) 
Responses in vivo
OVA-specific DTH responses were assessed as decribed in detail elsewhere [112]. 
20 days after s.c. immunisation with OVA/CFA in the rear footpad, mice were anaesthetised 
with halothane and the thickness of the unimmunised rear footpad measured using skinfold 
calipers (0-10mm in 0.1mm; Kroeplinn Langenmesstecknik, Kingston-on-Thames, Surrey, 
U.K.). The footpads were then injected intradermally (i.d.) with lOOpg HAO in 50pl saline 
and after a further 24 hours, the increases in individual footpad thickness were measured. 
The mean increment of each group was calculated and the OVA-specific DTH responses 
obtained by subtracting the increment found in CFA unimmunised mice challenged with 
HAO.
Measurement of Antigen-specific Serum IgG Responses
Enhanced protein binding, 96-well ELISA plates (Immulon-4; Dynatech, 
Billingshurst, Sussex, U.K.) were coated overnight at 4°C with lOOjil of a 10pg/ml 
solution of OVA in 0.1M carbonate buffer (pH 9.3: Appendix I). After three washes with
36
150pl/well PBS/0.05% Tween 20 (Sigma), IOOjllI aliquots of doubling dilutions of 
(NH4 )2 SC>4 -purified anti-OVA hyperimmune serum IgG standard (described previously) 
and serum samples, both diluted 1:400 in PBS/0.05% Tween 20/1 %FCS (Gibco Life 
Technologies, Paisley, U.K.), were added to the plates. After incubation at room 
temperature for 2.5 hours, the plates were washed as before, and incubated for a further 3 
hours at room temperature with lOOpl/well alkaline phosphatase-conjugated goat anti-mouse 
IgG (Sigma) diluted 1:500 in PBS/Tween 20. After a final wash step, 100|il/well of 
phosphatase substrate (lmg/ml in 10% diethanolamine, DEA, dissolved in distilled water; 
both from Sigma) was added and 5-30 minutes later, the plates read at 405nm (reference 
filter 5 lOnm) using a MR5000 automatic microplate reader (Dynatech). The anti-OVA IgG 
concentration of test supernatants was determined with reference to a standard curve 
constructed using serial dilutions of the hyperimmune anti-OVA standard.
Measurement of Antigen-specific Serum IgG Isotype Antibodies
Enhanced protein binding, 96-well ELISA plates (Immulon-4) were coated overnight 
at 4°C with 100pl of a lOpg/ml solution of OVA in 0.05M carbonate buffer. After three 
washes with PBS/0.05% Tween 20, non-specific protein-binding sites were blocked with 
lOOpl/well of a 3% solution of bovine serum albumin (BSA; Sigma) in PBS/Tween 20 for 1 
hour at room temperature. After three washes with PBS/Tween 20, 50|il aliquots of test 
sera in doubling dilutions (beginning at 1:400 for IgGl or 1:20 for IgG2a assays) in 
PBS/Tween 20 were added to the plate, as were doubling dilutions of the (NH4 )2 SC>4 - 
purified anti-OVA IgG hyperimmune serum standard (described above), diluted 1:400 in 
PBS/Tween 20, and incubated at room temperature for 1.5 hours. After three further 
washes, biotinylated rat anti-murine IgGl (Serotec Ltd. Kidlington, Oxford, U.K.), diluted 
1:16000, or biotinylated rat anti-murine IgG2a (both AMS Biotechnology, Witney, Oxon, 
U.K.) diluted 1:1000 in PBS/Tween 20 was added at 50jil/well and incubated at room 
temperature for 1 hour. The plates were then washed four times and 75pl/well extravidin- 
peroxidase (Sigma) in PBS/Tween 20 was added at 2|ig/ml. After a final incubation for 1 
hour at room temperature, the plates were washed six times before 100pl of 3,3',5,5'-
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tetramethylbenzidine peroxidase (TMB) substrate (Dynatech) was added to each well. The 
plates were read at 630nm (reference filter 405nm) using a MR5000 automatic reader. 
Concentrations of anti-OVA antibody isotypes in test supernatants were determined with 
reference to a standard curve constructed using serial dilutions of the hyperimmune anti- 
OVA standard.
Preparation of Lymphoid Cells
Single-cell suspensions of spleen and popliteal lymph node (PLN) were prepared in 
RPMI-1640 by rubbing gently through a stainless steel mesh using a syringe plunger and 
passed through Nitex mesh (gauge 100pm, Cadisch & Sons, London, U.K.) to remove any 
clumps. After washing the cells twice in RPMI 1640 by centrifugation at 4°C for 7 minutes 
at 450g and resuspending in 10ml RPMI 1640, viable cells were counted by phase contrast 
microscopy ( x40 objective; Nikon Labophot microscope, Nikon House, Surrey, U.K.) 
using a haemocytometer (Neubauer). Cells were finally resuspended in complete medium 
supplemented with 25mM Hepes (Sigma).
Measurement of T Cell Proliferation in vitro
200pl aliquots of lymphoid cells resuspended at 10^/ml in complete medium 
supplemented with 25mM Hepes were added to quadruplicate wells of flat-bottomed 96-well 
tissue culture plates (Costar, Northumbria Biologicals, Cramlington, Northumberland), 
either alone or in the presence of OVA, PPD or Con A, at concentrations previously shown 
(unpublished data) to be optimal for generating effector immune responses in vitro (1 mg/ml, 
50|ig/ml or lOjig/ml, respectively). The plates were covered with plate sealers (FLOW ICN 
Biomedicals Inc., Costa Mesa, CA , U.S.A.) and incubated in a 5% CO2 humidified 
incubator at 37°C. Proliferation was assessed at various times by addition of lpGi/well 
[^H] thymidine (West of Scotland Radionucleotide Dispensary, Western Infirmary, 
Glasgow) for the last 24 hours of culture. Cell bound DNA was harvested onto glass fibre 
filter mats and [^H] thymidine incorporation measured on a 1205 Betaplate scintillation 
counter (both Wallac Oy, Turku, Finland).
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Measurement of Cytokine Production in vitro
Lymphoid cells resuspended at 4xl0^/ml in complete medium containing 25mM 
Hepes were added in 1ml aliquots to 24-well tissue culture plates (Costar), either alone or 
with OVA, PPD or Con A at the concentrations described above. The plates were covered 
with plate sealers and incubated in a 5% CO2 humidified incubator at 37°C. Supernatants 
were harvested at various times of culture, centrifuged at 13000rpm for 5 minutes to remove 
non-adherent cells and stored at -20°C until assayed for cytokine content.
Cytokine production was quantified using sandwich ELISA techniques, for which 
optimal conditions had previously been established in the laboratory. Enhanced protein- 
binding 96-well plates (Immulon 4; Dynatech) were coated overnight at 4°C with 50pl of 
monoclonal anti-cytokine antibody (Table 1) in 0.1M NaHC03 buffer (pH8.2, Appendix 1). 
The plates were then washed twice with PBS/0.05 % Tween 20, before non-specific binding 
was blocked by incubation with 200|il of PBS/10%FCS for 1 hour at 37°C. After three 
washes, 50jj,l/well of neat culture supernatant was added to quadruplicate wells, while 
doubling dilutions of standard recombinant murine cytokine (Table 2) in PBS/10% FCS, 
was added to duplicate wells. The plates were then incubated for 3 hours at 37°C and 
washed four times before 50jxl/well biotinylated anti-murine cytokine antibody (Table 1) 
diluted in PBS/10% FCS was added. After incubation for 1 hour at 37°C, the plates were 
washed six times before addition of lOOjil/well of TMB substrate. The plates were read at 
630nm (reference filter 405nm) using a MR5000 automatic microplate reader. Cytokine 
concentrations in test supernatants were determined with reference to a standard curve, 
constructed using serial dilutions of the standard cytokines and analysed using Mikrotek 
software (Dynatech).
Generation and Measurement of Antigen-specific CTL Responses in vitro
a) Restimulation of Splenocytes in vitro
EG7 OVA cells were incubated at 10^/ml in RPMI 1640 medium containing 50|ig/ml 
mitomycin C (Sigma) for 75 minutes at 37°C and washed 5 times in RPMI 1640 by
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centrifuging at 400g for 5 minutes. Immune spleen cells were obtained from mice 
immunised 10 or 14 days previously by i.p. or s.c. injection of OVA ISCOMS or OVA/CFA 
respectively. 3x10^ pooled splenocytes were restimulated for 5 or 6 days in 25cm^ tissue 
culture flasks (Costar) with 1.5x10^ mitomycin C-treated EG7 OVA cells in a final volume 
of 10ml CTL medium (RPMI-1640, containing 10% FCS, 5% NCTC 135 (Gibco), 
lOOU/ml penicillin/1 OOjig/ml streptomycin, 2mM glutamine and 0.05M 2-ME) in a 5% C02 
humidified incubator at 37°C.
b) Microcytotoxicity Assay for OVA-specific CTL
i) Labelling of Target Cells with 5 1 c  r
Aliquots of 2.5x10^ EG7 OVA target cells were labelled with 51q - by incubation in 
lml RPMI 1640/5% newborn calf serum (NCS; Gibco BRL) containing 2 MBq N a2^C r04 
(West of Scotland Radionucleotide Dispensary), for 60 minutes at 37°C. After washing 5 
times in 10ml RPMI/5% NCS, by centrifuging at 450g for 5 minutes, the cells were 
recounted before being used in the microcytotoxicity assay.
ii)Microcytotoxicity Assays
After culture, the restimulated effector splenocytes were washed twice in RPMI/5% 
NCS and recounted, before being incubated at different effector cell:target cell (E:T) ratios in 
V-bottomed microtitre plates (Flow Labs Ltd.) with 51cr-labelled target cells in a total 
volume of 200(il/well CTL medium. After a 4 hour incubation period in 5% CO2 at 37°C, 
lOOjul of supernatant was removed from each well and ^Cr-specific activity measured in a 
1282 Compugamma counter (Wallac). Results were calculated as the percentage cytotoxicity 
for triplicate assays, determined using 10% Triton-X (Sigma) to obtain total release and 
unimmunised B6 spleen cells to obtain spontaneous release. Percentage cytotoxicity was 
calculated as follows:
experimental release - spontaneous release 
% cytotoxicity = -----------------------------------------------------------  x 100%
total release - spontaneous release
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In all assays, cytotoxicity against EL4 cells was also determined to control for non-OVA- 
specific activity.
Phenotypic Analysis of Lymphocytes by Flow Cytometry
1()6 lymphoid cells, either freshly prepared or removed from restimulation cultures, 
were resuspended in plastic conical tubes (Falcon, Cowley Oxford, U.K.) in 50pl staining 
buffer (SB, Appendix 1) containing primary Mab at the appropriate concentration (Table 3). 
The samples were incubated in the dark on ice for 30-40 minutes before the cells were 
washed twice in 2ml SB by centrifugation for 7 minutes at 450g. Biotinylated (Bio)- 
antibodies were detected by reincubating the cells in 50pl of either a 1:50 dilution of 
phycoerythrin (PE)-streptavidin or a 1:100 fluorescein dilution of (FITC)-streptavidin (both 
Vector, Bretton, Peterborough, U.K.) in SB for 30-40 minutes on ice. The cells were then 
washed twice in SB and any red blood cells present were lysed by resuspending in 1ml 
FACSLyse (diluted 1:10 in distilled water; Becton Dickson, San Jose, CA, U.S.A.) at room 
temperature for 10 minutes. After a final wash in 1ml PBS, cells were resuspended in 0.5ml 
of ice cold FACSFlow (Becton Dickson) and analysed using a FACScan IV flow cytometer 
(Becton Dickson). A 488nm argon ion laser was used to detect green and red fluorescence, 
while dead cells were excluded from analysis by gating on forward and side light scatter 
properties. The data were analysed using Lysis II software (Becton Dickinson). In all 
experiments, negative control samples were cells incubated with FITC-Streptavidin or PE- 
Streptavidin in the absence of any primary antibody.
Assessment of Lymphocyte Morphology
Cytospin preparations of freshly isolated or cultured lymphocytes were made by 
spinning 10^ cells on to glass slides at 450g for 2 minutes using a Shandon cytocentrifuge. 
Slides were allowed to air dry for 15 minutes before fixing in methanol for 15 minutes. The 
slides were then immersed in May-Grunwald stain (BDH, Poole, Dorset, U.K.) for 4 
minutes, rinsed and allowed to stand for 2-3 minutes in distilled water, before staining with
41
Giemsa (BDH) diluted 1:10 in distilled water for 10 minutes. Finally, the slides were 
washed with tap water and allowed to air dry before being mounted in DPX mountant 
(BDH). Cells remaining adherent to culture wells were stained in situ, by a similar method 
after removal of non-adherent cells by vigorous washing with PBS/10% FCS.
The numbers of intact and apoptotic lymphocytes on cytospin slides were assessed 
by light microscopy (Olympus BH-2 biological microscope, Olympus Optical Co. Ltd., 
London, U.K.) under oil immersion at xlOO magnification. Apoptotic cells were identified 
as those with clearly blebbed membranes and condensed chromatin in their nucleus.
Assessment of Ultrastructural Morphology
Electron microscopy (EM) was performed by Mrs J. Hare (Department of 
Pathology, Western Infirmary, Glasgow). 10^ lymphoid cells from culture plates were 
pelleted by centrifugation at 450g for 5 minutes in conical-bottomed centrifuge tubes 
(Falcon). Cell pellets were fixed overnight in 2% glutaraldehyde (Agar Scientific Ltd., 
Stanstead, U.K.) in Sorensen's buffer (pH7.4, Appendix 1) and after a brief rinse in 1% 
osmium tetroxide (Agar Scientific Ltd.), were dehydrated through graded alcohol and rinsed 
briefly with propylene oxide (BDH) before embedding in araldite epoxy resin (Agar 
Scientific Ltd.) and polymerising at 60°C overnight. Sections 2pm thick, were cut on a 
Reichert Jung Ultracut E microtome, stained with toludine blue (BDH) and examined by 
light microscopy. Ultrathin sections 90pm thick, were cut, mounted on 200-mesh copper 
grids (Emitek, Ashford, U.K.) and stained with uranyl acetate and lead citrate (Agar 
Scientific Ltd.) prior to examination using a Philips CM 10 transmission electron microscope 
at a final magnification of 73000x.
Analysis of Cellular DNA Content in vitro
To assess the position of cultured cells in cell cycle, flow cytometric analysis of 
propidium iodide (PI; Sigma) [309] stained cells was performed. Aliquots of 10^ cells were 
resuspended in lOOpl of PBS and incubated for 10 minutes at room temperature with 450pl 
trypsin solution (0.03mg/ml; Sigma) dissolved in stock buffer (Appendix 1) to permeabilise
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the cell membrane. 325|il of a solution of 0.5mg/ml trypsin inhibitor and 0.1 mg/ml 
ribonuclease A (both Sigma) in stock buffer was then added and the mixture incubated at 
room temperature for a further 10 minutes. Finally, 250|il of a solution of 0.42mg/ml PI 
and 1 mg/ml spermine tetrahydrochloride (Sigma) in stock buffer was added and incubated 
for 10 minutes at 4°C in the dark to allow PI incorporation into the nuclear DNA. Stained 
cells were analysed for PI fluorescence at an excitation wavelength of 488nm on a Coulter 
EPICS XL flow cytometer (Coulter, Luton, U.K.) using DNA Analysis software, where 
chicken erythrocyte nuclei (Beckton Dickinson) were used as a source of diploid DNA for 
standardisation.
Depletion of T Cell Subsets in vitro
CD4+ and CD8+ T cell subsets were depleted in vitro by complement-mediated 
lysis. PLN cells were resuspended at 10^/ml in RPMI 1640 supplemented with 5% FCS 
and 25mM Hepes, and containing either anti-CD4 mAb (YTS 191.1.2) or anti-CD8 mAb 
(YTS. 169.4.2.1) at 100|Hg/ml. After incubation for 1 hour at 4°C, the cells were washed in 
10 ml RPMI 1640/5% FCS, by centrifuging for 7 minutes at 450g and resuspended at 
10^/ml in RPMI 1640/5% FCS containing 10% (v/v) rabbit complement (Low-Tox M, 
Vector). After a final incubation for 1 hour in 5%CC>2 at 37°C, the cells were washed twice 
in RPMI 1640/5% FCS, counted and resuspended at 2x10^ cells/ml in complete medium for 
assessment of proliferative responses and cytokine production in vitro. Control cells were 
incubated in the absence of MAb or complement under identical conditions.
Blocking Fas-dependent Apoptosis in vitro
To aliquots of lymphoid cells resuspended in complete medium for measurement of 
either proliferation or cytokine production in vitro, 20jig/ml hfas-Fc fusion protein (kindly 
provided by Dr. T. Brunner, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 
U.S.A.) was added in an attempt to block fas-dependent apoptosis, as has been shown by 
previous reports [310].
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Statistical Analysis
Results are represented as the mean ±  1 SEM where indicated and were analysed 
using Student's t-test.
IgG isotypes and IgA antibodies were not normally distributed and were compared 
using Wilcoxon's Rank test.
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Table 2.1: Monoclonal Antibodies used in Cytokine Sandwich ELIS As
i) Capture Antibodies
Specificity Clone Isotvpe Cone, ipg/mT)
Murine IL2 JES6-1A12 Rat IgG2a 2
Murine EL3 MP2-8F8 Rat IgGi 2
Murine IL4 BVD4-1D11 Rat IgG2b 2
Murine IL5 TRFK5 Rat IgGi 4
Murine IL10 JES5-2A5 Rat IgGi 4
Murine IFNy P4-6A2 Rat IgGi 2
ii) Biotinylated Detecting Antibodies
Specificity Clone Isotvpe Cone. Ipg/mT)
Murine IL2 JES6-5H4 Rat IgG2b 1
Murine IL3 MP2-43D11 Rat IgG2a 0.5
Murine LL4 BVD6-24G2 Rat IgGi 1
Murine EL5 TRFK4 Rat IgG2a 4
Murine ELIO SXC-1 Rat IgM 2
Muime IFNy XMG1.2 Rat IgGi 1
All of the above monoclonal antibodies were purchased from PharMingen, San Diego, 
U.S.A.
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Table 2.2: Recombinant Murine Cytokine Standards used in Sandwich 
ELISAs
Cytokine Source
IL2 Pharmingen
IL3 Genzyme, West Mailing, Kent.
IL4 Genzyme.
IL5 Genzyme.
DL10 Both gifts from Prof. F.Y. Liew,
IFNy Department of Immunology, University of
Glasgow.
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Table 2.3: Primary Antibodies used in Flow Cytometric Analysis
Specificity Clone Isotvpe
Bio-anti-murine CD3e 145-2C11 Hamster IgG
PE-anti-murine CD4 (L3T4) GK1.5 Rat IgG2b
FITC-anti-murine CD8a (Lyt-2) 53.6.7 Rat IgG2a
Bio-anti-murine CD25 (IL2Ra) 7D4 Rat IgM
Bio-anti-murine CD69 H1.2F3 Hamster IgG
Bio-anti-murine CD40L (gp39) MR1 Hamster IgG
All of the above monoclonal antibodies were obtained from Pharmingen and used at 1:25 
dilutions in staining buffer.
47
Appendix 2.1: Buffers
Phosphate Buffered Saline (TBS)
80.0g NaCl
11.6g Na2 HP0 4  
2.0g KH2 PO4  
2.0g KC1.
Initially add to 7 litres distilled water (ddH20: Purite Prestige Analyst HP water 
purifier, Purite Ltd., Bandet Way, Thame, Oxon). Stir and allow to dissolve, then pH to 
7.0 and make up to a final volume of 10 litres.
Coating Buffer 
0.1MNaHCO3.
Add 8.4g NaHCC>3 to 11 ddH20 and allow to dissolve, then pH to 8.2.
0.05M Carbonate Buffer 
1.6g Na2CC>3 
2.95g NaHC03.
Add to 11 ddH20 and pH to 9.3.
0.1M Carbonate Buffer 
3.2g Na2C03 
5.9g NaHC0 3
Add to 11 ddH20 and pH to 9.3.
Staining Buffer 
PBS containing:
5%NCS,
0.05% (w/v) sodium azide (Sigma).
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Stock buffer
20mg trisodium citrate,
1.21mg Tris,
10.44mg spermine tetrahydrochloride,
20jll1 Nonidet P40 (all Sigma).
Add to 100ml ddH20 and allow to dissolve, then adjust pH to 7.6
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Chapter 3: The Role of Antigen Dose in Oral Tolerance and Priming
Introduction
The principal aim of my project was to investigate the mechanisms regulating 
peripheral immune responses to orally administered antigen. Previous studies of systemic 
immunity had shown that the effects of fed antigen could depend on the dose used, with 
very low antigen doses preferentially priming cell mediated immune responses (CMI) in vivo 
[120, 131], slightly higher doses producing selective tolerance of CMI [7, 133] and high 
doses inhibiting levels of both CMI and humoral immunity [131]. As the cellular and 
humoral arms of the immune response are now believed to be controlled by the Thl and Th2 
subsets of CD4+ T cells, respectively [220, 311, 312], it is possible that each T cell subset is 
differentially regulated by particular doses of fed antigen. Moreover, since each T cell 
subset can inhibit the activity of the other [221, 291] and this function has been proposed as 
a model of immunoregulation in some systems of peripheral tolerance [289], a similar 
mechanism may operate in oral tolerance. This possiblity is supported by observations of 
preferential Th2 cell activation and subsequent inhibition of Thl-dependent responses after 
feeding relatively low doses of antigen [313]. High doses of fed antigen are shown to 
inhibit both T cell subsets similarly [118], suggesting that the induction of distinct regulatory 
mechanisms may be associated with the dose of antigen administered.
As it is difficult to make valid comparisons between the effects of antigen dose in 
these different experimental models and few rigorous dose response studies have been 
performed, I examined the effects of feeding an extensive dose range of OVA on 
subsequent Thl- and Th2-dependent responses both in vivo and in vitro.
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Experimental Protocol
To induce oral tolerance or priming, a single dose of 10|ig-25mg OVA was 
administered orally to BALB/c mice 10 days prior to s.c. immunisation with OVA/CFA. 14 
days later, draining PLN cell suspensions were prepared in culture with medium, OVA or 
PPD for assessment of proliferation and cytokine production in vitro. Systemic DTH 
responses and serum levels of OVA-specific IgG were examined 21 days after 
immunisation.
In all experiments, control mice were fed 0.2ml saline.
Results 
Dose-dependent Effects of Fed OVA on Subsequent Effector Responses
(A) Oral Tolerance
In order to establish the range of antigen doses leading to oral tolerance, my first 
experiments assessed the sensitivity to inhibition displayed by individual Th cell effector 
responses in mice fed lOOpg, 1, 2, 5, 10 or 25mg OVA prior to parenteral challenge with 
OVA/CFA. These doses were chosen since previous studies had demonstrated their ability 
to tolerise [131].
In vivo Responses
OVA-specific DTH responses were significantly inhibited by feeding mice all these 
doses of OVA prior to parenteral antigen challenge (Fig 3.1a), with the tolerance becoming 
more profound with increasing doses of fed OVA (Fig 3.1a). A similar dose-dependent 
effect on the levels of specific serum IgG was observed, but significant suppression found 
only in mice fed 2mg OVA or greater (Fig 3.1b). These findings are consistent with 
previous reports that cell mediated immunity is more susceptible to oral tolerance induction 
than the humoral limb of the immune response [133].
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In order to determine how this dose-dependent immune regulation affected individual 
Th cell subsets, I next measured serum levels of OVA-specific IgG isotypes, using IgGi 
and IgG2a to reflect Th2 and Thl cell activity, respectively [314].
In comparsion with controls, OVA-specific IgGi antibody production was 
significantly reduced in mice fed 10 or 25mg OVA before immunisation, unaltered by 
feeding 2 or 5mg OVA and significantly raised in immunised mice fed lOOjig or lmg OVA 
(Fig 3.2a). In contrast, OVA-specific IgG2a antibody production was significantly reduced 
in mice receiving lOOpg or greater of fed OVA compared with immunised control mice (Fig 
3.2b). Although the IgG2a response of mice fed lOmg OVA did not differ significantly 
from that of controls (Fig 3.2b), this result was not reproducible in less detailed dose 
response studies and therefore considered to be erroneous. Taken together, these findings 
show that while most doses of fed OVA tolerise IgG2a responses, there is a biphasic effect 
on IgGi production, which is primed by low doses and tolerised by high doses.
In vitro Responses
In order to examine Th cell activity more directly, I assessed the dose-dependent 
effects of fed OVA on subsequent PLN cell proliferative responses and cytokine production 
in vitro. I measured proliferation and EFNy production as indicators of Thl cell activation 
and IL4, EL5 and IL10 production to reflect the activity of Th2 cells [220]. I also measured 
IL3, a cytokine secreted by both cell subsets [220].
Proliferation
The OVA-specific proliferation of PLN cells from all mice increased over the culture 
period, with the highest responses being found after 120h (Fig 3.3a). The level of 
proliferation was significantly reduced by feeding mice 2mg OVA or greater before 
immunisation (Fig 3.3a) and this OVA-specific tolerance became more profound with
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increasing doses of fed OVA (Fig 3.3a). Feeding 100p,g or lmg OVA had no significant 
effect (Fig 3.3a).
In these assays of proliferative activity, I also examined the possibility that feeding 
low doses of antigen might induce a state of bystander suppression, in which lymphocytes 
from a mouse tolerised to one antigen release inhibitory cytokines which suppress the 
response to an unrelated antigen given together with the original antigen at the time of 
challenge. This has been proposed in other models of oral tolerance induced by low doses 
of antigen (Miller, A. et.al. 1991 J.Exp. Med 174:701-798) and to investigate if it occurred 
in any of my experiments, I examined proilferative responses to PPD, as this antigen is 
present in the CFA used to challenge mice with OVA. As expected, cells from immunised 
control mice proliferated well to PPD, with optimal levels being found after 120h (Fig 3.3b). 
The maximal PPD responses of OVA fed mice were similar to those of controls, but at 48h 
of culture, cells from mice fed between lOOpg and 5mg OVA displayed significantly reduced 
proliferation compared with controls (Fig 3.3b), indicating that the kinetics of this response 
may have been delayed by feeding low doses of OVA. In a less detailed dose response 
study, where cells from mice fed 2 or 25mg fed OVA were restimulated in vitro with both 
OVA and PPD, the proliferative responses were comparable with controls at all time points 
examined (results not shown).
IFNy Production
Although the OVA-specific production of IFNy by PLN cells from all mice increased 
over the culture period of 120h, this response was significantly reduced in cells from mice 
fed all doses of OVA compared with controls (Fig 3.4a).
PPD-specific IFNy production also increased throughout culture, but cells from mice 
fed OVA did not differ significantly from controls in this response (Fig 3.4b) and similar 
findings were made in a less detailed dose response study where cells were cultured in the 
presence of OVA+PPD (results not shown).
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IL3 Production
The OVA-specific production of IL3 by PLN cells from all mice increased over the 
culture period, with the highest levels being found after 120h (Fig 3.4a). Throughout 
culture, this response was significantly reduced in cells from mice fed 25mg OVA compared 
with controls and by the end of culture, was also significantly inhibited in cells from animals 
fed lOmg OVA (Fig 3.4a). Feeding 100|ig or lmg OVA significantly primed the later 
production of IL3 in vitro, while feeding 2 or 5mg of OVA had no significant effect on this 
response (Fig 3.4a).
PPD-specific IL3 production was also found to increase over the culture period of 
120h and feeding OVA had no effect on this response at any time (Fig 3.4b). Similar 
findings were made in a less detailed dose response study where cells from mice fed 2 or 
25mg OVA were cultured in the presence of OVA+PPD (results not shown).
IL4 Production
Although there was no OVA-specific IL4 detected in any group (data not shown), 
this cytokine is required for the development of Th2 cells [290], and further evidence for 
their activity in OVA-restimulated control cultures is described below. Therefore, it seems 
likely that IL4 had been produced but was either used up before it could be detected in 
culture or was present at levels sufficient to induce Th2 cells but below the level of 
sensitivity for detection by ELISA.
Low levels of IL4 were found after restimulation of PLN cells by PPD and all 
groups displayed similar levels (Fig 3.4b).
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IL5 Production
OVA-specific IL5 production by PLN cells from all mice increased over the culture 
period, with the highest levels being found after 120h (Fig 3.4a). This response was 
significantly reduced by feeding mice between lOOpg and 25mg OVA before immunisation 
(Fig 3.4a) and the inhibition became more profound with increasing doses of fed OVA (Fig 
3.4a). The only exception was that IL5 secretion by cells from animals fed 2mg OVA did 
not differ significantly from controls until 120h of culture, when this response was 
significantly tolerised.
PPD-specific IL5 production also reached optimal levels after 120h (Fig 3.4b) and 
cells from mice fed OVA did not differ significantly from controls in this response (Fig 
3.4b). Similar findings were made in a less detailed dose response study where cells from 
mice fed 2 or 25mg OVA were cultured in the presence of OVA+PPD (results not shown).
IL10 Production
The OVA-specific production of IL10 by all cells reached optimal levels after 120h 
(Fig 3.4a). Throughout culture, this response was significantly reduced in cells from mice 
fed 25mg OVA compared with controls (Fig 3.4a) and by the end of culture, was also 
significantly inhibited in cells from animals fed lOmg OVA (Fig 3.4a). Feeding lmg OVA 
significantly primed the production of IL10 at 120h, while lOOjig, 2 and 5mg fed OVA had 
no significant effect on this response (Fig 3.4a).
PPD-specific IL10 production reached optimal levels after 120h and cells from mice 
fed OVA did not differ significantly from controls in this response (Fig 3.4b). Similar 
findings were made in a less detailed dose response study where cells from mice fed 2 or 
25mg OVA were cultured in the presence of OVA+PPD (results not shown).
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These findings show that oral tolerance was induced by feeding a wide range of 
antigen doses, where as little as lOOpg fed OVA reduced specific DTH responses and IgG2a 
antibodies in vivo, as well as the production of IL5 and IFNy by PLN cells in vitro. Total 
OVA-specific IgG antibody production and PLN cell proliferation became susceptible to 
inhibition at doses of 2mg OVA, while at least lOmg fed OVA was required to reduce the 
specific production of IgGi, IL3 and IL10. Therefore, more responses became susceptible 
to tolerance as progressively higher doses of fed OVA were used and each response was 
then reduced to a greater extent by increasing OVA doses. Thl-dependent DTH, IgG2a, 
proliferation and IFNy responses were more susceptible to tolerance than the Th2-dependent 
IgGi and IL10 responses, indicating that each Th cell subset may be differentially regulated 
by fed antigen. Consistent with this idea, was the observation that Th2-dependent IgGi and 
IL10 production were actually primed by low doses of fed antigen which induced 
concomitant tolerance of Thl-dependent responses. However, Th2-dependent IL5 
production was neither resistant to tolerance nor primed by any tolerising dose of fed OVA 
examined, suggesting that the dose-dependent regulation of individual Th2-dependent 
effector responses may be distinct.
(B) Priming of Systemic Immunity by Feeding Low Doses of Antigen
In the experiments discussed above, I found that the lower doses of fed antigen 
were only partly effective in inducing oral tolerance and that this effect was different for 
some Thl and Th2 cell functions. As earlier reports showed that even lower doses of fed 
antigen (10-50pg OVA) could preferentially prime DTH responses in vivo [120, 131], I 
decided to extend my studies to study the regulation of Thl- and Th2-dependent responses 
by very low doses of fed OVA. I assessed individual Th cell effector responses in mice fed 
10 or 50|Hg OVA prior to systemic immunisation and, as a comparison, included a group 
tolerised by feeding OVA in a dose known to reproducibly inhibit all responses (25mg 
OVA).
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In vivo Responses
As expected, OVA-specific DTH and serum IgG responses were significantly 
reduced by feeding 25mg OVA prior to immunisation (Fig3.5a&b). However, the DTH 
and serum IgG responses of mice fed 10 or 50|ig OVA were not significantly different from 
those of control animals after immunisation (Fig3.5a&b). Therefore, my findings are 
inconsistent with other reports where these doses of fed OVA enhanced subsequent DTH 
responses [131]. One possible explanation for this discrepency would be if the OVA/CFA 
immunising regime was invoking maximal responses in my experiments, so that it was 
difficult to observe priming. To address this possibility, I compared the systemic immune 
responses of mice fed 10, 50pg or 25mg OVA before s.c. immunisation with either optimal 
(lOOjig) or suboptimal (2pg) doses of OVA/CFA.
The OVA-specific DTH responses induced in mice immunised with 2pg OVA/CFA 
were markedly lower than those seen with 100|ig OVA/CFA (Fig 3.6a). As before, the 
DTH responses of optimally challenged mice were significantly reduced by feeding 25mg 
OVA before immunisation and were not significantly altered by 10 or 50|ig fed OVA (Fig 
3.6a). In contrast, the DTH responses of suboptimally challenged mice fed 25mg OVA 
were not significantly altered by a prior feed of 25mg OVA, but were significantly enhanced 
by lOpg fed OVA (Fig 3.6a), suggesting that the CMI induced by immunisation with 2|ig 
OVA/CFA was so low that it became difficult to observe tolerance and easier to detecting 
priming. Athough the DTH responses of mice fed 50|ig OVA were also above control 
levels, these were not significantly different from those of the relevant control mice (Fig 
3.6a), indicating that this dose was less efficient than lOpg fed OVA in priming CMI.
The level of OVA-specific IgG antibody was also dependent on the dose of antigen 
used for parenteral immunisation and in the experiment shown, animals challenged with 
lOOjig OVA/CFA and fed 10, 50|ig or 25mg OVA had significantly reduced IgG responses 
compared with controls (Fig 3.6b). However, in two repeat experiments, the IgG responses 
of mice fed either 10 or 50jng OVA prior to immunisation with 100(Xg OVA/CFA were 
comparable with controls, indicating that these feeding doses of OVA were not tolerogenic.
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In suboptimally challenged mice, total OVA-specific IgG responses were also significantly 
reduced by a prior feed of 25mg OVA, but feeding 10 or 50|ig OVA had no significant effect 
on this response (Fig 3.6b ).
Therefore, extremely low doses of fed OVA did not prime the responses induced by 
subsequent immunisation with lOOpg OVA/CFA. However, oral priming of cell mediated, 
but not humoral, immune responses was observed if mice were fed lOjig OVA prior to 
immunisation with only 2|ig OVA/CFA.
In order to determine how this oral priming affected individual Th cell subsets, I next 
measured serum levels of OVA-specific IgG isotypes, again using IgGi and IgG2a to reflect 
Th2 and Thl cell activity, respectively.
Both IgGi and IgG2a isotype antibodies were elicited in a dose-dependent manner to 
OVA/CFA immunisation. In animals challenged with lOOpg OVA/CFA, a prior feed of 
25mg OVA significantly reduced the levels of each isotype (Fig 3.7a&b), while 10 or 50pg 
fed OVA did not significantly alter these specific responses (Fig 3.7a&b ). In suboptimally 
challenged mice, the levels of specific IgGi in mice previously fed either lOjLLg or 25mg 
OVA were comparable with those of controls (Fig 3.7a). In contrast, feeding 50pg OVA 
before suboptimal challenge significantly primed this response (Fig 3.7a ). However, no 
dose of fed OVA examined could significantly alter the subsequent levels of IgG2a generated 
upon suboptimal challenge (Fig 3.7b). These results suggest that IgGi and IgG2a serum 
antibodies are relatively resistant to modulation by extremely low doses of fed antigen, 
although some priming of IgGi may be feasible.
In vitro Responses
In order to assess Th cell activity more directly, I examined PLN cells from mice fed 
10 or 50pg OVA prior to normal or suboptimal challenge for specific proliferative responses 
and cytokine production in vitro, as before.
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Proliferation
The OVA-specific proliferative responses of PLN from mice immunised with 2|ig 
OVA/CFA were markedly lower than those seen with lOOpg OVA/CFA (Fig 3.8). This 
response was significantly enhanced if mice received a prior feed of 10 or 50(ig OVA prior 
to suboptimal, but not optimal, challenge (Fig 3.8).
Cytokine Production
The OVA-specific production of IL3, IL5 and IFNy by PLN cells from suboptimally 
challenged mice was significantly lower than observed for cells from optimally challenged 
animals with little or no LL3 and IL5 detected (Fig 3.9). Moreover, cytokine production by 
optimally challenged mice was never augmented by feeding either 10 or 50pg OVA before 
immunisation (Fig 3.9). Instead, IL5 production was significantly decreased by each dose 
of fed OVA and all other cytokines were produced at levels comparable to controls (Fig 3.9). 
In contrast, the levels of IL3, IL5 and IFNy produced by cells from suboptimally challenged 
animals were significantly enhanced by feeding mice 50|ig OVA before immunisation (Fig 
3.9). In addition, cells from mice fed 10|ig OVA before suboptimal challenge produced 
levels of IFNy significantly higher than control cells (Fig 3.9). However, this was the only 
cytokine found to be primed by feeding lOjig OVA, as IL3 and IL5 were produced at levels 
comparable to controls (Fig 3.9).
Taken together, these findings provide evidence that feeding mice lOjig OVA 
preferentially augments Thl-dependent DTH responses and PLN cell IFNy production, 
while a 50|ig dose of fed OVA primes both Thl and Th2 cell activity, as evidenced by raised 
levels of IgGi, IL3, IL5 and IFNy.
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Summary and Conclusions
The results presented in this chapter show that systemic immune responses can be 
primed or tolerised by the same antigen, depending on the dose at which it is fed. 
Moreover, the activity of Thl cells appears more sensitive to these effects than do Th2 cells, 
which show a varied response to both the priming and tolerising effects of orally 
administered OVA.
Tolerance of systemic immune responses was achieved by feeding between 100|ig- 
25mg OVA and was found to improve with each increasing antigen dose in terms of both the 
extent of inhibition and the range of responses affected. Although the threshold dose of 
antigen required to induce tolerance differed for individual effector responses, Thl- 
dependent functions were generally most susceptible to inhibition. OVA-specific DTH 
responses and IgG2a antibodies in vivo, as well as PLN cell IFNy production in vitro were 
tolerised by as little as 100|ig fed OVA, while PLN cell proliferative responses became 
inhibited at doses > 2mg fed OVA. The regulation of Th2-dependent responses was less 
clear cut. Levels of OVA-specific IL5 were tolerised by as little as 100p,g fed OVA, while 
serum IgGi and PLN cell IL10 production resisted the effects of tolerance induced by 
feeding between 100|ig-5mg OVA, only becoming significantly inhibited at doses of >10mg 
fed OVA. These findings indicate that the regulatory factors mediating IL5 production may 
differ from those controlling the other Th2-dependent responses and are consistent with a 
recent study of the functional diversity of T lymphocytes, which showed that the T cell 
production of IL5 required different costimulation from that required to induce IL4 
production [315, 316]. Moreover, since the Th2-dependent IgGi and IL10 responses were 
preferentially activated by low doses of fed antigen which tolerised most Thl-dependent 
effector functions, this finding is partially consistent with the current dogma that low dose 
oral tolerance is mediated by regulatory Th2 cells. The precise role of these cells in oral 
tolerance will be addressed in the following chapter.
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Priming of systemic immunity could be elicited by feeding mice extremely low doses 
of OVA, where lOjug fed OVA enhanced subsequent Thl-dependent PLN cell proliferation 
and IFNy production in vitro, while 50|ig fed OVA primed these responses in addition to 
increasing Th2-dependent IgGi levels in vivo and PLN cell IL3 and IL5 secretions in vitro. 
Therefore, although Thl-dependent responses were most sensitive to oral priming, the 
activity of both Thl and Th2 cell subsets could be upregulated by feeding an appropriate 
dose of OVA. However, it should be noted that priming could only be demonstrated if mice 
were challenged systemically with suboptimal doses of antigen in CFA, indicating that 
systemic priming by soluble antigen may not be particularly efficient and therefore of limited 
use as an oral vaccination strategy.
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Figure 3.1 Effects of Feeding Different Doses of OVA on Subsequent 
Systemic Immunity to OVA in vivo
a) OVA-specific DTH responses in mice s.c. immunised 21 days before with 
OVA/CFA. Results shown are mean specific increments in footpad thickness ± 1 SEM for 6 
mice per group in animals fed saline (Ctrl), 100p,g, 1, 2, 5, 10 or 25mg OVA 10 days prior 
to immunisation. (*p<0.05 versus Ctrl), b) Total OVA-specific IgG responses 21 days 
after immunisation with OVA/CFA. Results shown are % hyperimmunised control serum 
and are the means ±  1 SEM for individual sera from 6 mice per group. (*p<0.05 versus 
Ctrl). Similar results were obtained in 2 replicate experiments.
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Figure 3.2 Effects of Feeding Different Doses of OVA on Specific Serum 
IgG Isotypes
Primary OVA-specific a) IgGi and b) IgG2a responses 21 days after immunisation 
with OVA/CFA. The results shown are reciprocal dilutions giving an OD value equivalent to 
5% hyperimmunised control serum and are the means ± 1 SEM for individual sera from 6 
mice per group in animals fed saline (Ctrl), lOOpg, 1, 2, 5, 10 or 25mg OVA 10 days prior 
to immunisation. (*p<0.05 versus Ctrl). Similar results were obtained in 2 replicate 
experiments.
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Figure 3.3 Effects of Feeding D ifferent Doses of OVA on Proliferative 
Responses in vitro.
Proliferative responses o f  PLN cells removed 14 days after s.c. immunisation of 
mice with O V A/CFA and cultured a) with 1 mg/ml OVA for 120h or b) with 50jig/ml PPD 
for 48 and 120h. Results shown are mean ^H-TdR incorporation (CPM ) ±  1 SEM  in 
quadruplicate cultures of cells pooled from 5 animals per group in mice fed saline (Ctrl), 
lOOpg, 1, 2, 5, 10 or 25mg OV A 10 days prior to immunisation. (*p<0.05 versus Ctrl). 
Similar results were obtained in 2 replicate experiments.
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Figure 3.4a Effects of Feeding Different Doses of OVA on Cytokine 
Production in vitro.
OVA-specific production of IL3, LL5, IL10 and IFNy by PLN cells removed 14 days 
after immunisation of mice with OVA/CFA and restimulated for 120h with 1 mg/ml OVA. 
Results shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM in culture supernatants of 
cells pooled from 5 animals per group in mice fed saline (Ctrl), lOOpg, 1, 2, 5, 10 or 25mg 
OVA 10 days prior to immunisation. (*p<0.05 versus Ctrl). Similar results were obtained 
at 48 and 72h in culture and in 2 replicate experiments.
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Figure 3.4b Effects of Feeding Different Doses of OVA on Cytokine 
Production in vitro.
PPD-specific production of IL3, EL4, IL5, IL10 and IFNy by PLN cells removed 14 
days after immunisation of mice with OVA/CFA and restimulated for 120h with 50|Hg/ml 
PPD. Results shown are mean cytokine levels (U/ml or ng/ml) ±  1 SEM in culture 
supernatants of cells pooled from 5 animals per group in mice fed saline (Ctrl), 100|ig, 1, 2, 
5, 10 or 25mg OVA 10 days prior to immunisation. (*p<0.05 versus Ctrl). Similar results 
were obtained at 48 and 72h in culture and in 2 replicate experiments.
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Figure 3.5 Effects of Extremely Low Doses of Fed OVA on Subsequent 
Systemic Immunity in vivo.
a) OVA-specific DTH responses in mice s.c. immunised 21 days before with 
OVA/CFA. Results shown are mean specific increments in footpad thickness ± 1 SEM for 6 
mice per group in animals fed saline (Ctrl), 10, 50pg or 25mg OVA 10 days prior to 
immunisation. (*p<0.05 versus Ctrl), b) Total OVA-specific IgG responses 21 days after 
immunisation with OVA/CFA. Results shown are % hyperimmunised control serum and are 
the means ± 1 SEM for individual sera from 6 mice per group. (*p<0.05 versus Ctrl).
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Figure 3.6 Effects of Extremely Low Doses of Fed OVA on Suboptimal and 
Optimal Systems.
a) OVA-specific DTH responses in mice s.c. immunised 21 days before with lOOpg 
(Optimal Challenge) or 2pg (Suboptimal Challenge) OVA/CFA. Results shown are mean 
specific increments in footpad thickness ± 1 SEM for 6 mice per group in animals fed saline 
(Ctrl), 10, 50pg or 25mg OVA 10 days prior to immunisation. (*p<0.05 versus optimally 
challenged Ctrl; **p<0.05 versus suboptimally challenged Ctrl), b) Total OVA-specific 
IgG responses 21 days after immunisation with lOOpg (Optimal Challenge) or 2|ig 
(Suboptimal Challenge) OVA/CFA. Results shown are % hyperimmunised control serum 
and are the means ± 1 SEM for individual sera from 6 mice per group. (*p<0.05 versus 
optimally challenged Ctrl; **p<0.05 versus suboptimally challenged Ctrl). Similar results 
were obtained in a replicate experiment.
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Figure 3.7 Effects of Extremely Low Doses of Fed OVA on Serum IgG 
Isotypes in Suboptimal and Optimal Systems.
Primary OVA-specific a) IgGi and b) IgG2a responses 21 days after immunisation 
with lOOpg (Optimal Challenge) or 2pg (Suboptimal Challenge) OVA/CFA. The results 
shown are reciprocal dilutions giving an OD value equivalent to 15% hyperimmunised 
control serum and are the means ±  1 SEM for individual sera from 6 mice per group in 
animals fed saline (Ctrl), 10, 50jig or 25mg OVA 10 days prior to immunisation. (*p<0.05 
versus optimally challenged Ctrl; **p<0.05 versus suboptimally challenged Ctrl). Similar 
results were obtained in a replicate experiment.
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Figure 3.8 Effects of Extremely Low Doses of Fed OVA on OVA-specific 
Proliferative Responses in Suboptimal and Optimal Systems.
OVA-specific proliferative responses of PLN cells removed 14 days after s.c. 
immunisation of mice with 100pg (Optimal Challenge) or 2pg (Suboptimal Challenge) 
OVA/CFA and cultured with OVA (lmg/ml) for 120h. Results shown are mean 3H-TdR 
incorporation (CPM) ± 1 SEM in quadruplicate cultures of cells pooled from 5 animals per 
group in mice fed saline (Ctrl), 10 or 50jig OVA 10 days prior to immunisation. (*p<0.05 
versus suboptimally challenged Ctrl). Similar results were obtained in a replicate 
experiment.
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Figure 3.9 Effects of Extremely Low Doses of Fed OVA on OVA-specific 
Cytokine Production in Suboptimal and Optimal Systems.
OVA-specific production of IL3, IL5 and IFNyby PLN cells removed 14 days after 
immunisation of mice with lOOpg (Optimal Challenge) or 2jng (Suboptimal Challenge) 
OVA/CFA and restimulated for 120h with OVA (1 mg/ml). Results shown are mean 
cytokine levels (U/ml or ng/ml) ± 1 SEM in culture supernatants of cells pooled from 5 
animals per group in mice fed saline (Ctrl), 10 or 50pg OVA 10 days prior to immunisation. 
(*p<0.05 versus optimally challenged Ctrl; **p<0.05 versus suboptimally challenged 
Ctrl). Similar results were obtained in a replicate experiment.
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Chapter 4: The Role of Cytokines in Oral Tolerance
Introduction
The results presented in the previous chapter indicated that although all immune 
functions could be tolerised by appropriate doses of fed antigen, certain effector responses 
appeared to be more resistant to oral tolerance than others. When OVA was fed at low 
doses, antigen-specific responses characteristic of a Th2 phenotype, including serum IgGl 
antibodies in vivo and IL10 production in vitro, were generally the most difficult to tolerise. 
These findings are consistent with reports that CD4+ T cells of the Thl subset are more 
susceptible to the induction of tolerance than Th2 cells in vivo and in vitro [254, 317]. As a 
result, it has been suggested that certain forms of tolerance, including oral tolerance induced 
by low doses of fed antigen, reflect the preferential activation of Th2 cells, with subsequent 
down-regulation of Thl-dependent, cell-mediated immune responses via the production of 
inhibitory cytokines such as IL4, IL10 [271, 282, 289, 318], TGFp [274], or a combination 
of these [285]. Conversely, IFNy has also been implicated in certain models of nasal 
tolerance [128] and may regulate immune responses via its cytostatic properties [293, 319].
In this chapter, I investigated whether these cytokines played a direct role in oral 
tolerance to OVA using animals depleted of individual cytokines either by antibody or 
genetic manipulation. I also examined the influence of the dose of fed antigen, as it has been 
suggested that only low dose regimes stimulate active suppressor mechanisms mediated by 
Th2 cells.
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Experimental Protocol
Mice were tolerised by feeding either 2 or 25mg OVA 10 days before s.c. 
immunisation with OVA/CFA. 14 days later, draining PLN cells were prepared for 
assessment of antigen-specific proliferative responses and cytokine production in vitro, 
while systemic DTH responses and serum levels of OVA-specific IgG were measured 21 
days after immunisation. Control mice were fed 0.2ml saline.
To examine the role of IL4 and EFNy, IL4'/_ and IFNyR_/" mice were used and IFNy 
was also neutralised in vivo in normal BALB/c mice by i.p. administration of 0.5mg anti- 
EFNy mab given two days before and two days after feeding antigen. A similar protocol was 
used to examine the role of TGFp. C57B1/6 mice were used as controls for the H-2b knock­
out mice, while isotype-matched antibodies were used as controls for neutralising 
antibodies.
The role of TGFp was also investigated by addition of a neutralising antibody during 
restimulation of PLN cells with OVA in vitro.
Results 
A) Oral Tolerance does not Require Th2-dependent Cytokines
In the previous chapter I found that IL10 production in vitro was somewhat resistant 
to the effects of oral tolerance, with occasionally enhanced levels found using some low 
doses of fed antigen which induced tolerance of other effector functions. Since this cytokine 
can not only suppress Thl cell activity via down-regulation of macrophage IL12 production 
[221], but its absence in IL10"/_ mice allows the development of intestinal pathology due to 
hyperreactivity to components of the normal gut flora [187], I thought it important to clarify 
whether my findings were consistent with the growing evidence for a role for Th2- 
dependent crossregulation in low dose oral tolerance [271, 282, 289, 318]. Therefore, I
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examined the effects of feeding either 2 or 25mg OVA to IL 4 /_ mice, which have a 
genetically engineered lack of IL4 and hence are impaired in all Th2-dependent responses, 
including IL10 [306].
In vivo Responses
The DTH responses of saline fed IL4'/_ mice were significantly lower than those of 
control WT mice after immunisation with OVA/CFA (Fig 4.1a). Despite this, both WT and 
IL4_/~ mice fed either 2 or 25mg OVA exhibited significantly reduced DTH responses 
compared with saline fed WT and rL4'/_ mice, respectively (Fig 4. la). Saline fed IL4_/_ mice 
also displayed significantly lower total OVA-specific IgG antibody levels compared with 
control WT mice and again, this response was reduced in WT mice by a prior feed of either 
2 or 25mg OVA and also in IL4-/- mice fed 25mg OVA before immunisation (Fig 4.1b). 
Although the IgG levels of IL4-/- mice fed 2mg OVA were not significantly different from 
their unfed controls in this instance, similar experiments showed that OVA-specific IgG 
responses could be significantly tolerised by feeding IL4 mice_/_ 2mg OVA (data not 
shown). Therefore, the absence of IL4 in vivo does not prevent the induction of oral 
tolerance of OVA-specific DTH or serum IgG responses.
To investigate the scope of oral tolerance in these animals, I measured OVA-specific 
IgG isotypes. Consistent with previous reports [306], the serum levels of IgGl were 
virtually neglible in all IL4_/_ mice (Fig 4.2a), making it difficult to determine the effect of 
feeding OVA and perhaps explaining why I had observed particularly low total OVA-specific 
IgG responses in these mice. In contrast, IgGl antibodies were readily detectable in control 
WT animals and were significantly reduced by feeding 25mg, but not 2mg OVA (Fig 4.2a). 
Saline fed IL4’/_ produced significantly more OVA-specific serum IgG2a than WT controls 
(Fig 4.2b), suggesting that Th2-dependent crossregulation of Thl cell activity was important 
for modulating this response. Both IL4_/' and WT IgG2a responses were significantly
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reduced by feeding either 2 or 25mg OVA before immunisation (Fig 4.2b), demonstrating 
that oral tolerance of this isotype did not involve Th2-dependent suppression.
In vitro Responses
The OVA-specific proliferation of PLN cells from saline fed IL4_/_ mice after 
immunisation was significantly higher than that of WT control cells (Fig 4.3). The 
proliferative responses of cells from both WT and IL4_/_ mice fed 2 or 25mg OVA prior to 
immunisation were significantly reduced compared with their respective controls (Fig 4.3). 
All proliferative responses were negligible in medium alone (results not shown).
The OVA-specific cytokine profile of saline fed IL4_/_ mice differed from that of WT 
controls with more IFNy, less IL5 and equivalent levels of IL3 being produced in vitro (Fig 
4.4). The production of both EL3 and IFNy was significantly suppressed in WT and IL4'/" 
mice by feeding 2 or 25mg OVA prior to immunisation (Fig 4.4). The high levels of EL5 
production in WT mice were also significantly reduced by feeding OVA and the very low 
IL5 response in IL4'/_ animals was completely abrogated by prior feeding of either dose of 
OVA (Fig 4.4). OVA-specific IL4 and IL10 production was also measured in these 
experiments, but levels were negligible in all groups (results not shown). All cytokine 
responses were also negligible in medium alone (results not shown). Therefore, the Th2- 
depleted cytokine profile of IL4_/' animals was still susceptible to tolerance in mice fed either 
a low or high dose of OVA.
Together, these findings are not consistent with a role for IL4 or Th2 cells in 
tolerance induced by feeding either a high or a low dose of OVA.
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(B) Oral Tolerance is Induced in the Absence of IFNy
Since the findings above suggested that Th2 cells were not important for oral 
tolerance, I next investigated if the characteristic product of the other CD4+ T cell subset, 
IFNy, was involved. This may seem unlikely, since I have shown in Chapter 3 that OVA- 
specific IFNy production in vitro after immunisation in vivo is particularly susceptible to 
inhibition by oral tolerance. However, chapter 6 describes the preferential release of OVA- 
specific IFNy in the first few days after feeding OVA. This cytokine has well known 
cytostatic properties [293, 319] and its production is relatively preserved in mice tolerized by 
i.v. injection of staphylococcal enterotoxin B [228]. Furthermore, IFNy is required for the 
tolerance induced in rats by intranasal administration of OVA [128]. Therefore, I considered 
it important to address the role of endogenous IFNy in the induction of oral tolerance .
I first attempted to determine if oral tolerance could be induced in the absence of 
IFNy by administering a depleting anti-IFNy mab to animals around the time of feeding 
either saline or 25mg OVA. Although the OVA-specific DTH responses generated in 
OVA/CFA immunised control animals were significantly reduced by anti-IFNy antibody, 
this response was tolerised normally in mice fed 25mg OVA before immunisation (Fig 
4.5a). The levels of OVA-specific serum IgG were also significantly reduced in control 
animals treated with anti-IFNy and again this response was tolerised normally in mice fed 
25mg OVA before immunisation (Fig 4.5b).
Serum levels of OVA-specific IgGl in saline fed immunised control mice were 
similar, irrespective of whether animals had received anti-IFNy or isotype-matched antibody 
and these responses were significantly reduced to a similar extent by prior feeding of 25mg 
OVA (Fig 4.6a). In marked contrast, the levels of IgG2a were significantly reduced in 
control mice treated with anti-IFNy compared with isotype-matched antibody (Fig 4.8b), 
highlighting the importance of IFNy for this isotype and perhaps explaining the low levels of 
total OVA-specific IgG responses in these mice. However, IgG2a responses were tolerised 
normally both in anti-IFNy and isotype antibody treated mice fed 25mg OVA before
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immunisation (Fig 4.6b). Together, these findings do not support a role for IFNy in the 
induction of oral tolerance by feeding a high dose of antigen.
I had intended to extend this study to address the role of IFNy in tolerance induced 
by a low dose of fed OVA. However, insufficient antibody prevented this work from being 
carried out in normal animals. Instead, I used IFNyR_/_ mice, which are genetically 
engineered to lack the receptor for IFNy and hence are unresponsive to the cytokine [307]. 
This system also allowed me to examine the role of IFNy in both the induction and 
expression of oral tolerance induced by either 2 or 25mg fed OVA without the need for 
chronic administration of antibody.
In vivo Responses
The DTH responses of WT control animals were significantly higher than those of 
IF N yR /_ control mice after immunisation with OVA/CFA (Fig 4.7a). Despite this 
difference, DTH responses were significantly reduced in both WT and IFNyR/_ mice by 
feeding 25mg OVA before immunisation (Fig 4.7a). Individual WT mice fed 2mg OVA 
showed considerable variability in DTH responses and were therefore not significantly 
different from their WT controls (Fig 4.7a). However, when IFNyR/_ mice were fed this 
low antigen dose prior to immunisation, their subsequent DTH responses were significantly 
reduced in comparison to controls (Fig 4.7a), indicating that endogenous IFNy was not 
required for the inhibition of cell mediated responses in vivo by feeding either a high or low 
dose of OVA.
OVA-specific IgG responses were comparable in WT and IFNyR'/_ control mice after 
immunisation (Fig 4.7b). As with DTH responses, feeding 25mg OVA to either WT or 
IFN yR /_ mice before immunisation significantly inhibited IgG responses (Fig 4.7b). 
Furthermore, a 2mg dose of fed OVA produced significant IgG tolerance in IFNyR_/-, but 
not WT, mice (Fig 4.9b), indicating that endogenous IFNy was not required for the 
inhibition of humoral immune responses in vivo by feeding OVA.
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Although OVA-specific IgGl responses were significantly lower in saline fed 
IFNyR_/_ mice compared with WT controls after immunisation, the responses of both groups 
were significantly reduced by feeding either 2 or 25mg OVA before immunisation (Fig 
4.8a). OVA-specific levels of IgG2a were comparable in saline fed EFNyR"  ^mice and WT 
controls and again were significantly reduced by feeding OVA before immunisation (Fig 
4.8b). Therefore, a lack of responsiveness to IFNy does not preclude the normal induction 
of oral tolerance in vivo .
In vitro Responses
In contrast to CMI in vivo, the OVA-specific proliferative responses of control 
IFNyR"/_ cells in vitro were significantly higher than those of WT controls (Fig 4.9), 
suggesting that the cytostatic effects of IFNy may normally inhibit this response. However, 
feeding either 2 or 25mg OVA prior to immunisation of both WT and IFNyR‘/_ mice 
significantly reduced their specific proliferative responses (Fig 4.9), implying that IFNy was 
not required for tolerance of proliferation in vitro.
OVA-specific production of IFNy was virtually negligible in cultures of control 
IFNyR_/_ cells, whereas OVA-specific IL5 was produced in levels comparable with WT 
controls and OVA-specific IL3 and IL10 were significantly enhanced beyond control levels 
(Fig 4.12). Feeding either 2 or 25mg OVA prior to immunisation of both WT and EFNyR/_ 
mice significantly reduced every specific cytokine response examined, indicating that IFNy 
was not required for this tolerance in vitro.
Taken together with the normal oral tolerance induced in mice depleted of IFNy, my 
findings show that oral tolerance is induced normally both in vivo and in vitro in the absence 
of endogenous IFNy.
(C) The Role of TGFp in Oral Tolerance
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As the experiments described so far in this chapter appeared to exclude a role for 
conventional cytokine mediators produced by either Thl or Th2 cells, I went on to examine 
the possibility that an alternative cytokine,TGFp, might be important. Abundant in the 
normal intestine [299, 320], TGFp is immunosuppressive in many situations [299] and has 
recently been implicated as a mediator of oral tolerance in rodents [282, 285]. Moreover, 
others in this lab have detected TGFP in vitro early in the response to fed OVA [321].
(i) Effects of Neutralising TGFP in vivo
I first examined the role of endogenous TGFp in the induction of oral tolerance by 
administering anti-TGFP antibody to animals around the time of feeding saline, 2 or 25mg 
OVA. Although I did not address the effectiveness of this treatment in removing 
endogenous TGFp, the antibody used and the dose chosen were identical to other published 
work where TGFP was neutralised in vivo [322].
In vivo Responses
When saline fed control animals were treated with anti-TGFp, their subsequent DTH 
responses after immunisation were raised significantly above those of controls given 
isotype-matched antibody (Fig 4.11a), confirming that anti-TGFp was having some 
biological effect in vivo. However, anti-TGFP could not prevent the inhibition of DTH 
responses which occurred in mice fed either 2 or 25mg OVA before immunisation (Fig
4.1 la), indicating that depletion of TGFp did not prevent tolerance of CMI in vivo.
The serum levels of OVA-specific total IgG were comparable in control animals 
treated with either isotype-matched control antibody or anti-TGFp (Fig 4.1 lb). However, 
only those mice given the isotype-matched control antibody and fed either 2 or 25mg OVA 
showed a significant reduction in specific IgG antibodies compared with their controls (Fig
4.1 lb). Although the IgG levels in OVA fed mice given anti-TGFp were generally slightly
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lower than those of anti-TGFp treated controls, this difference was not significant, perhaps 
due to the small numbers of mice which had to be used because of the limited supply of anti- 
TGFp. Alternatively, the possibility remains that TGFp is required for oral tolerance of 
humoral, but not CMI responses.
In vitro Responses
The OVA-specific proliferative responses of PLN cells from mice given isotype- 
matched antibody showed the expected reductions when animals were fed either 2 or 25mg 
OVA before immunisation (Fig 4.12). The OVA-specific proliferative responses of all 
groups treated with anti-TGFp were very low in comparison (Fig 4.12), but still 
significantly higher than observed in medium alone, where proliferation was virtually 
negligible (results not shown). In addition, the OVA-specific responses of anti-TGFP- 
treated mice fed 25mg OVA were significantly higher than those of animals fed the same 
dose of antigen and given isotype antibody (Fig 4.12), suggesting that this aspect of oral 
tolerance may be modulated by depletion of TGFp. However, low levels of response make 
it difficult to interpret.
In contrast, the production of OVA-specific IL5, IL10 and IFNy by cells from saline 
fed mice given anti-TGFp was comparable with those of controls receiving the isotype- 
matched antibody (Fig 4.13). In addition, cytokine secretion by cells from mice fed either 2 
or 25mg OVA was significantly inhibited compared with immunised controls, regardless of 
whether the animals had received anti-TGFp or isotype antibody (Fig 4.13). Every cytokine 
response was negligible for all groups cultured in medium alone. Therefore, endogenous 
TGFp was not required for tolerance of cytokine secretion in vitro .
Overall, my findings suggest that TGFp is not required for the induction of most 
aspects of oral tolerance, although its role in tolerance of antibody and proliferative 
responses remain unclear. Unfortunately, I could not repeat this study in vivo due to the 
limited supply of antibody.
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(ii) The Role of TGFP in the Expression of Oral Tolerance in vitro
Most studies which have indicated a role for TGFp in oral tolerance examined the 
effector phases when tolerance has been induced and recalled [274], As it is therefore 
conceivable that TGFp might only be required to maintain immune suppression, I explored 
the effect of neutralising TGFp during culture of tolerised PLN cells in vitro. Again, I chose 
a dose of neutralising antibody above that which had been used in other published work to 
deplete TGFp actively in vitro [323].
In this experiment, the OVA-specific proliferation of all groups of cells cultured in 
the presence of isotype control antibody was very low (Fig 4.14), preventing detection of 
tolerance in cells from OVA fed mice. Although the reasons for this remain unclear, OVA- 
specific proliferative responses were observed in the presence of anti-TGFp antibody and 
these were significantly reduced in cells from mice fed either 2 or 25mg OVA (Fig 4.14). 
All groups made low proliferative responses when cultured in the absence of OVA, although 
this response was somewhat enhanced by the addition of anti-TGFp (results not shown). 
Thus TGFp appears not to be required for expression of this aspect of oral tolerance.
The production of OVA-specific EL3, IL5 and IL10 by cells from saline fed mice was 
observed in the presence of isotype antibody and augmented by addition of anti-TGFp to the 
cultures (Fig 4.15). The secretion of most of these cytokines by cells from mice fed either 2 
or 25mg OVA was significantly inhibited compared with immunised controls, regardless of 
whether or not anti-TGFp was present in the cultures (Fig 4.15). One exception to this 
pattern was that very little IFNy was produced by any cells cultured in the presence of 
isotype control antibody (Fig 4.15), paralleling the defective proliferative responses under 
the same conditions. In contrast, the addition of anti-TGFp to cells from saline fed mice 
increased their IFNy production above the level of detection by ELISA (Fig 4.15), making it 
difficult to discern the effects of feeding OVA. Only cells from mice fed 2mg OVA appeared 
to produce less IFNy than controls in the presence of anti-TGFp (Fig 4.15). Insufficient
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supernatants remained to investigate if this was a problem with the ELISA or not. All 
cytokine responses were negligible in medium alone, even in the presence of anti-TGFp.
Overall, the results above do not support a critical role for TGFP in the expression of 
oral tolerance in vitro.
Summary and Conclusions
The results presented in this chapter show that mice fed 2 or 25mg OVA in the 
absence of IL4, IL10, TGFp or IFNy develop oral tolerance normally, indicating that these 
cytokines are not required for the induction of unresponsiveness. In addition, I found no 
evidence that they are involved in maintaining unresponsiveness in tolerised mice, as oral 
tolerance was expressed normally in IL4_/_ mice, IFNyR_/' mice and in tolerant cell cultures 
treated with anti-TGFp.
IL 4 /_ mice displayed normal oral tolerance of specific DTH and IgG levels in vivo 
and of proliferative, IL3, IL5 and IFNy responses in vitro despite their anticipated defects in 
IL4 and IL10 production [306]. These findings show that oral tolerance can be induced and 
maintained in the absence of IL4 or IL10, and that this applies to feeding either a high or low 
dose of antigen.
In addition, no role was found for endogenous IFNy in either the induction or 
maintenance of oral tolerance, as normal immune suppression of effector responses occurred 
in animals depleted of IFNy at the time of feeding as well as in IFNyR"/_ mice.
Mice given neutralising anti-TGFp antibody also developed specific tolerance of 
DTH responses in vivo and IL5, IL10 and IFNy responses in vitro after feeding 2 or 25mg 
OVA. Furthermore, neutralisation of TGFP in vitro did not reverse the inhibition of 
proliferation and secretion of IL3, IL5 or IL10 seen in cells from orally tolerised animals. 
However, some exceptions to these findings occurred, with apparently no tolerance of IgG 
or proliferation in anti-TGFp treated mice and with variable effects on the in vivo and in
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vitro inhibition of IFNy. Therefore, TGFp remains a potential mediator of some aspects of 
oral tolerance and this possibility requires further investigation.
The results of this chapter do not support other reports that tolerance induced in mice 
by feeding low doses of antigen is mediated entirely by suppressive cytokines. However, it 
remains possible that oral tolerance does reflect active regulation by an effector function 
other than cytokine secretion. Equally, oral tolerance could reflect direct inactivation of 
antigen responsive cells. Both theories will be addressed in subsequent chapters.
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Figure 4.1 IL4-/_ Mice Display Normal Oral Tolerance of Effector
Responses in vivo.
a) OVA-specific DTH responses in C57B1/6 (WT) and IL4_/_ mice immunised 21 
days before with OVA/CFA s.c. The results shown are mean specific increments in footpad 
thickness ± 1 SEM for 6 mice per group in animals fed saline (Ctrl), 2 or 25mg OVA 10 
days prior to immunisation. (*p<0.05 versus WT Ctrl; **p<0.05 versus IL4_/_ Ctrl), b) 
Total OVA-specific serum IgG responses of C57B1/6 (WT) and IL4_/_ mice 21 days after 
immunisation with OVA/CFA. Results shown are % hyperimmunised control serum and are 
the means ± 1 SEM for individual sera from 6 mice per group in mice fed saline (Ctrl), 2 or 
25mg OVA 10 days prior to immunisation. (*p<0.05 versus WT Ctrl; **p<0.05 versus 
IL4/- Ctrl). Similar results were obtained in 2 other experiments examining 2mg and 25mg 
fed OVA individually.
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Figure 4.2 IL4_/_ Mice Display Normal Oral Tolerance of Serum IgG
Isotypes.
Primary OVA-specific IgGl a) and IgG2a b) responses in C57B1/6 (WT) or IL4_/- 
mice 21 days after immunisation with OVA/CFA. The results shown are reciprocal dilutions 
giving an OD value equivalent to 10% of hyperimmunised control serum and are the means ± 
1 SEM for individual sera from 6 mice per group in animals fed saline (Ctrl), 2 or 25mg 
OVA 10 days prior to immunisation. (*p<0.05 versus WT Ctrl; **p<0.05 versus IL4_/_ 
Ctrl). Similar results were obtained in 2 other experiments examining 2mg and 25mg fed 
OVA individually.
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Figure 4.3 IL4_/_ Mice Display Normal Oral Tolerance of Proliferative
Responses in vitro.
Proliferative responses of PLN cells removed 14 days after s.c. immunisation of 
C57B1/6 (WT) or IL 4/_ mice with OVA/CFA and cultured for 120h with OVA (1 mg/ml). 
Results shown are mean 3H-TdR incorporation (CPM) l SEM in quadruplicate cultures of 
cells pooled from 5 animals per group in saline (Ctrl), 2 or 25mg OVA fed mice. (*p<0.05 
versus WT Ctrl; **p<0.05 versus IL4_/_ Ctrl). Similar results were obtained in 2 other 
experiments examining 2mg and 25mg fed OVA individually.
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Figure 4.4 IL4'/_ Mice Display Normal Oral Tolerance of Specific Cytokines 
in vitro.
OVA-specific production of IL3, IFNy and IL5 by PLN cells removed 14 days after 
s.c. immunisation of C57B1/6 (WT) or IL4“/_ mice with OVA/CFA and restimulated for 72h 
with OVA (1 mg/ml). Results shown are mean cytokine levels (U/ml) ± 1 SEM in cultures 
of cells pooled from 5 mice per group in saline (Ctrl), 2 or 25mg OVA fed mice. (*p<0.05 
versus WT Ctrl; **p<0.05 versus IL 4 /_ Ctrl). Similar results were obtained in 2 other 
experiments examining 2mg and 25mg fed OVA individually.
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Figure 4.5 Effects of Neutralising IFNy in vivo on the Induction of Oral 
Tolerance.
a) OVA-specific DTH responses in BALB/c mice immunised 21 days before with 
OVA/CFA s.c. Results shown are mean specific increments in footpad thickness ± 1 SEM 
for 6 mice per group in animals fed saline (Ctrl) or 25mg OVA (Tol) 10 days prior to 
immunisation and treated with 0.5mg either of anti-IFNy or an isotype-matched control 
antibody 2 days before and 2 days after feeding, b) Total OVA-specific serum IgG 
responses 21 days after immunisation with OVA/CFA. Results shown are % 
hyperimmunised control serum and are the means ± 1 SEM for individual sera from 6 mice 
per group. (*p<0.05 versus Ctrl given isotype ab; **p<0.05 versus Ctrl given anti-IFNy).
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Figure 4.6 Effects of Neutralising IFNy in vivo on Oral Tolerance of Serum 
IgG Isotypes.
Primary OVA-specific IgGl a) and IgG2a b) responses 21 days after immunisation 
with OVA/CFA. The results shown are reciprocal dilutions giving an OD value equivalent to 
5% of hyperimmunised control serum and are the means ± 1 SEM for individual sera from 6 
mice per group in animals fed saline (Ctrl) or 25mg OVA (Tol) 10 days prior to 
immunisation and treated with 0.5mg either of anti-IFNy or an isotype-matched control 
antibody 2 days before and 2 days after feeding. (*p<0.05 versus Ctrl given isotype ab; 
**p<0.05 versus Ctrl given anti-IFNy).
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Figure 4.7 IFNyR'/_ Mice Display Normal Oral Tolerance of Effector 
Responses in vivo.
a) OVA-specific DTH responses in IFNyR/_ and C57BL/6 (WT) mice immunised 
s.c. 21 days before with OVA/CFA. Results shown are mean specific increments in footpad 
thickness ± 1 SEM for 6 mice per group in animals fed saline (Ctrl), 2 or 25mg OVA 10 
days prior to immunisation. (*p<0.05 versus WT Ctrl; **p<0.05 versus IFNyR/_ Ctrl),
b) Total OVA-specific serum IgG responses 21 days after immunisation with OVA/CFA. 
Results shown are % hyperimmunised control serum and are the means ±  1 SEM for 
individual sera from 6 mice per group. (*p<0.05 versus WT Ctrl; **p<0.05 versus 
IFNyR'/_ Ctrl). Similar results were obtained in a replicate experiment.
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Figure 4.8 IFNyR_/“ Mice Display Normal Oral Tolerance of Specific Serum 
IgG Isotypes.
Primary OVA-specific IgGl a) and IgG2a b) responses in C57B1/6 (WT) or IFNyR- 
mice 21 days after immunisation with OVA/CFA. The results shown are reciprocal 
dilutions giving an OD value equivalent to 5% of hyperimmunised control serum and are the 
means ± 1 SEM for individual sera from 6 mice per group in animals fed saline (Ctrl), 2 or 
25mg OVA 10 days prior to immunisation. (*p<0.05 versus WT Ctrl; **p<0.05 versus 
IFNyR"^ Ctrl). Similar results were obtained in a replicate experiment.
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Figure 4.9 IFNyR_/_ Mice Display Normal Oral Tolerance of Specific 
Proliferative Responses in vitro.
OVA-specific proliferative responses of PLN cells removed 14 days after s.c. 
immunisation of C57B1/6 (WT) or IFNyR/_ mice with OVA/CFA and cultured over 120h 
with OVA (1 mg/ml). Results shown are mean 3H-TdR incorporation (CPM) ± 1 SEM in 
quadruplicate cultures of cells pooled from 5 animals per group in saline (Ctrl), 2 or 25mg 
OVA fed mice. (*p<0.05 versus WT Ctrl cells; **p<0.05 versus IFNyR_/_ Ctrl cells). 
Similar results were obtained in a replicate experiment.
92
IL3 IL5
[U/ml)
□  WT
□  IFNgR -/-
150 -
100 -
50 -
C tr l 2 2 5
50 n(U /m l)
40 -
30 -
20  -
10 -
C trl 2 2 5
IL10
20 n
(ng/m l)
15 -
10 -
C trl 2 2 5
50 h
IFN gamma
(ng/m l)
40 - 
30 -  
20 -  
10 -  
0
I
i
C trl 2 5
Dose of Fed OVA (mg)
Figure 4.10 IFNyR'/_ Mice Display Normal Oral Tolerance of Specific 
Cytokine Production in vitro.
OVA-specific production of IL3, IL5, IL10 and IFNy by PLN cells removed 14 days 
after s.c. immunisation of C57BL/6 (WT) or IFNy“/_ mice with OVA/CFA and restimulated 
for 72h with 1 mg/ml OVA. Results shown are mean cytokine levels (U/ml or ng/ml) ± 1 
SEM in cultures of cells pooled from 5 mice per group in saline (Ctrl), 2 or 25mg OVA fed 
mice. (*p<0.05 versus WT Ctrl; **p<0.05 versus IFNy~/- Ctrl). Similar results were 
obtained in a replicate experiment.
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Figure 4.11 Neutralisation of TGFp in vivo May Not Prevent the Induction 
of Oral Tolerance.
a) OVA-specific DTH responses in BALB/c mice immunised 21 days before with 
OVA/CFA s.c. Results shown are mean specific increments in footpad thickness ± 1 SEM 
for 5 mice per group in animals fed saline (Ctrl), 2 or 25mg OVA 10 days prior to 
immunisation and treated with 0.5mg of either anti-TGFp or an isotype-matched control 
antibody 2 days before and 2 days after feeding. (*p<0.05 versus Ctrl given isotype ab; 
**p<0.05 versus Ctrl given anti-TGFp). b) Total OVA-specific serum IgG responses 21 
days after immunisation with OVA/CFA. Results shown are % hyperimmunised control 
serum and are the means ±  1 SEM for individual sera from 4 or 5 mice per group. 
(*p<0.05 versus Ctrl given isotype ab; **p<0.05 versus Ctrl given anti-TGFp). This
experiment was not repeated.
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Figure 4.12 Neutralisation of TGFP in vivo May not Prevent Oral Tolerance 
of Proliferative Responses in vitro.
OVA-specific proliferative responses of PLN cells removed 14 days after s.c. 
immunisation of mice with OVA/CFA and cultured for 96h with 1 mg/ml OVA. Results 
shown are mean 3H-TdR incorporation (CPM) ± 1 SEM in quadruplicate cultures of cells 
pooled from 5 animals per group in saline (Ctrl), 2 or 25mg OVA fed mice treated with 
either anti-TGFP or an isotype-matched control antibody 2 days before and 2 days after 
feeding. (*p<0.05 versus Ctrl cells given isotype ab, **p<0.05 versus 25mg fed OVA+ 
isotype ab group).
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Figure 4.13 Neutralisation of TGFp in vivo Does not Prevent Oral Tolerance 
of Cytokine Production in vitro.
OVA-specific production of IL5, IL10 and IFNyby PLN cells removed 14 days after 
s.c. immunisation of mice with OVA/CFA and restimulated for 72h with 1 mg/ml OVA. 
Results shown are mean cytokine levels (U/ml, OD values or ng/ml) ± 1 SEM in cultures of 
cells pooled from 5 mice per group in saline (Ctrl), 2 or 25mg OVA fed mice treated with 
either anti-TGFp or isotype-matched control antibody 2 days before and 2 days after 
feeding. (*p<0.05 versus Ctrl cells given isotype ab; **p<0.05 versus Ctrl cells given 
anti-TGFP).
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Figure 4.14 Effects of Neutralising TGFp in vitro on Oral Tolerance of 
Proliferative Responses.
OVA-specific proliferative responses of PLN cells removed 14 days after s.c. 
immunisation of mice with OVA/CFA and cultured for 96h with lmg/ml OVA ± anti-TGFp 
or isotype-matched control antibody (both at 50|Hg/ml). Results shown are mean 3H-TdR 
incorporation (CPM) ± l SEM in quadruplicate cultures of cells pooled from 5 animals per 
group in saline (Ctrl), 2 or 25mg OVA fed mice. (*p<0.05 versus Ctrl cells given anti- 
TGFp).
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Figure 4.15 Effects of Neutralising TGFp in vitro on Oral Tolerance of 
Cytokine Production.
OVA-specific production of IL3, IL5, EL10 and IFNyby PLN cells removed 14 days 
after s.c. immunisation of mice with OVA/CFA and restimulated for 72h with lmg/ml OVA 
anti-TGFp or isotype-matched control antibody (both at 50|ig/ml). Results shown are 
mean cytokine levels (U/ml or ng/ml) -+• 1 SEM in cultures of cells pooled from 5 mice per 
group in saline (Ctrl), 2 or 25mg OVA fed mice. The dotted line respresents upper detection 
limit for ELISA. (*p<0.05 versus Ctrl cells given isotype ab; **p<0.05 versus Ctrl cells 
given anti-TGFP).
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Chapter 5: The Role of CD8+ T Cells in Oral Tolerance
Introduction
The findings presented in the previous chapters did not support a role for regulatory 
CD4+ T cell subsets in the peripheral tolerance induced by feeding a high or low dose of 
antigen. However, this work does not preclude the possibility that oral antigen could induce 
active suppression mediated by other regulatory T cells, such as those expressing CD8 
coreceptor. This idea would be compatible with early studies of oral tolerance, which 
demonstrated a suppressive mechanism transferable to naive recipients with CD8+ T cells 
[93, 97, 109, 324]. Although the presence of functional CD8+ suppressor T (Ts) cells 
remains controversial, it is now apparent that CD8+ T cells can play a regulatory role in a 
number of immune responses, either through classical cytotoxic effects on APC [275] or via 
the production of suppressive cytokines such as IFNy [128] and TGFp [274]. Furthermore, 
recent studies of oral tolerance have also suggested that CD8+ T cells can transfer 
suppression [117].
In an attempt to clarify this issue, I examined the regulatory function of CD8+ T cells 
in our model of oral tolerance to OVA by measuring class I MHC-restricted T cell activity in 
vitro and assessing the induction of oral tolerance in CD4- or CD8-depleted mice. I also 
determined how this was influenced by the dose of fed antigen, as it has been suggested that 
only low dose regimes stimulate active suppressor mechanisms.
Experimental Protocol
Tolerance was induced by feeding mice 2 or 25mg OVA and systemic immune 
responses were assessed after parenteral challenge with lOOpg of either OVA ISCOMS i.p 
or OVA/CFA s.c.. To detect class I MHC-restricted CTL activity, spleen cells from 
immunised C57B1/6 mice were restimulated for 5 days in vitro with EG7.0VA cells before 
analysis of cytotoxicity using 51Cr labelled EG7.0VA or EL4 cells.
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To deplete CD4+ and CD8+ T cells, BALB/c mice were given 0.5mg anti-CD4/8 
monoclonal antibody 4 days prior to and on the day of feeding OVA. Controls received rat 
IgG or serum.
Results
(A) Effects of Fed OVA on Subsequent Immune Responses Generated by 
OVA ISCOMS
To determine if class I MHC-restricted cytotoxicity was important in regulating oral 
tolerance, I first examined how conventional CD8+ CTL responses were influenced by 
feeding tolerogenic doses of OVA. To generate OVA-specific CD8+ T cells in vivo, I took 
advantage of an immunisation model developed in the lab using OVA incorporated into 
ISCOMS containing the adjuvant Quil A [325].
DTH and Antibody Production in vivo
I first ensured that OVA-specific DTH and serum IgG responses generated in mice 
immunised with OVA ISCOMS could be reduced by prior feeding of OVA. This was found 
with both 2mg and 25mg fed OVA (Fig 5.1a&b), demonstrating normal oral tolerance 
under these immunisation conditions.
Systemic CTL Responses
Control mice immunised with OVA ISCOMS were also primed to develop high 
levels of splenic CTL activity after restimulation in vitro (Fig 5.2). This response was 
already known to be entirely due to CD8+ T cells and mediated by classical class I MHC- 
restricted CTL [325]. In my hands, the cytotoxicity was OVA-specific since significant 
levels of killing were only found against EG7.0VA cells and not the parental EL4 cells, 
which do not express the OVA gene (Fig 5.2). Feeding either 2 or 25mg OVA prior to 
immunisation abolished the subsequent CTL response to OVA ISCOMS (Fig 5.2), 
indicating that this function was also suppressed by oral tolerance and that classical CTL 
were unlikely to mediate oral tolerance in vivo.
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(B) CD4-dependence of Orally Tolerised CTL Responses Generated by OVA 
ISCOMS
Although these results showed that feeding OVA could directly suppress CD8+ T cell 
function, the CTL responses primed by OVA ISCOMS immunisation have been found to be 
dependent on the helper activity of CD4+ T cells [326]. Thus the suppression of the CTL 
responses in OVA fed mice could reflect the profound inhibition of CD4+ T cell responses 
documented in the previous chapters. In order to clarify this, I first examined whether the 
defective ability of tolerised spleen cells to generate CTL when restimulated in vitro could be 
overcome by addition of functional OVA-specific CD4+ T cells. In the restimulation assay I 
therefore depleted CD4+ or CD8+ T cells from the immunised control or tolerant mice and 
recombined them before restimulation with EG7.0VA cells (see Table 5.1). FACS analysis 
confirmed the depletion of >95% of the appropriate cell population (Fig 5.3). However, on 
the two occasions when this experiment was performed, no OVA-specific cytotoxic 
response could be detected in any of the recombined cell populations or in the unseparated 
spleen cells from control mice (results not shown), suggesting that the batches of OVA 
ISCOMS used for immunisation had been ineffective in priming a CTL response in vivo. 
Consistent with this explanation, I was also unable to detect priming of OVA-specific DTH 
responses in animals immunised with the same batches of OVA ISCOMS (results not 
shown). Unfortunately, time restraints prevented me from repeating these experiments.
(C) Effects of Fed OVA on CD8+ T Cell Responses Generated by OVA/CFA
As an alternative means of addressing the CD4-dependency of CTL tolerance, I 
attempted to induce OVA-specific CTL responses which did not require CD4+ T cells in 
vivo, by exploiting a recent report that s.c. immunisation of mice with OVA/CFA generated 
CD4-independent CD8+ CTL [327]. Consistent with these results, I found that C57B1/6 
mice immunised with OVA/CFA displayed high levels of OVA-specific CTL activity after 
restimulation with EG7.0VA in vitro. These CTL responses did not require CD4+ T cells in 
vivo, as depletion of CD8+, but not CD4+ T cells around the time of immunisation abolished
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subsequent CTL activity (Fig 5.4). However, previous work showed that the CTL effector 
cells themselves were CD8+, class I MHC-restricted T cells that recognise OVA257-264 an(3 
Kb [327].
Feeding either 2 or 25mg OVA had no efffect on the CTL responses primed by 
OVA/CFA (Fig 5.5a), despite the fact that the presence of oral tolerance was confirmed in 
the OVA fed animals by a lowered OVA-specific serum IgG response compared with 
immunised control mice (Fig 5.5b). Thus, neither a low nor a high dose of fed OVA could 
reduce CD4-independent CTL responses in mice immunised with OVA/CFA.
(D) Effects of Depleting CD4+ or CD8+ T Cells on the Induction of Oral 
Tolerance
As the above results indicated that fed OVA could not tolerise CD4-independent CTL 
responses, I next examined if the presence of CD8+ T cells was required for oral tolerance 
induciton, by depleting them in vivo around the time of feeding. Additional mice were 
depleted of CD4+ T cells to explore their requirement in the phenomenon.
These regimes depleted ^95% CD4+ or CD8+ cells (Fig 5.6), but depleted mice were 
able to mount systemic DTH and IgG responses which were comparable to those of 
undepleted control mice (Fig 5.7a&b), indicating that functional levels of CD4+ and CD8+ T 
cells had recovered by the time systemic immune responses were assessed. As expected, 
these responses were significantly reduced in mice fed 25mg OVA prior to immunisation and 
equivalent suppression was observed in OVA fed mice depleted of CD8+ cells (Fig 5.7a&b). 
In contrast, OVA fed mice depleted of CD4+ cells showed no suppression of DTH and 
antibody responses, which were comparable to those of immunised control animals (Fig 
5.7a&b).
Similar results were obtained in mice tolerised by feeding 2mg OVA, where the 
tolerance of IgG and DTH responses was unaffected by depleting CD8+ T cells at the time of 
feeding (Fig 5.8a&b). Although DTH tolerance was reversed in mice depleted of CD4+ T 
cells (Fig 5.8a), CD4-depleted mice had no antibody responses in this experiment (Fig
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5.8b), suggesting that helper T cell function had not recovered by the time of immunisation 
and making interpretation of the results in tolerant mice impossible.
Thus, CD4+, but not CD8+ T cells are required for the induction of oral tolerance to 
OVA, irrespective of the feeding dose.
Summary and Conclusions
The results from this chapter demonstrate that the peripheral immune responses 
suppressed by feeding either a high or low dose of OVA include CD8+ CTL responses and 
require the presence of CD4+, but not CD8+ T cells during the induction phase.
Although CTL responses mediated by CD8+ T cells were suppressed, only CD4- 
dependent CTL were inhibited by oral tolerance, suggesting that this effect was secondary to 
tolerance of IL2-producing CD4+ T cells rather than direct suppression of specific CD8+ T 
cells by the fed antigen. However, preliminary experiments performed to address this issue 
were unsuccessful and lack of time prevented further studies examining whether 
administering exogenous IL2 to restimulation cultures might have overcome CTL 
unresponsiveness. Nevertheless, even if CD8+ T cells are not tolerised directly by feeding 
OVA, my other experiments show that this population probably does not mediate oral 
tolerance. Thus, the CD4-independent CTL induced by OVA/CFA immunisation were 
neither primed nor suppressed by feeding OVA, suggesting that these cells were ignorant of 
fed antigen. Furthermore, oral tolerance was induced normally by both low and high doses 
of OVA in mice depleted of CD8+ cells.
Taken together, my findings indicate that CD8+ T cells do not play a role in the 
induction of oral tolerance, irrespective of the dose of antigen used. In contrast, my results 
show that CD4+ T cells are essential for the induction of oral tolerance and the mechanisms 
underlying this effect will be explored in more detail in the following chapter.
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Figure 5.1 Suppression of OVA ISCOMS-induced Systemic DTH and 
Antibody Production by Feeding OVA.
a) OVA-specific DTH responses in mice 21 days after i.p. immunisation with 3pg 
OVA ISCOMS. The results shown are mean specific increments in footpad thickness ± 1 
SEM for 6 mice per group in C57B1/6 mice fed saline (Ctrl), 2 or 25mg OVA 10 days prior 
to immunisation. (* p<0.05 versus Ctrl), b) Total OVA-specific serum IgG responses 21 
days after i.p. immunisation with 3pg OVA ISCOMS. The results shown are % 
hyperimmunised control serum and are the means ± 1 SEM for individual sera from 6 mice 
per group. (* p<0.05 versus Ctrl). Similar results were obtained in a replicate experiment.
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Figure 5.2 Effects of Feeding OVA on Systemic CTL Responses Induced by 
OVA ISCOMS
Systemic CTL responses in mice 14 days after i.p. immunisation with 3|ig OVA 
ISCOMS. Spleen cells were removed and restimulated for 5 days in vitro with OVA- 
transfected EG7.0VA cells, before being assayed for OVA-specific CTL activity in a 51Cr- 
release assay using EG7.0VA (bold line) or non-OVA-expressing EL4 (dotted line) target 
cells at the indicated effector:target cell ratios. The results shown are from quadruplicate 
assays using lymphocytes pooled from 6 mice per group in C57BL/6 mice fed saline (Ctrl), 
2 or 25mg OVA 10 days before immunisation. Similar results were obtained in a replicate 
experiment.
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Figure 5.3 Efficacy of in vitro Purification CD4+ and CD8+ Spleen Cells by 
A ntibody-m ediated Lysis.
Spleen cells removed from mice 14 days after i.p. immunisation with lOOpg OVA 
ISCOMS were depleted by incubation with lOOpg/ml of anti-CD4 (YTS-191) or anti-CD8 
(YTS-169) antibody and complement before staining with anti-CD4-PE and anti-CD8-FITC 
antibodies. The results shown are FACS plots of undepleted, CD4- or CD8-depleted 
lymphocytes from 3 mice per group in animals fed saline (Ctrl) or 25mg OVA (Tol) 10 days 
before immunisation.
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Figure 5.4 Effects of Depleting CD4+ or CD8+ Cells in vivo on the 
Generation of Systemic CTL by OVA/CFA.
Systemic CTL responses in mice 14 days after s.c. immunisation with 100|ig 
OVA/CFA. Spleen cells were removed and restimulated for 5 days in vitro with OVA- 
transfected EG7.0VA cells, before being assayed for OVA-specific CTL activity in a 51Cr- 
release assay using EG7.0VA (bold line) or non-OVA-expressing EL4 (dotted line) target 
cells at the indicated effector:target cell ratios. The results shown are from quadruplicate 
assays using lymphocytes pooled from 6 mice per group in C57BL/6 mice injected i.p. with 
0.2ml saline (Ctrl), 0.5mg of anti-CD4 (YTS-191) or anti-CD8 (YTS-169) antibody 4 days 
before and on the day of immunisation. Similar results were obtained in a replicate 
experiment.
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Figure 5.5a Effects of Feeding OVA on the CD4-independent CTL 
Responses Induced by OVA/CFA.
Systemic CTL responses in mice 14 days after s.c. immunisation with lOOpg 
OVA/CFA. Spleen cells were removed and restimulated for 5 days in vitro with OVA- 
transfected EG7.0VA cells, before being assayed for OVA-specific CTL activity in a 51Cr- 
release assay using EG7.0VA (bold line) or non-OVA-expressing EL4 (dotted line) target 
cells at the indicated effector:target cell ratios. The results shown are from quadruplicate 
assays using lymphocytes pooled from 6 mice per group in C57BL/6 mice fed saline (Ctrl), 
2 or 25mg OVA 10 days before immunisation.
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Figure 5.5b Effects of Feeding OVA on Systemic Antibody Responses 
Induced by OVA/CFA.
Total OVA-specific serum IgG antibody responses in mice 21 days after s.c. 
immunisation with 100(ig OVA/CFA. The results shown are % hyperimmunised control 
serum and are the means ± 1 SEM for individual sera from 6 mice per group. The mean IgG 
levels of mice fed 2mg OVA were 33% lower than those of Ctrl mice. (* p<0.05 versus 
Ctrl). Similar results were obtained in a replicate experiment.
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Figure 5.6 Efficacy of D epleting CD4+ or CD8+ Cells by Antibody 
T reatm ent in vivo.
To confirm  depletion at the tim e o f feeding, spleen cells w ere rem oved from  a 
B ALB/c m ouse after i.p. injection with 0.5m g o f anti-C D 4 (Y TS-191) or anti-CD8 (YTS- 
169) antibody 4 days before and on the day o f sacrifice w hen the rem aining anim als in this 
experim ent w ere treated as described in Fig 5.8. The results show n are the proportion of 
C D 4+ and C D 8+ T cells after staining with anti-CD 4-PE and anti-CD 8-FITC antibodies, as 
analysed by flow cytom etry.
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Figure 5.7 Effects of Depleting CD4+ or CD8+ Cells in vivo on Oral 
Tolerance Induced by Feeding a 25mg Dose of OVA.
a) OVA-specific DTH responses in BALB/c mice 21 days after s.c. immunisation 
with lOOpg OVA/CFA. The results shown are mean specific increments in footpad 
thickness ± 1 SEM for 5 mice per group in animals fed saline (Ctrl) or 25mg OVA (Tol) 10 
days before immunisation and injected i.p. with 0.2ml saline or 0.5mg either of anti-CD4 
(YTS-191) or anti-CD8 (YTS-169) antibody 4 days before and on the day of feeding. 
(*p<0.05 versus Ctrl), b) Total OVA-specific serum IgG responses in mice 21 days after 
s.c. immunisation with lOOpg OVA/CFA. The results shown are % hyperimmunised 
control serum and are the means ± 1 SEM for individual sera from 5 mice per group. (* 
p<0.05 versus Ctrl). Similar results were obtained in a replicate experiment.
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Figure 5.8 Effects of Depleting CD4+ or CD8+ Cells in vivo on Oral 
Tolerance Induced by Feeding a 2mg Dose of OVA.
a) OVA-specific DTH responses in BALB/c mice 21 days after s.c. immunisation 
with lOOpg OVA/CFA. The results shown are mean specific increments in footpad 
thickness ± 1 SEM for 6 mice per group in animals fed saline (Ctrl) or 2mg OVA (Tol) 10 
days before immunisation and injected i.p. with 0.2ml saline or 0.5mg either of anti-CD4 
(YTS-191) or anti-CD8 (YTS-169) antibody 4 days before and on the day of feeding. 
(*p<0.05 versus Ctrl), b) Total OVA-specific serum IgG responses in mice 21 days after 
s.c. immunisation with lOOpg OVA/CFA. The results shown are % hyperimmunised 
control serum and are the means ± 1 SEM for individual sera from 6 mice per group. (* 
p<0.05 versus Ctrl). Similar results were obtained in a replicate experiment.
112
Table 5.1 Spleen Cell Restimulation Cultures.
Spleen cells were removed from C57B1/6 mice 14 days after s.c. immunisation with 
lOOpg OVA/ISCOMS and used in the following combinations after depletion with lOOpg/ml 
of anti-CD4 (YTS-191) or anti-CD8 (YTS-169) antibody and complement:
Group Unfractionated CD4-depleted CD8-depleted
1 Unimmunised
2 Control
3 Tolerant
4 Control Control
5 Tolerant Tolerant
6 Control Tolerant
7 Tolerant Control
Table shows recombination groups of spleen cells pooled from 10 mice per group in naive 
animals (Unimmunised) or mice fed either saline (Control) or 25mg OVA (Tolerant) 10 days 
prior to immunisation.
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Chapter 6: The Role of Cell Death and Anergy in Oral Tolerance
Introduction
In the previous chapters, I have shown that feeding mice a single dose of OVA can 
inhibit all CD4-dependent effector T cell functions normally induced by subsequent systemic 
immunisation with OVA. Furthermore, my findings indicated that the oral tolerance induced 
by a wide range of doses is unlikely to arise through active suppression mediated by 
preferential induction of CD4+ Th2 lymphocytes or CD8+ T cells, but instead may reflect 
direct inactivation of specific T cells either by clonal anergy or deletion. Although direct 
inactivation has been documented in many models of peripheral tolerance induced 
parenterally and orally with exogenous superantigens [328, 329] or by administering 
conventional antigen to TcR transgenic animals [300, 330], neither anergy or deletion has 
been identified conclusively in physiologically relevant models of peripheral tolerance to 
nominal antigens in normal animals.
In this chapter I assessed the role of direct inactivation of T cells in oral tolerance 
mainly by examining for deletion via apoptosis in vitro and in vivo using both normal mice 
and lpr mice, which have a genetic defect in fas-mediated apoptosis. In preliminary studies, 
I also investigated a role for anergy in oral tolerance by attempting to reverse T cell 
unresponsiveness in vitro in the presence of IL2, a procedure well documented for this 
purpose [258]. Furthermore, as T cell anergy or deletion are often preceded by a period of 
partial activation [328, 331, 332], I assessed whether tolerogenic doses of fed OVA induced 
antigen specific immune activation before unresponsiveness.
Experimental Protocol
Oral tolerance was induced by feeding mice 2 or 25mg OVA prior to s.c. 
immunisation with OVA/CFA. PLN cells were subsequently removed to be assessed in
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vitro for evidence of cell death using light and electron microscopy, flow cytometric analysis 
and nuclear DNA analysis.
To investigate the molecular mechanism(s) of apoptosis in oral tolerance, I examined 
fas-fasL interactions, as these have been implicated in cell death [235]. Fas-Fc fusion 
protein was employed in an attempt to block apoptosis of tolerant lymphocytes in vitro, 
while fas-mediated apoptosis in vivo was studied using OVA fed fas-defective MRL lpr 
mice.
To determine the potential contribution of anergy to oral tolerance, I restimulated 
PLN cells from orally tolerised animals for 5 days ± rIL2 (50U/ml) before assessing their 
proliferative responses to OVA (1 mg/ml).
I also determined if T cells were activated prior to becoming unresponsive to oral 
antigen by using animals which had been fed OVA up to 10 days previously but were not 
parenterally immunised. Spleen, MLN and Peyer's patches from these mice were assessed 
for antigen-specific proliferation, cytokine production and entry into cell cycle in vitro.
Results
(A) Cells From Orally Tolerised Mice are Predisposed to Die by Apoptosis 
in vitro
(i) Compromised Viability of Cells From Orally Tolerised Animals in 
Culture
I first suspected that cells from tolerised mice were unusually susceptible to die in 
vitro during casual inspection of the PLN cells cultured for collection of supernatants for 
cytokine analysis. As these tolerant cultures displayed marked cell loss, I decided to explore 
this phenomenon in more detail. PLN cells from mice fed 2 or 25mg OVA prior to 
immunisation were cultured under different conditions and their viability assessed by phase 
contrast microscopy. When lymphocytes were cultured in medium without antigen, cell loss 
occurred in all groups over 120h (Fig 6.1a). However, at each time point assessed, cultures 
from mice fed OVA prior to immunisation showed more cell loss than those from immunised
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control animals. By the end of the culture, 45.3% of control cells remained viable, 
compared with 10.3 or 19.3% of cells from animals fed 2 or 25mg OVA (Fig 6.1a). 
Although addition of OVA enhanced the cell survival in every culture, the number of viable 
cells from OVA fed mice was consistently lower than control cell numbers at each time point 
assessed (Fig 6.1b). By the end of the culture, 61.5% of control cells remained viable 
compared with 34.5 or 29.0% of cells from animals fed 2 or 25mg OVA, respectively (Fig 
6. lb). In contrast, the number of viable cells in both control and tolerant cultures containing 
PPD were more comparable at each time point examined (Fig 6.1c). The cell death in these 
cultures was less marked than that observed upon restimulation with OVA and, by the end of 
culture, 78.3% control cells remained compared with 69.5 or 73.0% of cells from animals 
fed 2 or 25mg OVA, respectively (Fig 6.1c), indicating that tolerant cultures could sustain 
growth of viable lymphocytes, providing an antigen recognised by functionally active cells 
was present.
To investigate further the apparent predisposition of tolerant cells to die in vitro, I 
compared their viability to that of naive cells. When cultured in medium alone, the number 
of viable cells in both groups was strikingly similar, but far lower than that found in 
immunised control cultures at each time point examined (Fig 6.2a), suggesting that tolerant 
and naive cells display a similar susceptibility to cell death in vitro. However, differences 
between these groups became apparent upon the addition of OVA, which enhanced cell 
survival in tolerant and immunised control cultures with no appreciable effect on naive cell 
viability (Fig 6.2b). As observed previously under these conditions, the number of viable 
cells in tolerant cultures remained lower than control cell numbers throughout the culture 
period (Fig 6.2b).
(ii) Morphological Analysis of Tolerised Lymph Node Cells
I next examined if the loss of cell viability in tolerant cultures correlated with altered 
morphology in vitro. Phase contrast light microscopy showed that PLN cells from 
immunised control animals remained small and phase bright during a 120h culture in the 
absence of OVA (Fig 6.3a). In contrast, cultures of cells from mice fed 25mg OVA prior to
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immunisation showed a rapidly increasing number of small, phase dark cells after 48h with 
few intact cells and lots of cellular fragments with the appearance of apoptotic bodies present 
by 120h (Fig 6.3b). In parallel, increasing numbers of large, granulated cells became 
apparent, many seeming to contain ingested cellular debris (Figs 6.3b) and having the 
appearance of activated macrophages. These features are consistent with apoptosis of some 
cells, followed by their ingestion by macrophages. Addition of OVA to the cultures induced 
immunised control cells to become activated as evidenced by their increased size (Fig 6.3c), 
polarisation (not shown) and blastogenesis (Fig 6.3d). These features were first apparent by 
48h and increased progressively thereafter. In contrast, OVA restimulated cells from tolerant 
cultures showed greatly reduced polarisation, with little blastogenesis (Fig 6.3e). Rather, 
these cells had a morphology similar to control cells cultured in the absence of specific 
antigen, with more small and phase bright cells than was observed in parallel cultures in the 
absence of OVA.
To analyse these changes in more detail, the cultures were examined by electron 
microscopy. In the absence of antigen, immunised control cultures were comprised mainly 
of small cells with the appearance of resting lymphocytes (Fig 6.4a). These were present to 
a far lesser extent in tolerant cultures, which contained large numbers of cells with the 
pyknotic nuclei and membrane blebbing characteristic of apoptosis (Fig 6.4b). Upon 
addition of OVA, the vast majority of cells in the control cultures were enlarged with the 
appearance of activated lymphocytes (Fig 6.4c). In marked contrast, tolerant cells cultured 
with OVA had an appearance similar to control cells cultured without antigen, showing little 
evidence of apoptosis (Fig 6.4d).
(iii) Flow Cytometric Analysis of Lymph Node Cells from Tolerant Cultures
To determine whether these morphological changes affected all populations of tolerant 
T cells, I analysed the size, granularity and phenotype of lymphocytes gated for expression 
of CD4 or CD8 by flow cytometry. After 120h in the absence of OVA, cultures from 
immunised control mice comprised cells mainly with the size and granularity of resting 
lymphocytes, with a few other cells of larger size and slightly increased granularity,
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presumed to be lymphoblasts (Fig 6.5a). In marked contrast, there were far fewer resting 
lymphocytes detected in cultures from 25mg OVA fed mice and there were virtually no 
lymphoblasts, consistent with the microscopic findings above. The loss of conventional 
lymphocytes affected both CD4+ and CD8+ T cell subsets, which were reduced to only 5.4 
and 5.9% total, respectively, whereas 42.8% CD4+ and 35.8% CD8+ T cells remained in 
control cultures after 120h (Figs 6.5a,c,e&g). The cells lying outside the regions defined 
for live lymphocytes are likely to be dead. This population was particularly enhanced in 
tolerant cultures gated for either CD4+ or CD8+ cells (Table 6.1), consistent with the 
previous findings.
After restimulation of immunised control cultures with OVA, both the CD4+ and 
CD8+ T cell subsets contained an expanded proportion of cells with increased forward light 
scatter indicative of lymphoblasts (Figs 6.5b&f). Restimulation of tolerant cells with OVA 
resulted in the appearance of CD4+ and CD8+ T cells with the size and granularity of small 
lymphocytes, but these were still less than found in restimulated control cultures (46.1% of 
control CD4+ and 67.8% of control CD8+ T cells) and there was little evidence of 
blastogenesis (Figs 6.5d&h). Again, the proportion of CD4+ or CD8+ cells presumed dead 
were increased for tolerant cultures (Table 6.1).
Similar evidence for cell loss was observed in cultures from mice fed 2mg OVA 
compared with controls (Table 6.2). In the absence of antigen, the numbers of both CD4+ 
and CD8+ cells from mice fed 2mg OVA were markedly lower than their respective controls, 
but not as low as observed in cultures from mice fed 25mg OVA (Table 6.2). When OVA 
was present in culture, the cell loss was less marked, but again lower numbers of both CD4+ 
and CD8+ cells remained in culture from mice fed 2mg OVA compared with controls (Table 
6.2) and the cultures from mice fed 25mg OVA contained even fewer CD4+ and CD8+ cells 
(Table 6.2).
These findings are consistent with the cell viability studies and show that cells of 
both CD4+ and CD8+ subsets from orally tolerant mice exhibit an increased propensity to die 
in vitro.
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(iv) Analysis of DNA Content of Tolerised Lymph Node Cells
The preceding studies show that lymphocytes from orally tolerant mice are less 
viable than immunised control cells in culture and have a morphology consistent with 
apoptosis. To confirm and quantify these findings, I next examined nuclear DNA content 
using PI staining and flow cytometry. Small, resting lymphocytes have normal diploid 
DNA content and are in the G0/G1 phase of cell cycle. Activated lymphocytes contain more 
DNA and are in either the S or G2/M phase, while cells dying by apoptosis show a 
hypodiploid DNA content due to fragmented nuclear DNA leaching from the cell. These 
features are readily distinguished using PI staining (Fig 6.6).
After 72h culture in the absence of OVA, 56.1% lymphocytes from immunised control 
animals were in the G0/G1 phase of cell cycle and 32.5% cells displayed a hypodipoid DNA 
content (Fig 6.7a&b). Under the same conditions, cultures from animals fed 2 or 25mg 
OVA contained only 27.8 or 34.9% cells in G0/G1 phase, respectively, with the proportion 
of hypodiploid cells increasing to 61 and 50.5%, respectively (Fig 6.7a&b). The frequency 
of cells in the S and G2/M phases of cycle was similar for all cultures (Fig 6.7c). These 
findings are consistent with the previous morphological evidence that, in the absence of 
antigen, control cultures contained mainly quiescent lymphocytes, whereas tolerant cultures 
contained more cells with an apoptotic phenotype.
In the presence of OVA, more cells from every group were found in G0/G1 phase (Fig 
6.7a) and the proportion of control cells with hypodiploid DNA content was reduced to 
17.5% (Fig 6.7b). OVA-restimulated cultures from tolerant animals fed 2 or 25mg OVA 
also displayed a lower proportion of hypodiploid cells (32.5 or 26.4%, respectively) 
compared with values detected in the absence of antigen (Fig 6.7b). However, the numbers 
of hypodiploid cells in tolerant cultures never decreased to the same extent as that observed 
in control cultures under the same conditions (Fig 6.7b). In addition, the proportion of cells 
in S and G2/M phases of cycle was always lower for tolerant cells than for control cells after 
restimulation with OVA (Fig 6.7c), suggesting that antigen-specific activation of the tolerant 
cells was impaired. These results agree with the previous morphological study of OVA-
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restimulated cultures, where both control and tolerant cells showed little evidence of 
apoptosis and control cultures contained more large blasting lymphocytes.
After restimulation of cultures with PPD, all groups contained a similarly decreased 
proportion of cells with hypodiploid DNA (Fig 6.7b) and more cells in the S and G2/M 
phases of cell cycle than observed in cultures containing OVA (Fig 6.7c). These findings 
are consistent with the cellular proliferation observed in the same cultures, where the 
responses of every group to PPD were always of greater magnitude than those directed 
against OVA.
(B) Molecular Mechanism of Apoptosis in Oral Tolerance
As my previous results suggested that lymphocytes from orally tolerised animals were 
more susceptible than control cells to die by apoptosis when cultured in the absence of 
antigen, it became important to determine the underlying molecular mechanism of this cell 
death. Given the evidence that a failure of fas-mediated apoptosis is associated with the 
breakdown of self-tolerance in some autoimmune disorders, such as systemic lupus 
erythematosus (SLE) [245, 333], and has been implicated in peripheral tolerance to 
superantigens [334], it seemed possible that this mechanism might also be important in oral 
tolerance.
Role of Fas-dependent Apoptosis in the in vitro Manifestations of Oral 
Tolerance
I first used a recently described fas-Fc fusion protein [310] to examine whether the 
apoptosis of cells from tolerant mice in vitro occurred by a fas-dependent mechanism. In 
parallel, I investigated the effect of this treatment on the immune effector responses 
generated by control and tolerant cells in vitro. Due to limited supplies of the reagent, it was 
not possible to carry out detailed dose response studies and therefore the fusion protein was 
used only at the concentration reported to be maximally effective in blocking fas-dependent 
apoptosis [335]. A TNFR-Fc fusion protein was used as a control since this molecule is
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also effective in preventing apoptosis but blocks a fas-independent signalling pathway 
induced by TNFa [335].
(i) OVA-specific Proliferation
As expected, the proliferative response of PLN cells from mice fed 2 or 25mg OVA 
prior to immunisation was significantly reduced compared with that of control cells after 
restimulation with OVA (Fig 6.8). The addition of either fas-Fc fusion protein or control 
TNFR-Fc fusion protein to the cultures did not significantly alter the OVA-specific 
proliferative response of any group and did not restore the proliferative capacity of tolerant 
lymphocytes to control levels (Fig 6.8). The proliferative response of every group was 
negligible when cultured in the absence of antigen and was not influenced by fas-Fc fusion 
protein (results not shown).
(ii) Cytokine Production
OVA-specific IL3 and IFNy secretion was also significantly reduced in cells from 
mice fed 2 or 25mg OVA prior to immunisation when compared with control cells (Fig 6.9) 
and this was not altered by the addition of fas-Fc fusion protein (Fig 6.9). Similarly, the 
fas-Fc fusion protein had no effect on control cytokine production. In the experiment 
shown, there was little or no production of OVA-specific IL5 and IL10 by either control or 
tolerant cells and these levels were not affected by the presence of fas-Fc fusion protein (data 
not shown). Due to a limited supply of reagents, this experiment did not include the TNFR- 
Fc fusion protein as a control and further studies were not possible.
(iii) Apoptosis
The hypodiploid cell content of cultures was assessed after 72h by PI staining. 
However, at this time point, the tolerant cultures contained no more hypodiploid cells than 
were observed in control cultures in the presence or absence of OVA (Fig 6.10) and the 
addition of fas-Fc fusion protein to tolerant cultures did not lower the proportion of 
hypodiploid cells to any greater extent than observed with control cultures (Fig 6.10). These
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findings were unexpected since I normally find that tolerant cultures contain a greater 
proportion of hypodiploid cells than controls. However, it is possible that different effects 
might have been observed if a full kinetic study had been possible. Therefore, it remains to 
be determined conclusively if apoptosis of control or tolerised cells is differentially 
influenced by the addition of fas-Fc fusion protein.
As the reduced in vitro responsiveness of OVA-specific cells from orally tolerant 
animals was not altered by addition of fas-Fc fusion protein, these findings suggest that fas- 
mediated apoptosis is not required to maintain oral tolerance. However, it also remains 
possible that the fas-Fc fusion protein did not work in these experiments.
Role of Fas-dependent Apoptosis in Oral Tolerance in vivo
The apparent lack of effect of fas in vitro did not precude a role in the induction or 
maintenance of oral tolerance in vivo and to examine this directly, I performed a series of 
experiments feeding OVA to MRL lprmice, which have a mutation in the fas gene, 
rendering it non-functional.
In vivo Responses
As observed in other normal mouse strains, the DTH responses of control MRL lpr+/+ 
mice were significantly reduced in animals fed 2 or 25mg OVA before immunisation with 
OVA/CFA (Fig 6.1 la). Unfed MRL lpr mice made significantly higher DTH responses than 
their littermate controls, but despite this, feeding either 2 or 25mg OVA induced significant 
tolerance, equivalent to or greater than that in the MRL+/+ mice (Fig 6.1 la).
Control MRL lpr mice also displayed higher total OVA-specific IgG and IgG2a serum 
antibody responses compared with control MRL+/+ mice (Fig 6.11b & 6.12b), while IgGl 
levels were similar in both groups (Fig 6.12a). All of these responses were significantly 
reduced in MRL lpr mice fed 25mg OVA prior to immunisation compared with control MRL 
lpr mice (Fig 6.11b & 6.12). In addition, the total IgG and IgG2a antibody levels were 
significantly reduced in immunised MRL lpr mice by a prior feed of 2mg OVA (Fig 6.1 lb &
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6.12b). In this experiment, none of the antibody responses were reduced by feeding either 
dose of OVA to normal MRL+/+ mice (Fig 6.11 & 6.12).
Thus, fas-mediated cell death is not required for orally induced tolerance of DTH or 
antibody responses in vivo.
In vitro Responses
The OVA-specific proliferation of PLN cells removed from MRL+/+ mice after 
immunisation was significantly higher than that observed with MRL lpr control cells (Fig
6.13). Despite this difference, cells from both MRL+/+ and MRL lpr mice fed 2 or 25mg 
OVA prior to immunisation were significantly reduced by equivalent extents compared with 
their respective controls (Fig 6.13).
The OVA-specific production of IL3 and IFNy cytokines by PLN cells from MRL 
lpr mice was higher than that of MRL+/+ animals, whereas IL5 production was reduced (Fig
6.14), indicating that the genetic defect had skewed immune responses to a Thl-like profile.
The OVA-specific production of IL3, IL10 and IFNy was significantly reduced by 
feeding MRL lpr mice 2 or 25mg OVA prior to immunisation (Fig 6.14). Secretion of 
antigen-specific IL5 was also significantly reduced in MRL lpr mice by prior feeding of 
25mg OVA (Fig 6.14), while 2mg fed OVA delayed the release of this cytokine (results not 
shown) but could not prevent it reaching levels comparable with controls by 120h culture 
(Fig 6.14). The reduction in cytokine production by cells from MRL+/+ animals fed OVA 
was less consistent and was only observed with IL3 and IL5, although secretion of IL10 and 
EFNy was also delayed by feeding 2 or 25mg OVA (results not shown). Therefore, normal 
functional tolerance was induced by feeding OVA to MRL lpr mice.
As OVA fed MRL lpr mice could be tolerised normally, I next examined whether the 
lpr mutation influenced the predisposition of tolerised cells to die by apoptosis when 
challenged in vivo and cultured in vitro. In this experiment, small, but dose-dependent, 
increases in the proportion of hypodiploid cells were detected by PI staining of cells from 
MRL+/+ mice fed OVA before immunisation (Fig 6.15). As usual, the hypodiploid cell 
content of cultures was markedly reduced in the presence of OVA (Fig 6.15). A similar
123
increase in hypodiploid content was observed when MRL lpr cells from OVA fed mice were 
cultured in the absence of antigen and again this was rescued by restimulation with OVA 
(Fig 6.15). Therefore, my findings do not support a role for fas in the apoptosis of orally 
tolerant cells when cultured in the absence of antigen.
Together with the results obtained using the fas-Fc fusion protein, my findings are 
not consistent with a role for fas-mediated apoptosis in either the cell death occurring in 
tolerant cultures in vitro, or in the expression of oral tolerance in vivo.
(C) Anergy in Oral Tolerance
Although the results of this chapter suggest that T cells from orally tolerant animals 
are predisposed to die by apoptosis in vitro, the addition of OVA to tolerant cultures reduced 
cell death without altering immune unresponsiveness. This could be interpreted as evidence 
that OVA-specific T cells remained present in the tolerant cultures but were functionally 
impaired. This would suggest a role for anergy as well as deletion in oral tolerance. To 
examine this in more detail, I attempted to reverse the presumed anergy by culturing PLN 
with rIL2, a procedure which has been reported to allow anergised T cells to regain 
responsiveness to antigen upon subsequent restimulation (DeSilva, D.R. et.al. 1991. J. 
Immunol. 147:3261). PLN cells from mice fed 2 or 25mg OVA prior to OVA/CFA 
immunisation had decreased OVA-specific proliferation if cultured for 5 days in medium 
before restimulation with OVA (Fig 6.16). However, this tolerance was no longer observed 
when cells from mice fed 2mg OVA were cultured for 5 days in the presence of 50U/ml 
rIL2, as these cells now had OVA-specific proliferation comparable to OVA/CFA immunised 
controls (Fig 6.16). Similar findings were also made with cells from immunised mice fed 
25mg OVA, where OVA-specific proliferation was significantly enhanced by prior exposure 
to rIL2 (Fig 6.16). However, these responses remained significantly lower than those of 
OVA/CFA immunised controls (Fig 6.16), indicating that the tolerance induced by a 25mg 
dose of OVA was only partly reversed. The subsequent OVA-specific proliferation of cells 
from control mice fed saline before parenteral immunisation with CFA ± OVA was not 
altered by prior exposure to rIL2 (Fig 6.16), indicating that this treatment did not induce a
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non-specific proliferative response. The proliferative responses of all groups in medium 
alone were very low or negligible (results not shown).
Interestingly, preculture with rIL2 also decreased the cell loss found when tolerant 
PLN cells were subsequently cultured in the absence of antigen, restoring the cell recovery 
to levels similar to those of immunised controls (Table 6.3). The viability of control cells 
was not influenced by the presence of rIL2 (Table 6.3). Therefore, these findings are 
consistent with the presence of anergic cells in the tolerant cultures.
(D) Feeding Tolerogenic Doses of OVA Primes T Lymphocytes in vivo
The results of this and previous chapters indicate that oral tolerance may be 
associated with both anergy and deletion and, in other models of tolerance, these cells have 
been associated with a transient period of T cell activation [328, 331, 332], To determine if 
a similar situation arose in oral tolerance, I examined for antigen-specific T cell priming 
immediately after feeding mice 25mg OVA, the dose which provokes the most profound 
tolerance.
(i) Proliferative Activity
Spleen cells taken from individual mice fed OVA 24h before showed consistent 
OVA-specific proliferation when restimulated over 96h culture (Fig 6.17a). Although these 
levels of proliferation varied between individual cultures, it was never observed with spleen 
cells from any unfed control mouse (Fig 6.17a), confirming the ability of feeding antigen to 
prime T cells. OVA-specific proliferative responses were also frequently observed using 
cells removed from individual mice examined 2 and 4 days after feeding OVA, but overall 
these responses were not significantly different from controls due to more variablity at these 
times (Fig 6.17b&c). This variability may reflect the low proportion of antigen-specific cells 
in normal mice fed OVA. The proliferative responses of all cells in medium alone were 
neglible (results not shown).
(ii) Entry into Cell Cycle
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Similar variability was observed in repeat experiments and to try and obtain further 
evidence of oral priming, I examined these cells using the more sensitive technique of PI 
staining and flow cytometric analysis of cell cycle. This confirmed the presence of antigen- 
specific priming in spleen cells from OVA fed mice, as defined by their entry into the S and 
G2/M phases of cell cycle after 72h culture in the presence of OVA. Spleen cells from mice 
fed OVA 1, 2 or 3 days previously entered cell cycle when restimulated with OVA (Fig 
6.18), with most activity being observed on day 1 and declining thereafter. Spleen cells 
from mice 4 or 10 days after feeding OVA or control animals fed saline, did not show 
increased numbers of cells in S or G2/M phases when cultured in the presence or absence of 
OVA (Fig 6.18a). However, when Con A was used to restimulate splenocytes, all groups 
showed a similar capacity to enter cell cycle (Fig 6.18b), demonstrating the viability and 
responsiveness of these cultures. Interestingly, there was no evidence of increased 
apoptosis in any cultures of OVA fed cells at any time of culture (data not shown), 
indicating that this phenomenon required in vivo challenge with OVA in adjuvant.
It is important to note that MLN or PP cells from either control or OVA fed mice 
could never be induced to enter cell cycle by OVA in vitro when examined at any time point 
after feeding (results not shown).
(iii) Cytokine Production
Further aliquots of cells taken from mice up to 10 days after feeding OVA were then 
assessed for the ability to produce cytokines when restimulated with OVA for up to 120h. 
Spleen cells from mice fed OVA up to 3 days previously, but not thereafter, produced 
detectable levels of OVA-specific IL3 and IFNy (Fig 6.19a), while no OVA-specific IL5 and 
IL10 could be detected in any culture supernatant. No OVA-specific cytokine production 
occurred in cultures of MLN or PP cells from either control or OVA fed mice at any time 
point analysed. However, when Con A was used to restimulate these cultures, all groups 
showed a similar capacity to secrete each cytokine (Fig 6.19b), confirming the viability of 
the cultures.
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These findings indicate that feeding OVA primes T cells in vivo to generate effector 
responses upon antigen-specific restimulation in vitro. However, this period of activation is 
transient, lasting for only a few days, and is followed by a state of immune 
unresponsiveness to identical restimulation in vitro.
To determine whether mice were tolerant to in vivo challenge during this period of 
immune priming, separate mice from these groups were immunised with OVA/CFA 1, 2, 3, 
4 or 10 days after feeding OVA. When PLN cells were removed 14 days after challenging 
OVA fed mice with OVA/CFA they produced significantly lower OVA-specific EL3, IL10 
and IFNy compared with control cells from mice fed saline prior to immunisation (Fig 6.20). 
Thus OVA fed mice were tolerant to challenge despite the presence of primed cells.
Summary and Conclusions
The results presented in this chapter show that lymphocytes from orally tolerant mice 
display an increased propensity to die following restimulation with antigen in vivo and 
subsequent culture in the absence of antigen in vitro. This was comparable with naive cell 
death, occurred in mice fed either 2 or 25mg doses of OVA and affected both CD4+ and 
CD8+ T cells. Dying lymphocytes from unstimulated cultures of tolerised cells developed 
morphological features indicative of apoptosis, including nuclear fragmentation and 
membrane blebbing, and these changes were accompanied by an increased proportion of 
cells with hypodiploid DNA content. The cell death was probably more extensive than could 
be reasonably accounted for by deletion of specific clones alone, but the addition of OVA to 
the tolerant cultures reduced levels of apoptosis, indicating that the cell death was influenced 
by antigen and suggesting that some OVA-specific T cells remained present when lymph 
node cells were removed from tolerant animals. These cells may have been anergic as their 
unresponsiveness was found to be reversed, at least in part, by exposure to rIL2 before 
restimulation with OVA in vitro.
Although the results are compatible with direct inactivation of T cells in oral 
tolerance, this did not involve fas-dependent apoptosis either in vivo or in vitro. Entirely
127
normal oral tolerance of all immune functions was observed in fas-deficient lpr mice and the 
functional defects associated with oral tolerance were not reversed by a fas-Fc fusion 
protein, which blocks fas-dependent apoptosis in other systems.
My findings also indicated that induction of a tolerant phenotype was preceded by 
transient T cell activation after feeding OVA. This was evidenced by the capacity of spleen 
cells from OVA fed mice to enter cell cycle and secrete cytokines when restimulated with 
OVA during the first 3 days after feeding but not thereafter. However, these mice were 
tolerant to challenge during this time.
Together, the findings presented in this chapter support the possibility that a transient 
priming of specific T lymphocytes by fed antigen leads to functional inactivation and 
increased susceptibility to apoptosis in the absence of antigen in vitro. These results support 
those in previous chapters showing that all T cell functions are profoundly tolerised by 
feeding antigen and suggest that this phenomenon may be exploited to treat a wide range of 
immunological disorders. For this reason, I thought it important next to study the longevity 
of oral tolerance.
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Figure 6.1 Viability of Lymphoid Cells from Orally Tolerised Animals is 
Compromised in vitro.
Viability of PLN cells removed 14d after immunisation of mice with OVA/CFA and 
cultured in (a) medium, (b) OVA (1 mg/ml) or (c) PPD (50|Lig/ml) for a period of 120h. The 
results shown are the absolute numbers of viable cells, pooled from 5 mice per group from 
animals fed saline (Ctrl), 2 or 25mg OVA 10 days before immunisation. Similar results 
were obtained in 3 repeat experiments.
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Figure 6.2 Viability of Lymphoid Cells from Orally Tolerant and Naive 
Animals is Similar
Viability of PLN cells removed 14d after immunisation of mice with OVA/CFA and 
cultured in (a) medium or (b) OVA (lmg/ml) for a period of 120h. The results shown are 
the absolute numbers of viable cells, pooled from 5 mice per group from naive mice or 
animals fed saline (Ctrl) or 25mg OVA 10 days before immunisation.
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Figure 6.3 M orphological Evidence fo r A poptosis of Lym phocytes from 
Orally Tolerant Animals.
PLN  were rem oved 14d after im m unisation o f m ice with O V A /CFA  and cultured in 
the absence (A & B) or presence (C, D & E) o f OVA for 120h. M icrographs show cells 
pooled from 5 mice per group from animals fed saline (A, C & D) o r 25m g OVA (B & E) 10 
days before  im m unisation. (A) G iem sa xlOOO. (B) T he sm all a rrow s indicate apoptotic  
bodies and the large arrow  show s an activated m acrophage con ta in ing  apop to tic  bodies 
(G iem sa xlOO). (C) The small arrow indicates a  lym phoblast and the large arrow  show s a 
small resting lym phocyte (G iem sa xlOOO). (D) M itotic lym phocyte (G iem sa xlOOO). (E) 
G iem sa xlOOO.

AFigure 6.4 E lectron M icroscopic A ppearance of Lym phocytes from  O rally 
Tolerised Anim als.
PL N  w ere rem oved 14d after im m unisation o f m ice w ith O V A /C FA  and cultured in 
the absence (A & B ) or presence (C& D) o f OVA for 120h. E lectron m icrographs show  cells 
pooled from  5 m ice per group from anim als fed saline (A& C) or 25m g OV A (B& D ) 10 days 
before  im m unisa tion . A rrow s indicate som e o f the apopto tic  cells p resen t, w hich  have 
condensed chrom atin (x2025).
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Figure 6.5 High Dose Oral Tolerance Results in Loss of Both CD4+ and 
CD8+ Lymphocytes During Culture in vitro.
Flow cytometric appearance of phenotypically defined populations of PLN cells 
removed 14d after immunisation of mice with OVA/CFA and cultured for 120h in the 
absence (A, C, E & G) or presence (B, D, F & H) of OVA (lmg/ml). The plots show the 
forward and side light scatter of lymphocytes pooled from 5 mice per group for animals fed 
saline (A, B, E & F) or 25mg OVA (C, D, G & H) and previously gated on the expression 
of CD4 (A, B, C & D) or CD8 (E, F, G & H). Similar results were obtained in 2 replicate 
experiments.
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Figure 6.6 Cell Cycle Profile Obtained by Staining with PI.
Flow cytometric cell cycle analysis of normal PLN cells removed 14d after 
immunisation of mice with OVA/CFA and cultured for 120 in medium alone. The histogram 
represents cells differentially stained with PI according to their position in cell cycle. In 
G0/G1 phase, cells are resting and contain normal diploid nuclear DNA (2n). In G2/M 
phase, cells are undergoing mitosis and have doubled their nuclear DNA content (4n). A 
nuclear DNA content between 2n and 4n indicates cells positioned in the S phase of cell 
cycle, while less than 2n DNA represents apoptotic cells with hypodiploid nuclear DNA.
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Figure 6.7 Orally Tolerant Cells Undergo DNA Fragmentation in vitro.
Flow cytometric cell cycle analysis of PI stained PLN cells removed from mice 14d 
after immunisation with OVA/CFA and cultured for 72h in medium ± OVA (lmg/ml) or PPD 
(50pg/ml). The results shown are percentages of cells positioned in (a) G0/G1 and (c) 
S+G2/M phases of cell cycle or (b) those containing hypodiploid DNA and pooled from 5 
mice per group for mice fed saline (Ctrl), 2 or 25mg OVA 10 days before immunisation. 
Similar results were obtained in three further experiments.
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Figure 6.8 Defective Proliferation of Tolerant Lymphocytes is not Fas 
Dependent.
OVA-specific proliferative responses of PLN cells taken 14d after immunisation of 
mice with OVA/CFA and restimulated for 72h with OVA (lmg/ml) ± either fas-Fc or TNFR- 
Fc fusion proteins (both 20jig/ml). The results shown are mean 3H-TdR incorporation 
(CPM) ± 1 SEM in quadruplicate cultures from cells pooled from 5 mice per group for 
animals fed saline (Ctrl), 2 or 25mg OVA 10 days before immunisation. (*p<0.05 versus 
OVA-restimulated Ctrl cells. **p<0.05 versus OVA-restimulated Ctrl cells in the presence 
of fas-Fc. ***p<0.05 versus OVA-restimulated Ctrl cells in the presence of TNFR-Fc).
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Figure 6.9 Defective OVA-specific Cytokine Production by Tolerant 
Lymphocytes is not Fas Dependent
OVA-specific IL3, IL5, IL10 and IFNy production by PLN cells taken 14d after 
immunisation of mice with OVA/CFA and restimulated with OVA (lmg/ml) ± fas-Fc fusion 
protein (20pg/ml) for 72h. The results shown are mean cytokine levels (U/ml or ng/ml) ± 1 
SEM from culture supernatants of cells pooled from 5 mice per group for animals fed saline 
(Ctrl), 2 or 25mg OVA 10 days before immunisation. There was little or no production of 
any cytokines from cells cultured in the absence of antigen. (*p<0.05 versus OVA- 
restimulated Ctrl cells; **p<0.05 versus OVA-restimulated Ctrl cells in the presence of fas- 
Fc).
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Figure 6.10 Role of Fas in the Predisposition of Tolerant Cells to Apoptose 
in vitro.
Flow cytom etric cell cycle analysis o f PI stained PLN cells rem oved from mice 14d 
after imm unisation with OVA/CFA and cultured for 72h in medium ± OVA (1 mg/ml) ± fasFc 
fusion protein (20pg/m l). The results show n are percentages o f cells w ith a hypodiploid 
nuclear DNA content from cells pooled from 5 mice per group for anim als fed saline (Ctrl), 
2 or 25mg OVA 10 days before immunisation.
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Figure 6.11 Induction of Oral Tolerance is Normal in MRL lpr Mice.
a) OVA-specific DTH responses in mice immunised 2 Id before with OVA/CFA. 
Results shown are mean specific increments in footpad thickness ± 1 SEM for 5 mice per 
group in MRL+/+ or MRL lpr animals fed saline (Ctrl), 2 or 25mg OVA. b) Total OVA- 
specific IgG responses in mice 2 Id after immunisation with OVA/CFA. The results shown 
are calculated with reference to a hyperimmunised control serum and are mean % ± 1 SEM 
for individual sera from 5 mice per group in MRL+/+ or MRL lpr animals fed saline (Ctrl), 2 
or 25mg OVA 10 days before immunisation. (*p<0.05 versus MRL+/+ Ctrl; **p<0.05 
versus MRL lpr Ctrl). Similar results were obtained in a replicate experiment.
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Figure 6.12 Suppression of Systemic Antibody Isotypes is Normal in OVA 
Fed MRL lpr Mice
OVA-specific serum IgGl (a) and IgG2a (b) responses in mice 2 Id after 
immunisation with OVA/CFA. The results shown are the reciprocal dilutions giving an OD 
value equivalent to (a) 5% or (b) 15% of a hyperimmunised control serum diluted (a) 1/400 
or (b) 1/20 and are for individual sera from 5 mice per group in MRL+/+ or MRL lpr animals 
fed saline (Ctrl), 2 or 25mg OVA 10 days before immunisation. (*p<0.05 versus MRL lpr 
Ctrl). Similar results were obtained in a replicate experiment.
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Figure 6.13 Suppression of OVA-specific Proliferation in vitro is Normal in 
MRL lpr Mice.
OVA-specific proliferative responses of PLN cells taken from mice 14d after 
immunisation with OVA/CFA and restimulated for 96h in OVA (lmg/ml). The results 
shown are mean 3H-TdR incorporation (CPM) ± 1 SEM in quadruplicate cultures from cells 
pooled from 5 mice per group in MRL+/+ or MRL lpr mice fed saline (Ctrl), 2 or 25mg OVA 
10 days before immunisation. (*p<0.05 versus MRL+/+; **p<0.05 versus MRL lpr). 
Similar results were obtained in a replicate experiment.
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Figure 6.14 Suppression of OVA-specific Cytokine Production in vitro is 
Normal in MRL lpr Mice.
OVA-specific production of IL3, EL5, IL10 and EFNyby PLN cells taken from mice 
14d after immunisation with OVA/CFA and restimulated for 96h in OVA (1 mg/ml). The 
results shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM in cultures of cells pooled 
from 5 mice per group in MRL+/+ or MRL lpr mice fed saline (Ctrl), 2 or 25mg OVA 10 
days before immunisation. (*p<0.05 versus MRL+/+; **p<0.05 versus MRL lpr). 
Similar results were obtained in a replicate experiment.
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Figure 6.15 Cell Death of Orally Tolerant MRL lpr cells in vitro
Flow cytom etric  cell cycle analysis o f PLN cells rem oved from  m ice 14d after 
imm unisation with OVA/CFA and cultured for 96h in medium alone or with OVA (1 mg/ml). 
The results shown are the percentages o f hypodiploid cells from  M R L+/+ or M RL lpr mice 
fed saline (Ctrl), 2 or 25m g OVA 10 days prior to im m unisation, as determ ined by flow 
cy tom etric  analysis o f PI stained cells. S im ilar results w ere ob tained  in a replicate 
experiment.
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Figure 6.16 OVA-specific Proliferative Responses of Tolerant Cells are 
Restored by Preculture with IL2.
OVA-specific proliferative responses of PLN cells removed from mice 14 days after 
immunisation with OVA/CFA and cultured for 5 days ± rIL2 (50U/ml) before washing, 
resting overnight and culturing with mitomycin C-treated naive spleen cells (1.25xl06 
cells/ml) ± OVA (1 mg/ml) for 96h. The results shown are mean 3H-TdR incorporation 
(CPM) ± 1 SEM in quadruplicate cultures of cells pooled from 11 mice per group in animals 
fed saline, 2 or 25mg OVA 10 days before immunisation or untreated mice. (*p<0.05 
versus saline fed cells + rIL2; **p<0.05 versus saline fed cells - rIL2)
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Figure 6.17 Priming of Antigen-specific Proliferation by Feeding a 
Tolerogenic Dose of OVA.
OVA-specific proliferative responses of spleen cells removed from individual mice 
(a) 1, (b) 2 or (c) 4 days after feeding either saline (Ctrl) or 25mg OVA and cultured with 
OVA (lmg/ml) for 96h. The results shown are mean 3H-TdR incorporation (CPM) in 
quadruplicate cultures of cells from individual mice.
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Figure 6.18 Feeding a Tolerogenic Dose of OVA Induces Cell Activation in 
vitro.
Flow cytometric cell cycle analysis of spleen cells removed 1, 2, 3, 4 or 10 days 
after feeding mice saline (Ctrl) or 25mg OVA and cultured for 72h either with (a) OVA 
(1 mg/ml) or (b) Con A (lOjug/ml). The results shown are the percentages of cells in the S 
and G2/M phases of cell cycle with background levels in medium subtracted, as determined 
by flow cytometric analysis of PI stained cells.
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Figure 6.19a Priming of Antigen-specific Cytokine Production by Feeding a 
Tolerogenic Dose of OVA.
Secretion of IL3 and IFNyby spleen cells taken from mice 1, 2, 3 ,4  or 10 days after 
feeding saline (Ctrl) or 25mg OVA and cultured with OVA (lmg/ml) for up to 120h. The 
results shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM in culture supernatants of 
cells pooled from 5 mice per group. Negligible levels of OVA-specific IL5 and IL10 were 
detected by any group examined. (*p<0.05 versus Ctrl). Similar results were obtained in 
three replicate experiments.
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Figure 6.19b Priming of Antigen-specific Cytokine Production by Feeding a 
Tolerogenic Dose of OVA.
Secretion of IL3, IL5, IL10 and IFNyby spleen cells taken from mice 1, 2, 3, 4 or 
10 days after feeding saline (Ctrl) or 25mg OVA and cultured with Con A (lOpg/ml) for up 
to 120h. The results shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM in culture 
supernatants of cells pooled from 5 mice per group. (*p<0.05 versus Ctrl). Similar results 
were obtained in three replicate experiments.
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Figure 6.20 Tolerance to Parenteral Challenge is Induced Within a Day of 
Feeding OVA
OVA-specific production of IL3, DL10 and IFNyby spleen cells removed from mice 
14 days after immunisation with OVA/CFA and cultured for 120h in OVA (lmg/ml). The 
results shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM in culture supernatants of 
cells pooled from 5 mice per group for animals fed 1, 2, 3, 4 or 10 days previously with 
saline (Ctrl) or 25mg OVA. (*p<0.05 versus Ctrl). Similar results were obtained in three 
replicate experiments.
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Table 6.1: % CD4+ and CD8+ Non-viable PLN Cells in vitro
i) In the absence of antigen:
Group CD4+ CD8+
Ctrl 57.2 64.2
25mg OVA 94.6 94.1
ii) In OVA:
Group CD4+ CD8+
Ctrl 53.7 62.9
25mg OVA 78.7 74.8
Flow cytometric analysis of PLN cells from mice 14 days after s.c. immunisation 
with lOOjig OVA/CFA and cultured for 120h ± OVA (lmg/ml). Results shown are % non- 
viable cells after 120h culture of cells from mice fed saline (Ctrl) or 25mg OVA 10 days 
prior to immunisation. Similar results were obtained in 2 repeat experiments.
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Table 6.2: Absolute Numbers of CD4+ and CD8+ PLN Cells in Tolerant 
Cultures
i) In the absence of antigen:
Group No. CD4+ Cells/ml No. CD8+ Cells/ml
Ctrl 6.4xl05 2.5xl05
2mg OVA 2.8xl05 2.4xl05
25mg OVA 1.8xl05 0.84xl05
ii) In OVA:
Group No. CD4+ Cells/ml No. CD8+ Cells/ml
Ctrl 8.3xl05 3.3xl05
2mg OVA 6.1xl05 2.4xl05
25mg OVA 3.5x10s 1.63xl05
Flow cytometrical analysis of PLN cells removed from mice 14 days after s.c. 
immunisation with OVA/CFA and cultured at 4xl06cells/ml ±  OVA (lmg/ml). Results 
show absolute numbers of CD4+ or CD8+ cells/ml remaining after 120h culture of cells from 
mice fed saline (Ctrl), 2 or 25mg OVA 10 days prior to immunisation. Similar results were 
obtained in 2 repeat experiments.
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Table 6.3: % Cell Recovery After Exposure to rIL2
Fed Imm unised with % t-rIL2) % (+rIL2)
Saline CFA 16.5 9.6
Saline OVA/CFA 16.5 15.3
2mg OVA OVA/CFA 11.1 16.1
25mg OVA OVA/CFA 9.1 14.5
Cell recovery obtained for PLN cells removed from mice 14 days after parenteral 
immunisation with CFA ± OVA and cultured for 5 days ± rEL2. The results shown are % 
total cells present at the start of culture for cells pooled from 11 mice per group in animals 
fed saline (Ctrl), 2 or 25mg OVA 10 days before immunisation.
155
Chapter 7: The Longevity of Oral Tolerance
Introduction
Several experimental autoimmune disorders can be suppressed by inducing oral 
tolerance [94, 105, 193, 336, 337], and this approach is being proposed as a treatment for 
clinical disease. As most current immunosuppressive therapies are non-specific and have 
many side-effects, they are unsuitable for long-term use, and an alternative antigen-specific 
treatment, such as oral tolerance, would be of great benefit if it was sufficiently long-lasting.
The experiments I have described thus far illustrate that the peripheral tolerance 
induced by feeding OVA is profound, can inhibit effector responses of both Thl and Th2 
cell subsets and may reflect T cell anergy and/or deletion. It might be predicted that this 
would be likely to have long-lasting effects, an idea consistent with a single previous report 
that oral tolerance is a stable and persistent phenomenon [120]. However, this earlier work 
also demonstrated that the tolerance of cell-mediated immunity persisted longer than that of 
humoral immunity, which was present for only 3 months after feeding antigen. Although 
this might suggest that the use of oral tolerance as a long-lasting immunotherapy would be 
problematic, the long term effects of feeding antigen on a wide range of effector responses 
has never been examined either in experimental models or in clinical practice.
In this chapter, I therefore documented the longevity of oral tolerance both in vitro 
and in vivo from 10 days to 18 months after feeding mice a single bolus of OVA. I also 
examined both 2 and 25mg doses of fed OVA to determine how the feeding dose influenced 
the longevity of tolerance.
Experimental Protocol
Oral tolerance was induced by feeding BALB/c mice 2 or 25mg OVA and the mice 
were challenged s.c. with OVA/CFA 10 days, 3, 6, 9 or 18 months later. Control mice 
were fed saline before immunisation.
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Results
Approximately 25% of both OVA fed and control mice did not survive up to 18 
months, indicating that I was examining the longevity of oral tolerance virtually over the 
entire life span of the animals.
(A) Persistence of Oral Tolerance in vivo 
DTH Responses
The OVA-specific DTH responses of mice fed 25mg OVA were significantly lower 
than those of immunised controls at every time point examined after feeding (Fig 7.1a), with 
equivalent tolerance for at least 18 months. This was despite the general decrease in DTH 
responses displayed by ageing control mice (Fig 7.1a). Although feeding 2mg OVA also 
induced significant tolerance of DTH responses, this was only present until 9 months after 
feeding and the responses measured at 18 months were comparable to those of controls (Fig 
7.1a).
Serum Antibody Responses
As I found in previous chapters, the serum levels of OVA-specific IgG, IgGl and 
IgG2a antibodies could be significantly reduced by feeding either 2 or 25mg OVA before 
immunisation (Figs 7.1b & 7.2a&b). However, this pattern was only found in animals 
immunised 10 days after feeding (Fig 7.1b & 7.2a&b), with the exception that IgGl 
responses were also significantly tolerised 3 months after feeding 25mg OVA (Fig 7.2a). 
Thereafter, all antibody responses in OVA fed mice were comparable tothose of controls 
(Fig 7.1b & 7.2a&b), although it should be noted that the levels of both IgG isotypes in 
mice fed 25mg OVA were always somewhat lower than controls (Fig 7.2a&b). As with 
DTH responses, antibody responses declined with age in controls (Fig 7.1b & 7.2a&b).
These results confirm previous findings that oral tolerance of humoral immunity is 
less long-lasting than that of CMI [120].
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(B) Persistence of Oral Tolerance in vitro 
Proliferative Responses
To examine this phenomenon further, I examined cell-mediated immunity in vitro by 
measuring OVA-specific proliferation and cytokine production by PLN cells. Proliferative 
responses were tolerised significantly by feeding 2 or 25mg OVA, but unlike DTH 
responses in vivo, this only lasted up to 3 months after feeding either dose of OVA (Fig 
7.3).
Cytokine Production
As the different effects of oral tolerance on antibody and DTH responses in vivo 
might suggest the presence of different regulatory mechanisms acting via Thl and Th2 cells, 
I examined the cytokine responses of PLN cells taken from groups of mice fed 2 or 25mg 
OVA and parenterally immunised 10 days, 3, 6, 9 or 18 months later.
10 Days
As I described previously, feeding mice 2 or 25mg OVA 10 days before s.c. 
immunisation with OVA/CFA reduced the subsequent production of IL3, IL5, IL10 and 
IFNy when their PLN cells were restimulated with OVA in vitro (Fig 7.4a, b, c & d, 
respectively). The cytokine responses of mice fed either 2 or 25mg OVA were reduced to a 
similar extent compared with controls, again consistent with my previous experiments.
3 Months
A similar pattern was found in mice challenged 3 months after feeding, when the 
production of OVA-specific IL3, IL5, IL10 and IFNy was significantly reduced in 
comparison to controls (Fig 7.5a, b, c & d, respectively). This effect was generally similar 
in extent to that found 10 days after feeding for both Thl- and Th2-dependent cytokines.
6 Months
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Oral tolerance of OVA-specific IL3, IL5 and IL10 production was still apparent in 
PLN cells removed from mice immunised 6 months after feeding 25mg OVA (Fig 7.6a, b & 
c). This was similar in extent to the inhibition found at earlier times, but was accompanied 
by a significantly enhanced OVA-specific IFNy response compared with controls (Fig 7.6d), 
indicating that tolerance of Th2-dependent cytokines was conserved while Thl-dependent 
responses may be augmented in these animals. In contrast, by this time there was no longer 
tolerance of any cytokine responses in mice fed 2mg OVA. The OVA-specific production of 
IL3, IL5 and IFNyby PLN cells from these animals was comparable to controls (Fig 7.6a, b 
& d respectively), while OVA-specific IL10 responses were now significantly increased 
beyond control levels (Fig 7.6c), suggesting that termination of low dose tolerance was 
associated with preferential upregulation of Th2 cell activity.
9 Months
A similar pattern was observed in mice challenged 9 months after feeding. Thus, 
production of OVA-specific IL3, IL5 and IL10 was significantly reduced in mice fed 25mg 
OVA compared with controls, while production of OVA-specific IFNy, although no longer 
augmented, was comparable to control levels (Fig 7.7a, b, c & d, respectively). In contrast, 
animals fed 2mg OVA showed no evidence of tolerance of any cytokines. Their production 
of OVA-specific IL3 and IFNy remained comparable with controls (Fig 7.7a & d), while 
OVA-specific IL10 continued to be significantly enhanced (Fig 7.7c) and was now 
accompanied by significantly increased levels of OVA-specific IL5 compared with controls 
(Fig 7.7b). These findings provide further evidence for a skewed immune response in 
favour of Th2-dependent cytokine production when low dose tolerance had declined.
18 Months
The OVA-specific production of every cytokine examined in control mice immunised 
18 months after feeding saline was very low (Fig 7.8a, b, c & d). However, mice fed 25mg 
OVA and immunised 18 months later continued to display significant tolerance of OVA- 
specific IL3, IL5 and IL10 (Fig 7.8a, b & c). This was accompanied by an IFNy response 
similar to that observed in controls (Fig 7.8d). All the cytokine responses of animals fed
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2mg OVA prior to immunisation were comparable to controls (Fig 7.8 a, b, c & d), 
indicating that both oral tolerance and skewing towards Th2-dependent cytokine production 
were no longer present by this time.
Summary and Conclusions
The results presented in this chapter confirm and extend previous studies by 
demonstrating that oral tolerance is a persistent phenomenon with different long-term effects 
on individual effector responses. In addition, these effects are dependent on the initial dose 
of fed antigen.
Peripheral immune unresponsiveness was most persistent when antigen was fed in 
high doses. Animals fed 25mg OVA showed some degree of tolerance for virtually their 
entire life-span, with significantly reduced DTH responses in vivo and inhibited OVA- 
specific IL3, EL5 and IL10 production in vitro when challenged for up to 18 months after 
feeding. However, other effector responses recovered more quickly. The tolerance of 
OVA-specific serum IgGl antibody production and antigen-specific proliferation did not last 
beyond 3 months after feeding, while OVA-specific IgG and IgG2a antibodies were only 
tolerant when animals had been challenged 10 days after feeding. The effects of tolerance 
were generally less persistent in mice fed 2mg OVA, where DTH responses were not 
tolerised beyond 9 months after feeding and the tolerance of OVA-specific PLN cell 
proliferative and cytokine responses wained after 3 months. More strikingly, the inhibition 
of OVA-specific IgG, IgGl and IgG2a responses was not observed beyond 10 days after 
feeding.
The differential persistence of tolerance displayed by individual functions was 
somewhat unpredictable. Contrary to expectation, the recovery in production of IFNy in 
OVA fed mice did not correlate with that displayed by either the DTH or serum IgG2a 
responses. The reasons for this are unclear, and, although consistent with my previous 
findings that DTH and IFNy responses were not always related, they conflict with the 
general view that IFNy is critically required for a switch to IgG2a production [338].
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Some evidence was provided that the persistence of tolerance may be accompanied 
by upregulation of certain responses. Thus, the long-lasting tolerance induced by feeding 
25mg OVA was associated with a switch to enhanced IFNy production upon immunisation 6 
months later. Although transient, it is possible that this effect might be necessary for the 
maintenance of high dose oral tolerance. An opposite effect was seen in low dose oral 
tolerance, since the decline of tolerance in animals fed 2mg OVA was concomitant with 
increased OVA-specific ELIO production, which was observed at both 6 and 9 months after 
feeding and was accompanied by enhanced IL5 responses at 9 months. This suggests that 
the loss of oral tolerance in these mice was followed by a skewing of immune responses in 
favour of the production of Th2-dependent cytokines and thereby provides further evidence 
against a suppressive role for Th2 cells in low dose oral tolerance.
In summary, these results highlight that oral tolerance can be manipulated, by 
altering the feeding dose, to be a long-lasting and dynamic phenomenon. However, its 
long-term effects on individual responses differ and therefore its use as a therapy for 
immunopathology will require that individual responses be assessed directly.
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Figure 7.1 Duration of Oral Tolerance in vivo.
a) OVA-specific DTH responses in mice 21 days after s.c. immunisation with 
OVA/CFA. Results shown are mean specific increments in footpad thickness ± 1 SEM for 6 
mice per group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised 10 days, 3, 6, 9 
or 18 months later. (*p<0.05 versus Ctrl), b) Total OVA-specific IgG responses in mice 21 
days after immunisation. The results shown are calculated with reference to a 
hyperimmunised control serum and are mean % ± 1 SEM for individual sera from 6 mice per 
group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised at the times indicated 
after feeding. (*p<0.05 versus Ctrl).
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Figure 7.2 Duration of Oral Tolerance of Serum IgG Isotypes.
OVA-specific serum IgGl (a) and IgG2a (b) responses in mice 21 days after 
immunisation with OVA/CFA. The results shown are the mean reciprocal dilutions giving 
an OD value equivalent to (a) 3% and (b) 10% of a hyperimmunised control serum and are 
for individual sera from 6 mice per group in animals fed saline (Ctrl), 2 or 25mg OVA and 
immunised at the indicated times after feeding. (*p<0.05 versus Ctrl).
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Figure 7.3 Duration of Oral Tolerance of Antigen-specific Proliferative 
Responses in vitro.
OVA-specific proliferative responses of PLN cells taken from mice 14 days after 
immunisation with OVA/CFA and restimulated with 1 mg/ml OVA. The results shown are 
mean 3H-TdR incorporation (CPM) ± 1 SEM in quadruplicate cultures of cells pooled from 
4 mice per group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised at the times 
indicated after feeding. (*p<0.05 versus Ctrl).
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Figure 7.4 Oral Tolerance of Antigen-specific Cytokine Responses 10 Days 
after Feeding OVA.
OVA-specifc production of IL3, IL5, IL10 and IFNyby PLN cells taken from mice 
14 days after immunisation with OVA/CFA and restimulated with lmg/ml OVA. The results 
shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM for cells pooled from 4 mice per 
group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised 10 days later. (*p<0.05 
versus Ctrl).
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Figure 7.5 Oral Tolerance of Antigen-specific Cytokine Responses 3 Months 
after Feeding OVA.
OVA-specifc production of IL3, IL5, IL10 and IFNyby PLN cells taken from mice 
14 days after immunisation with OVA/CFA and restimulated with 1 mg/ml OVA. The results 
shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM for cells pooled from 4 mice per 
group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised 3 months later. (*p<0.05 
versus Ctrl).
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Figure 7.6 Oral Tolerance of Antigen-specific Cytokine Responses 6 Months 
after Feeding OVA.
OVA-specifc production of IL3, IL5, IL10 and IFNyby PLN cells taken from mice 
14 days after immunisation with OVA/CFA and restimulated with 1 mg/ml OVA. The results 
shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM for cells pooled from 4 mice per 
group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised 6 months later. (*p<0.05 
versus Ctrl).
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Figure 7.7 Oral Tolerance of Antigen-specific Cytokine Responses 9 Months 
after Feeding OVA.
OVA-specifc production of 1L3, IL5, IL10 and IFNyby PLN cells taken from mice 
14 days after immunisation with OVA/CFA and restimulated with in lmg/ml OVA. The 
results shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM for cells pooled from 4 
mice per group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised 9 months later. 
(*p<0.05 versus Ctrl).
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Figure 7.8 Oral Tolerance of Antigen-specific Cytokine Responses 18 
Months after Feeding OVA.
OVA-specifc production of IL3, IL5, IL10 and IFNyby PLN cells taken from mice 
14 days after immunisation with OVA/CFA and restimulated with lmg/ml OVA. The results 
shown are mean cytokine levels (U/ml or ng/ml) ± 1 SEM for cells pooled from 4 mice per 
group in animals fed saline (Ctrl), 2 or 25mg OVA and immunised 18 months later. 
(*p<0.05 versus Ctrl).
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Chapter 8: Discussion
Introduction
At the time I began my study, the dogma in oral tolerance was that distinct regulatory 
mechanisms could predominate depending on the dose of fed antigen administered [132, 
136, 138]. However, as the findings made in a number of different systems were not 
always consistent in every aspect, a clearer understanding of the immunological basis of the 
phenomenon was required to determine its full potential as a clinical therapy for 
immunopathological disorders. The results presented in this thesis have used a well 
established model of tolerance induced by feeding OVA in single doses to confirm and 
extend many of the previous findings concerning the regulatory mechanisms of oral 
tolerance and the factors influencing them. This work involved study of a number of 
features, including the dose-dependency of tolerance, the requirement for individual 
suppressive cytokines, regulatory lymphocytes and direct T cell inactivation in the 
expression of unresponsiveness, as well as the longevity of the phenomenon. Since the 
dose of antigen was a critical component of most of the experiments described in this thesis, 
I shall first consider the work designed to assess this aspect before discussing the 
experiments relating to regulatory mechanisms involved in the induction and persistence of 
oral tolerance.
The Effect of Antigen Dose in Oral Tolerance
It was known from early reports that the effects of oral tolerance could be influenced 
by the dose of antigen [131]. In light of the recent studies confirming this, it had become 
generally accepted that low doses of fed antigen induce active suppression, while high doses 
inactivate T cells directly [132]. However, this view was based on investigations made with 
no more than two antigen doses and with a limited number of functional readouts, which 
were not consistent in every aspect [132, 136]. In models of active regulation, several
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different T cell subpopulations had been implicated and proposed to exert suppression by a 
variety of means [117, 129, 281], while the studies demonstrating direct T cell inactivation 
after feeding antigen had failed to agree on whether this was mediated by anergy [118, 305] 
or deletion [300], or both [303, 329]. As will be discussed more fully below, active 
regulation and direct T cell inactivation will have different implications for the practical 
application of oral tolerance. Thus, I considered it important to clarify the regulatory 
mechanisms induced after feeding antigen in a broad range of doses (100|ig-25mg OVA).
My first important finding was that individual effector responses became more 
susceptible to tolerance induction with increasing doses of fed OVA. Thus the two highest 
doses of fed OVA (10 and 25mg) significantly reduced every OVA-specific immune 
response examined, including DTH and IgG responses in vivo and PLN cell proliferation 
and cytokine production in vitro. These results confirmed previous in vivo findings made 
with the same doses of OVA [120, 131] and extended them by showing that the activity 
associated with both Thl and Th2 cells was tolerised by high doses of fed OVA, including 
Thl-dependent DTH, IgG2a, proliferation and IFNy responses and Th2-dependent IgGl, 
DL5 and IL10 production. Under these cirmcumstances, it seems unlikely that either T cell 
subset was mediating the unresponsiveness of the other. Although it remains feasible that 
another, as yet unidentified, suppressive factor may have been involved, my findings are 
consistent with the increasing evidence that a high dose of fed antigen preferentially induces 
T cell inactivation directly [132, 305] and further evidence for this will be discussed below.
Individual effector responses were differentially susceptible to the tolerance induced 
by the range of doses lower than those described above. This appeared to follow a pattern 
generally consistent with individual T helper cell subsets, with Thl-dependent responses, 
such as DTH, IgG2a and IFNy production, being particularly susceptible to tolerance 
induction, whereas IgG and Th2-dependent IgGl and IL10 responses remained resistant to 
inhibition until >10mg OVA was fed. This finding is consistent with reports that Th2 cells 
are less susceptible to tolerance induction than Thl cells [254] and may explain previous in 
vivo observations that the humoral arm of the immune response was more difficult to tolerise 
than CMI responses [131]. In addition to finding that Th2-dependent responses were
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resistant to oral tolerance induced by 100|ig-5mg fed OVA, I showed that IgGl and IL10 
responses were actually enhanced by feeding 100|ig-lmg OVA. Taken together, these 
results suggested that Th2 cells could play an active role in low dose oral tolerance via Th2- 
dependent crossregulation of Thl cells. This type of regulatory activity has been shown in 
other studies of T cell activation [221, 291] and has been postulated to explain previous 
observations of upregulated Th2-dependent cytokines in oral tolerance induced by low doses 
of fed antigen [285, 313]. However, this interpretation is not consistent with my additional 
finding that IL5 production was readily inhibited by all tolerising doses of fed antigen. IL5 
is a classical Th2 cell product [220] and its susceptibility to oral tolerance induction suggests 
that the production of individual cytokines may be regulated independently by different 
doses of fed antigen, rather than following a strict Thl/Th2 dichotomy. Although the 
reasons for this will be discussed more fully in a mechanistic review below, it is noteable 
that others have recently reported differential production of individual cytokines using TcR 
transgenic T cells in vitro [315]. This study showed that, in the absence of accessory 
molecules, it was possible to generate IL4-producing "Th2 cells" which did not secrete IL5. 
It would be interesting to determine if a similar situation arose when T cells were stimulated 
by a low dose of fed antigen. This could be achieved by direct examination of cytokine 
production by individual T cells, using ELISPOT or intracellular FACS analysis of TcR 
transgenic mice.
Although my results were partly consistent with the presence of Th2-dependent 
crossregulation of Thl cells after feeding low doses of OVA, I was unable to detect evidence 
for the non-specific bystander suppression that is reported to accompany this form of 
tolerance [139, 284]. Under these circumstances, regulatory mechanisms induced initially in 
an antigen-specific manner inhibit subsequent responses to an unrelated antigen, provided it 
is presented to the immune system at the same time as the original antigen and within the 
same microenvironment [339]. To examine for the presence of bystander suppression in my 
experiments, I assessed the responses of orally tolerised cells when restimulated in vitro 
with the antigen PPD, which had been present in the CFA used for parenteral challenge with 
OVA. However, I found no evidence of suppressed PPD responses when cells from OVA
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fed mice were restimulated with PPD either in the absence or presence of OVA and 
irrespective of the dose of OVA used to induce tolerance. These findings indicate that the 
Th2 cell activity that could be primed by feeding low doses of OVA was unable to mediate 
bystander suppression. This discrepancy with other reports may reflect differences in the 
protocols used for assessing bystander suppression. The phenomenon has been 
demonstrated in vitro using either culture supernatants from orally tolerised cells to suppress 
the antigen-specific responses of T cell lines [117, 274] or transwells separating the orally 
tolerised cells from responding T cells, but permitting transfer of a soluble suppressive 
factor released from the tolerant cultures upon antigen stimulation [271]. As it has been 
suggested that cognitive interactions prevent bystander suppression by inhibiting TGFP 
release from tolerant cells in vitro [304], this may explain why I was unable to demonstrate 
evidence for the phenomenon in my experiment, where the T cells specific for both PPD and 
OVA were together in the same culture well. However, it is equally possible that bystander 
suppression was not a feature of oral tolerance in my system. The presence of bystander 
suppression has been documented in models of oral tolerance induced by repeated 
administration of low antigen doses, rather than the single dose, I used [271, 284]. 
Therefore, it may be possible that the tolerance induced by multiple and single doses of fed 
antigen reflects distinct mechanisms. In support of this theory, a recent study found that 
multiple, but not single, doses of fed antigen could protect mice from relapsing chronic EAE 
[340]. The authors suggested that protection from the disease might require upregulation of 
TGFP production as this activity has been implicated in the suppression of immune 
responses to the multiple autoantigens, which arise through epitope spreading in chronic 
forms of autoimmunity [339] but was not detected in their system after feeding antigen in 
single doses. Other work in oral tolerance has shown that multiple feeding regimes are 
required for enhanced TGFP production [300]. However, this contrasts with the findings 
made in my lab where enhanced TGFp production could be detected early during culture of 
cells from animals tolerised by a single dose of fed OVA. Taken together this work 
highlights the need for further detailed examination of the regulatory factors induced by 
feeding single and multiple doses of antigen.
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Unlike other groups, I did not examine for bystander suppression in vivo. The 
phenomenon has been previously demonstrated by feeding an antigen to induce suppression 
of subsequent responses to a third party antigen when administered parenterally along with 
the originally fed protein [271]. Therefore, similar studies of bystander suppression in vivo 
would be required to confirm my lack of support for the phenomenon in vitro.
Priming of Systemic Immunity by Feeding Low Doses of Antigen
As part of my dose response study, I also assessed the systemic effects of feeding 
very low doses of antigen as previous reports had found that 10-50|ig fed OVA could 
preferentially prime CMI in vivo [120, 131]. However, the immunological basis of oral 
priming had not been investigated and this would be desirable for oral vaccine development. 
The usual requirement for T cell priming is that antigen is presented by "professional" APC 
delivering the necessary costimulation required to activate responding T cells [249]. This 
effect can occur with antigens delivered via the intestine, provided that they are administered 
in a particulate or viable form likely to direct their passage across the intestine to M cells 
[17]. Thus, different forms of fed antigen may produce different outcomes for systemic 
immune responses by being presented in different microenvironments or by distinct APC. 
The reasons why both tolerance and oral priming can be induced by feeding an antigen in the 
same form but in different doses is intriguing and will be discussed more fully in a 
mechanistic review below.
I was unable to reproduce previous findings of oral priming with 10-50|ig fed OVA 
[120, 131] unless I used a lower challenge dose of OVA in adjuvant. This immunisation 
protocol induced suboptimal responses in control mice and augmented both DTH responses 
and serum levels of IgGl in OVA fed mice, although their total OVA-specific IgG 
production was not altered. These results confirmed and extended previous findings that 
different limbs of the immune response differ in their susceptibility to oral priming [120, 
131] by indicating that, under the appropriate circumstances, both CMI and certain aspects 
of the humoral response could be primed by oral administration of protein.
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Individual immune responses varied in their susceptibility to upregulation by fed 
OVA, such that DTH, proliferation and IFNy responses were enhanced by feeding 10-50|ig 
OVA, while upregulation of IgGl, IL3 and IL5 responses required feeding 50|ig OVA. 
Although this pattern appears to reflect a dichotomy in the sensitivity of Thl and Th2 cells to 
different doses of OVA, this is inconsistent with the observed OVA-specific IgG2a 
production, which did not behave in the same way as the other Thl-dependent responses 
measured. Serum levels of this secondary antibody were unaltered by either dose of fed 
OVA and inspite of the enhanced IFNy production. The dose-dependent sensitivity of 
individual effector functions in oral priming would be especially useful for oral vaccination 
strategies as it might allow targetted upregulation of the protective responses associated with 
pathogens of different etiology. However, as the extent of systemic priming appeared to be 
relatively weak in my study, it would be important to determine if this could be improved by 
increasing the frequency of oral administration using a boosting regime. In addition, as the 
effects of oral priming will vary with different antigens, it will be necessary to characterise 
the dose-dependent effects for individual proteins prior to their clinical application.
My results also highlight the potential hazards of feeding antigen in doses too low to 
tolerise. In terms of immunotherapy, an insufficient amount of fed antigen might exacerbate 
immunopathology rather than suppress it. This effect has been reported in an experimental 
model of EAE [340] and could explain a recent report where the development of autoimmune 
diabetes was prevented by feeding antigen to chimeric mice expressing OVA in the islet p 
cells of the pancreas until they were bone marrow reconstituted with OVA-specific TcR 
transgenic CD8+ T cells [341]. When the proportion of autoaggressive CD8+ T cells was 
enhanced in this way, the dose of fed antigen was not increased to compensate and therefore 
it may have been more equivalent to the very low doses of fed antigen associated with oral 
priming. Taken together with my own results, these studies highlight the importance of 
establishing optimal tolerising doses for individual antigens before their use in clinical 
practice.
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The Role of Cytokines in Oral Tolerance
The results discussed above suggested that oral tolerance may involve different 
mechanisms depending on the dose of fed antigen administered and that Th2 cell activity was 
somewhat resistant to tolerance induction. I therefore examined whether Th2-dependent 
cytokines played a direct role in oral tolerance and I explored the requirement for other 
potentially suppressive cytokines in the induction and/or maintenance of the 
unresponsiveness after feeding a high (25mg) or low (2mg) dose of OVA .
i) Oral Tolerance does not Require Th2-dependent Cytokines
Of the many interleukins associated with regulatory functions in the immune system, 
IL4 has been demonstrated to play a central role [220]. In particular, it has been found to be 
responsible for the generation of Th2 functions in CD4+ T cells [287, 342] and the 
subsequent downregulation of Thl-dependent responses [221, 291]. Moreover, IL4 has 
been associated with peripheral T cell tolerance [289] and reports of increased IL4 mRNA in 
the lymph nodes of orally tolerised mice suggest that IL4 may also have a regulatory 
function in oral tolerance [283]. However, my experiments in IL4_/_ mice showed for the 
first time that oral tolerance could be induced and maintained normally despite a lack of IL4 
expression and hence of Th2 cells [306].
As expected, these animals produced very low or negligible levels of OVA-specific 
IgGl, IL4, IL5 and IL10 after immunisation with OVA/CFA. Instead, their Thl-dependent 
responses were augmented so that both PLN cell proliferation and IFNy production were 
higher than found in wild type controls. Others have also reported that mice lacking IL4 
exhibited Thl-dominated immune responses with strong IgG2a/IgG3 and low or no IgGl 
and IgE antibodies [343, 344], consistent with the idea that Th2 cells normally crossregulate 
Thl activity [291]. More surprisingly, and despite the enhanced IFNy production, I found 
that IL4'/_ mice displayed lower DTH responses than their wild type littermates after 
parenteral immunisation, indicating that some Thl-dependent functions were not augmented 
in the absence of IL4. This finding suggests that IFNy may not be as critical a factor for 
DTH as is often assumed and agrees with its presence in the IFNyR'/_ mice (see below).
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Feeding OVA to IL4_/_ mice induced systemic unresponsiveness of every OVA- 
specific effector function examined, including DTH, IgG and IgG2a responses in vivo and 
PLN cell proliferation and production of IL3 and IFNy production in vitro. This indication 
that oral tolerance may be induced in Thl cells in the complete absence of Th2 cells or their 
associated cytokines is consistent with findings from a similar study of oral tolerance in IL4" 
/- mice [345] and with the recent report that mice treated with anti-ILlO remain permissive to 
the induction and maintenance of oral tolerance to OVA [292]. The unresponsiveness 
induced in IL4_/_ mice was irrespective of the dose of fed OVA used, indicating that the 
preservation or priming of Th2-dependent cytokines after feeding low antigen doses, is not 
required for oral tolerance to occur. A similar situation has been reported in another model 
of peripheral tolerance induced by continuous administration of low doses of soluble 
proteins, delivered subcutaneously by mini-osmotic pump [346]. In this study, 
unresponsiveness was also characterised by down regulation of Thl-dependent cytokines 
and a concomitant priming of Th2 cells. However, inhibition of endogenous IL4 did not 
restore Thl cell responsiveness despite preventing Th2 cell expansion, indicating that the 
development of Th2 cells and the inhibition of Thl cells were independent pathways. My 
findings indicate that this is also the case for oral tolerance and the possible mechanisms will 
be discussed later.
ii) Oral Tolerance is Induced in the Absence of IFNy
Although the results described above showed that IL4 and Th2 cells played no role in 
either the induction or maintenance of oral tolerance, it remained possible that the 
unresponsiveness was being mediated by another suppressive cytokine. IFNy has well 
known cytostatic properties [293, 319] and its production is relatively preserved in mice 
tolerized by i.v. injection of staphylococcal enterotoxin B [228]. Furthermore, IFNy is 
required for the tolerance induced in rats by intranasal administration of OVA [128]. 
However, most studies of oral tolerance report that IFNy production is particularly sensitive 
to inhibition and therefore a regulatory role for this cytokine is not usually considered. Due
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to my finding that IFNy was transiently upregulated during the first few days after feeding 
OVA, its potential as a mediator of oral tolerance required further assessment.
After neutralising endogenous IFNy, OVA-specific DTH and serum IgG antibodies, 
including both IgGl and IgG2a isotypes, were inhibited by feeding mice 25mg OVA, 
suggesting that IFNy is not required for the induction of high dose oral tolerance. But as it 
was difficult to prove that all active IFNy had been neutralised in this experiment, I also 
examined IFNyR/_ mice, which lack the receptor for IFNy and hence are unresponsive to the 
cytokine [307]. Unfed IFNyR/_ mice had normal serum IgG and IgG2a levels after 
parenteral immunisation, but displayed impaired DTH, IgGl and IFNy responses. In 
parallel, they exhibited augmented PLN cell proliferation and production of IL3, IL5 and 
IL10 in vitro. Although most of these findings were as expected, the IgG isotype results 
were surprising, since IFNy is believed to be involved in Ig isotype regulation [338] and 
other reports have shown that IFNyRV" mice are impaired in their IgG2a response [307]. A 
corresponding decrease in IgGl might also have been expected, but I found the opposite 
effect, despite the fact that other Th2-dependent responses, including IL5 and IL10, were 
augmented. As I am unable to explain these findings, the effects of oral tolerance on IgG 
isotypes were difficult to interprete.
Despite their unusual immunological phenotype, IFNyR_/_ mice displayed normal 
oral tolerance, irrespective of the dose of OVA fed. This included inhibition of OVA- 
specific DTH, IgG, IgGl and IgG2a responses in vivo and PLN cell proliferation and 
production of IL3, IL5 and IL10 in vitro. These findings clearly show that a lack of 
responsiveness to IFNy does not prevent the normal induction and maintenance of oral 
tolerance and confirm my antibody depletion results. My findings are consistent with the 
fact that IFNy production is particularly sensitive to inhibition by oral tolerance and imply 
that my later observation of preferential release of this cytokine during the first few days 
after feeding OVA is unlikely to play a pivotal role in the induction of oral tolerance.
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iii) The Role of TGFp in Oral Tolerance
As the experiments described so far appeared to exclude a role for conventional 
cytokine mediators produced by either Thl or Th2 cells, I went on to examine the possibility 
that an alternative cytokine, TGFp, might be important. TGFp can function as a potent 
immunosuppressive factor either by direct cytostatic effects on lymphocytes or by inhibition 
of functional activities such as IFNy production, cytolysis or expression of adhesion 
molecules [347]. The importance of these inhibitory functions is underscored by the finding 
that TGFpi null mice exhibit multiorgan inflammation, lymphocytic infiltrates, and early 
death [348, 349]. Abundant in the normal intestine [296-298], TGFp has been found to 
downregulate the immunopathology of murine colitis [350, 351] and intestinal graft-versus- 
host reaction (GvHR) [320]. In addition, TGFp has been implicated as a mediator of oral 
tolerance in rodents. CD4+ T cell clones [282] and CD8+ populations [274, 285] derived 
from mice fed MBP have been reported to inhibit the induction of EAE by a mechanism that 
involved TGFp. Moreover, others in this lab have detected TGFp production when 
tolerised PLN cells were restimulated in vitro [321].
I assessed the role for TGFP in oral tolerance by neutralising its production in vivo. 
This treatment failed to prevent the induction of oral tolerance of most aspects of the immune 
response, including OVA-specific DTH responses and IL5, IL10 and IFNy production, 
indicating that endogenous TGFp was not required for tolerance of CMI in vivo or of Thl or 
Th2 effector functions in vitro. I obtained similar findings irrespective of the dose of OVA 
fed and these results disagree with the adoptive transfer studies described above. In 
addition, they contrast with another study in which neutralisation of TGFp in vivo abrogated 
the protection from EAE and the suppression of DTH responses which were induced by oral 
administration of low doses of MBP [274]. These discrepancies are likely to reflect 
differencies in the protocols used both for depleting TGFp and for feeding antigen, but may 
also reflect the effects of residual TGFp in vivo, as I was unable to prove that all active 
TGFp was neutralised in my experiment. This could have been achieved by measuring the 
release of TGFp in vitro using a sandwich ELISA, bioassay or by examining the binding of 
125I-labelled TGFP to splenocytes from TGFP-depleted or control mice [352], while
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immunoperoxidase staining for TGFp would have revealed its presence in vivo [353]. This 
latter technique would also address whether TGFp had been depleted from the intestinal 
tissues, which are a potential site for oral tolerance induction [35].
One aspect of the immune response which did appear to require endogenous TGFP 
for its suppression in my hands was serum IgG production. Oral tolerance of this response 
was prevented in mice treated with anti-TGFp, although it should be noted that there was 
still slight suppression of IgG responses in TGFP-depleted mice. If TGFp was 
preferentially required for oral tolerance of humoral immunity, it might explain previous 
reports that the cellular and humoral limbs of the immune response are differentially 
regulated by fed antigen [131]. However, this differential effect has been associated 
primarily with tolerance induced by low doses of antigen, whereas my findings were similar 
irrespective of whether I fed a high or low dose of OVA, implicating a potential role for 
TGFp in both situations. Indications that TGFp could be involved in high dose oral 
tolerance contrast with previous reports that increasing the dose of fed antigen inactivates T 
cells directly [118, 132, 300] and reduces the amount of TGFp secreted [284]. Therefore 
my results require further investigation, particularly as they were somewhat variable and 
could not be repeated due to the limited supply of reagent. An alternative approach to 
address this issue using TGFp mice_/' might not be feasible because of their lethal multiple 
organ disease [348, 349]. However, the technique of recombination-activating gene (RAG)- 
2-deficient blastocyst complementation [354], in which mouse embryonic stem cells 
disrupted in both copies of the gene of interest are injected into RAG-2-deficient blastocyts, 
may allow the generation of a chimeric mouse with disrupted TGFp expression targetted to 
the T and B cell compartments for direct examination of a role for TGFp in oral tolerance.
Another aspect of oral tolerance which appeared to be modulated by neutralisation of 
endogenous TGFp was OVA-specific PLN cell proliferation and indeed TGFp-depleted 
mice fed 25mg OVA displayed enhanced proliferative responses in vitro. However, the 
response was very low in control immunised mice that had been depleted of TGFP and it 
was therefore difficult to interpret the additional effects of feeding OVA.
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Neutralisation of TGF(3 production in vitro showed that this cytokine was not 
required to maintain oral tolerance of several OVA-specific responses, including proliferation 
and production of IL3, IL5 and IL10. These data provide further evidence against an 
exclusive role for TGFp in the expression of oral tolerance. However, its role in the 
suppression of IFNy production remains to be determined, as every culture treated with anti- 
TGFp contained IFNy beyond the level of detection by ELISA making it difficult to discern 
the effects of feeding OVA. Only cells from mice fed 2mg OVA appeared to produce less 
IFNy than controls in the presence of anti-TGFp.
Overall, the results above do not support a crtical role for TGFp in the induction of 
oral tolerance in vivo or for its expression in vitro. If time had permitted, I would also have 
examined its role in the maintenance phase of unresponsiveness in vivo by neutralising 
endogenous TGFp production around the time of parenteral immunisation.
Taken together, these parts of my study do not support the hypothesis that the 
induction of oral tolerance induced in mice by feeding single doses of antigen is critically 
dependent on the presence of suppressive cytokines. However, this work does not preclude 
the possibility that another form of active regulation might be involved and I will now 
discuss the findings from experiments designed to address this issue.
The Role of CD8+ T cells in Oral Tolerance
Early studies of oral tolerance, in which suppression was transferable to naive 
recipients with CD8+ T cells [93, 97, 109, 324], were the first to implicate a regulatory role 
for this T cell subset. Although the presence of functional CD8+ TS cells remains 
controversial, more recent studies of oral tolerance confirm that CD8+ T cells can transfer 
suppression [117] and that this lymphocyte subpopulation may be primed in the lamina 
propria by fed antigen [35]. CD8+ T cells can play a regulatory role in a number of immune 
responses, either through classical cytotoxic effects on APC [275] or via the production of 
suppressive cytokines such as IFNy [128] and TGFp [274]. As my findings above were 
inconsistent with a role for either of these cytokines in oral tolerance, I was particularly
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interested in the possibility that suppression was associated with the cytotoxic properties of 
CD8+ T cells.
In the first set of experiments, I confirmed that a single s.c. administration of OVA 
ISCOMS generated a wide range of OVA-specific effector responses, including DTH, serum 
IgG and class I MHC-restricted splenic CTL activity [325]. I then showed for the first time 
that the responses induced by this adjuvant could be suppressed by feeding low or high 
doses of OVA. Most importantly, complete abrogation of OVA-specific CTL, which have 
been shown to be CD8+ class I MHC-restricted T cells, extends the range of immune 
responses which can be modulated by oral tolerance. Similar findings have recently been 
made for the CD8+ CTL responses induced by parenteral administration of either EL4 cells 
or spleen cells loaded with OVA by osmotic lysis [341, 355].
However, all the regimes described above for priming CTL in vivo are known to be 
dependent on the presence of CD4+ T cells [326, 341] and I thought it important to 
determine whether the suppression of CTL responses in OVA fed mice was due to direct 
tolerization of OVA-specific CD8+ T cells or if it was secondary to inhibition of the IL2- 
producing CD4+ T cells necessary for the induction of CTL [356]. Unfortunately my 
attempts to examine whether the tolerance of CD8+ effector CTL activity could be overcome 
in vitro by addition of functional OVA-specific CD4+ T cells were unsuccessful. An 
alternative approach to address this issue could have involved administering exogenous IL2 
to the CTL cultures in an attempt to overcome oral tolerance of cytotoxicity by this means. 
Time restraints prevented me from performing this work. Instead, I decided to explore the 
issue by taking advantage of a recent report that CD4 independent OVA-specific CTL could 
be primed by immunisation with OVA/CFA [327]. I was able to confirm these findings by 
showing that parenteral immunisation with OVA/CFA induced OVA-specific class I MHC- 
restricted splenic CTL activity which developed normally in mice depleted of CD4+, but not 
CD8+, T cells. I then showed that those CTL responses were not altered by feeding OVA 
prior to OVA/CFA immunisation. This was irrespective of the antigen dose used and despite 
the presence of tolerised antibody production. This finding that fed antigen cannot influence 
the CD4-independent cytotoxic activity generated by OVA/CFA contrasts with another report
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showing that CTL responses primed in exactly the same way were tolerised by feeding 
multiple, low doses of OVA [355]. I did not have time to repeat this work and it would be 
important to determine if the discrepancies reflect different feeding regimes or not.
As the results discussed above indicated that a subset of CD8+ T cells might remain 
resistant to inhibition by fed antigen, I therefore assessed their requirement in the induction 
of oral tolerance by feeding OVA to animals depleted of CD8+ cells around the time of 
feeding. In parallel, I used the same approach to explore the requirement for CD4+ T cells in 
the phenomenon. Despite the fact that the antibody regimes produced successful systemic 
depletion of the appropriate T cell subset, the OVA-specific DTH and serum IgG responses 
generated after challenge with OVA/CFA were entirely normal, indicating that the T cell 
populations had recovered by the time of immunisation, 10 days after the final dose of 
antibody was given. Feeding either a high or low dose of OVA induced entirely normal 
tolerance of both the DTH and IgG responses in CD8-depleted mice, indicating that CD8+ T 
cells were not required for the induction of unresponsiveness. These findings have recently 
been confirmed by others using mice depleted of CD8+ cells either by antibody [281, 357] 
or by genetic manipulation [345]. In addition, one study has also shown that oral tolerance 
is unaffected if CD8+ cells are depleted after feeding [357].
At face value, these findings suggest that CD8+ T cells play no role whatsoever in 
oral tolerance. Moreover, as CTL responses were neither primed nor tolerised by fed OVA 
and as others in this lab have been unable to prime CTL after feeding alone, the class I 
MHC-restricted CD8+ T cells may be ignorant of fed OVA , perhaps because it does not 
enter the class I pathway for presentation. However, there is increasing evidence to suggest 
that this idea warrants reexamination. Primed CTL responses have been recently reported in 
mice fed OVA [341] and tolerance induced by feeding MBP or by nasal administration of 
OVA has been found to be transferable with CD8+ T cells which secrete TGFp or EFNy, 
respectively [128, 274]. In addition, intestinal lamina propria CD8+ T cells from antigen fed 
mice have been shown to secrete IFNy and TGFp, and to transfer tolerance to naive 
recipients [35]. As I only confimed the efficacy of the depletion in my experiments using 
splenocytes, it cannot be ruled out that intestinal CD8+ T cells remained in my mice and
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could have contributed to the continuing tolerance. Consistent with this idea, mucosal CD8+ 
T cells expressing the y5 form of the TcR have been implicated both in the model of nasal 
tolerance mentioned above [129, 276] as well as in oral tolerance of experimental 
autoimmune uveitis [277]. In addition, a report that the induction and maintenance of oral 
tolerance was blocked in OVA fed mice administered with anti-y8 antibody [278] suggests 
that y5 T cells may be important in the phenomenon. Indeed y5 T cells have already been 
found to downregulate ap  T cell responses [358], although the immunological basis of this 
remains to be elucidated. Unfortunately, time restraints prevented me from assessing the role 
of y/8 cells in my system of oral tolerance.
Despite these provisos, the overriding feature of my experiments was that CD4+ T 
cells were essential for the induction of oral tolerance, as mice depleted of CD4+ cells prior 
to feeding had DTH and IgG responses comparable with unfed mice. This finding has since 
been confirmed [357] and is consistent with the fact that oral tolerance of CD4 independent 
hapten-specific effector CD8+ T cell responses requires CD4+ T cells [359],
Thus, CD4+ T cells are not only the principal target of oral tolerance, but may also be 
required to mediate it. That this effect does not require Th2-dependent cytokines, TGFp or 
cytotoxicity suggests that oral tolerance may be induced by direct T cell inactivation rather 
than by an active regulatory mechanism. To examine this issue more closely, I examined the 
potential role of anergy and deletion in oral tolerance.
The Role of Cell Death and Anergy in Oral Tolerance
Clonal deletion is an important mechanism of central tolerance to self antigens [360] 
and is also found when peripheral tolerance is induced by exogenous superantigens [328] or 
after administration of conventional antigens to TcR transgenic animals [330]. Cell death by 
apoptosis has recently been demonstrated in situ after oral tolerance induction in TcR 
transgenic mice [300], but it remains to be identified in oral tolerance to nominal antigens in 
normal animals. In my first set of experiments to examine for direct T cell inactivation, I 
showed that PLN cells removed from orally tolerised mice after parenteral immunisation had 
compromised viability when cultured in the absence of antigen in vitro. This cell death
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affected up to 90% cells and involved both CD4+ and CD8+ T lymphocytes, implying that it 
was unlikely to be antigen-specific. The dying lymphocytes displayed morphological 
features indicative of apoptosis, including nuclear fragmentation and membrane blebbing, 
and these changes were accompanied by an increased proportion of cells with hypodiploid 
DNA content in the tolerant cultures, again consistent with apoptosis. An additional aspect 
of my experiments was that, unlike immunised control cells, lymph node cells from naive 
unimmunised mice showed a similar susceptibility to die in vitro. This suggests that the 
induction of oral tolerance renders antigen-experienced cells unresponsive to the 
growth/survival signals which primed cells normally react to.
Although these results could imply that deletion of OVA-specific T cells was 
occurring in vivo, the cell death was more extensive than would be anticipated from this. In 
addition, antigen-specific cells must still have been present at the time of in vitro culture, as 
the addition of OVA rescued a proportion of orally tolerised cells from dying in vitro. 
Although the cell viability failed to return to control levels under these conditions, the same 
phenomenon was not observed with naive lymph node cells. Thus, if deletion had occurred 
in vivo, it could not have been complete. It is also possible that cell death may only occur in 
vitro, with the presence of antigen and the lymphoid microenvironment allowing tolerant 
cells to remain alive but anergic in vivo. It would therefore be interesting to examine for 
apoptotic cells in tolerised mice using the terminal deoxynucleotidyl transferase (TdT)- 
mediated dUTP-biotin nick end-labelling (TUNEL) method, which detects apoptotic cells by 
virtue of their DNA strand breaks [361]. However, the frequency of antigen-reactive T cells 
in normal animals may be too low to allow detection of the apoptotic proportion by TUNEL 
and preliminary experiments performed to address this issue in the lab have been 
inconclusive. An alternative approach would involve exploitation of a recent model in which 
normal animals are given a defined number of TcR-transgenic T cells, which can then be 
traced with the appropriate anti-clonotypic ab [362]. In this way, the proportion of antigen- 
reactive T cells might be tailored to a level suitable for TUNEL detection of any apoptosis in 
antigen fed mice.
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To try and investigate whether apoptosis might be important in the development of 
oral tolerance in vivo and to examine the molecular nature of the cell death described in vitro, 
I decided to assess the role of fas. Fas-mediated apoptosis has been implicated in peripheral 
T cell tolerance induced by the superantigen SEB [334] or by crosslinking of TCR-CD3 
molecules [363], as well as in tolerance within immunologically privileged sites, such as the 
eye [364]. Moreover, T cell death in the human lamina propia has been reported after fas 
cross-linking [365], outlining a potential role for this mechanism in oral tolerance.
In the first series of experiments, I found that tolerance of OVA-specific effector 
functions in vitro was not altered by addition of fas-Fc fusion protein, which has recently 
been demonstrated to block fas-dependent cell death [244]. Cells from orally tolerant mice 
remained impaired in their proliferation and production of IL3 and IFNy, suggesting that fas- 
dependent apoptosis was not involved in this phenomenon. Unfortunately, I was unable to 
determine conclusively if the enhanced apoptosis in cultures from orally tolerised mice was 
fas-dependent. Although the addition of fas-Fc fusion protein did not influence the 
apoptosis observed in control and tolerant cultures, in this experiment, the levels of 
apoptosis were comparable for all groups, irrespective of whether the animals had been fed 
OVA. Although this result was found at a time point in culture when I usually observe 
enhanced apoptosis in tolerant cultures, this feature normally increases with time and 
therefore it is possible that differences in control and tolerant cultures might have been 
observed had the supply of fusion protein allowed a full kinetic study of apoptosis to be 
performed. It will be important to confirm this in future studies. It would also be important 
to confirm that the fas-Fc fusion protein was indeed effective in blocking fas-dependent 
apoptosis in vitro. Previous reports have shown that fas-Fc fusion protein can prevent the 
early fas-dependent cell loss induced by anti-CD3 treatment [335] and it would have been 
important for me to perform a similar test to confirm that the fas-Fc fusion protein was 
working in my experiments. Unfortunately, a limited supply of the fusion protein prevented 
this.
In the second series of experiment, I examined if fas-mediated apoptosis was 
required for oral tolerance in vivo, using fas-deficient MRL lpr mice [235]. I found that
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many of the immune responses generated by s.c. immunisation with OVA/CFA differed 
between MRL lpr and MRL+/+ control mice. OVA-specific DTH responses, serum IgG and 
IgG2a antibodies and PLN cell production of IL3 and EFNy were augmented in MRL lpr 
mice, while IgGl and IL5 responses were unaltered, indicating that disrupted fas expression 
may have skewed the immune response to a Thl-like phenotype. This is consistent with 
previous observations in MRL lpr mice [366] and is likely to reflect the differential 
expression of fasL by Thl and Th2 cells, as activated Thl cells express more fasL and 
display an enhanced susceptibility to fas-mediated cell death [244]. The altered immune 
phenotype of MRL lpr mice may reflect an attempt to downregulate effector responses in the 
absence of fas-dependent apoptosis via the release of inhibitory cytokines such as IFNy, 
which was enhanced in my study, or TGFp, which has recently been reported to be 
upregulated in MRL lpr mice [367]. These features might also explain my additional 
observation that the cells from immunised MRL lpr mice displayed a reduced capacity for 
OVA-specific proliferation.
Despite these abnormalities in systemic responsiveness, I found that MRL lpr mice 
displayed normal oral tolerance. Feeding OVA prior to immunisation reduced every effector 
response examined in MRL lpr mice, indicating that fas-dependent apoptosis was not critical 
for either the induction or maintenance of the phenomenon. This effect was irrespective of 
the antigen dose used to tolerise. Of particular importance was my finding that cells from 
orally tolerant MRL lpr mice also displayed an enhanced propensity to die in the absence of 
antigen in vitro. Although these findings exclude a role for fas in the in vivo or in vitro 
consequences of oral tolerance, they do not rule out the possibility that clonal deletion could 
occur via a fas-independent mechanism, as is the case for central tolerance [368]. One 
mechanism of this could be apoptosis via TNFR, which has been implicated in the deletion 
of CTL in vivo [247]. However, recent preliminary experiments performed by others in the 
lab suggest that oral tolerance is normal in (p55 x p75)"/_ mice, which lack both chains of 
the TNFR (Mowat, unpublished observations).
The absence of a role for fas, together with the evidence for residual OVA-specific T 
cells at the time of in vitro culture, highlight the possibility that anergy rather than deletion
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was occurring in tolerant mice. This has been reported previously with only high doses of 
antigen [118, 132, 304, 305]. To investigate this issue further, I attempted to restore 
responsiveness by culturing cells from orally tolerant mice in rIL2, a procedure reported to 
reverse anergy [258]. The OVA-specific proliferative responses of PLN cells from mice 
tolerised by 2mg OVA were reversed completely by IL2. This contrasts with the idea that 
has become increasingly accepted that oral tolerance induced by low doses of fed antigen is 
mediated entirely by active suppression [132, 136, 271, 274, 369], whereas high dose 
tolerance is due to anergy [118, 132, 304, 305]. However, since these reports relate to 
multiple, rather than to single, low doses of fed antigen, my novel finding implies that 
different forms of regulation may be induced depending on the frequency of feeding.
rLL2 also enhanced the proliferation of cells from mice fed 25mg OVA, but this effect 
was incomplete since the response failed to return to control levels, indicating that although 
oral tolerance induced by high doses of fed antigen may involve anergy, additional factors 
may also be operating. These findings are consistent with other reports of anergy in high 
dose oral tolerance [118, 132, 304, 305], but more so, with the idea that both anergy and 
partial deletion may occur in SEB-induced oral tolerance [329].
The fact that IL2 reduced cell loss in the tolerant cultures may also support a possible 
association between anergy and deletion in my system of oral tolerance. IL2 may either have 
prevented the death of inactivated cells or may have preferentially induced clonal expansion. 
The first possibility would be predicted if T cell anergy was followed by apoptosis, as 
observed in other tolerance models [370], while the second idea would be consistent with 
reports that anergic cells can proliferate to exogenous IL2 because they express IL2R [258]. 
Further studies on the effects of IL2 treatment on cell death and proliferation could 
discriminate between these possibilities. That the cell death I observed in orally tolerant 
cultures might reflect the eventual apoptosis of anergic cells is consistent with a recent report 
that anergized lymphocytes can undergo apoptosis [370]. The mechanism of this was also 
found to be fas-independent and this is consistent with the fact that fas-sensitivity may 
require IL2-driven proliferation [371] which is impeded in anergic T cells [262].
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Feeding Tolerogenic Doses of OVA Primes T Lymphocytes in vivo
In other models of peripheral tolerance, anergy and deletion have been reported to 
follow a transient period of T cell activation [328, 331, 332]. This may reflect incomplete T 
cell signalling, as others have shown that partial T cell activation can occur during the 
process of tolerance induction, such as T cell stimulation in the absence of appropriate 
costimulation [372] or by an altered peptide ligand [260, 261]. In my experiments, I found 
that feeding a tolerogenic dose of OVA primed spleen cells for OVA-specific proliferation, 
entry into cell cycle and production of IL3 and IFNy within the first 3 days of feeding, but 
not thereafter. I was unable to detect OVA-specific IL5 or IL10 production, suggesting that 
fed OVA had preferentially generated a Thl-dependent response. Smilar findings have been 
made in a study of nasal tolerance, where Thl-dependent cytokines were also transiently 
upregulated after peptide administration [332] and in a study of superantigen-induced T cell 
apoptosis, where exposure to BrdU in vivo revealed that transient proliferation was 
perequisite for the effect [373].
The restricted and transient cytokine production observed in OVA fed mice which 
were tolerant to challenge in vivo with antigen at this time is consistent with the induction of 
anergy after partial activation, in which T cells are unresponsive to further antigenic 
stimulation provided in an immunogenic manner [257]. These findings provide further 
support for the involvement of anergy in oral tolerance.
In summary, my results in chapter 6 highlight the possibility that fed antigen might 
induce anergy, perhaps along with a degree of deletion, in antigen-reactive T cells.
The Longevity of Oral Tolerance
In the final part of my study, I examined the long-term effects of feeding antigen and 
explored if the tolerance of different aspects of immunity in vivo persisted for equivalent 
periods of time.
These experiments confirmed earlier reports that feeding a high dose of OVA induced 
long lasting oral tolerance in vivo, which persisted for the entire life-span of the mouse 
[120]. This was despite the fact that the magnitude of the systemic immune responses
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generated by parenteral immunisation tended to decline with age. Thus, Thl-dependent 
responses, such as DTH and IFNy, diminished progressively in ageing control animals, 
although their IL5 and IL10 responses remained reasonably constant for up to 9 months, 
consistent with previous studies showing dysregulation of Thl and Th2 cells during 
senescence [374].
The longevity of the tolerant state depended on the dose of fed antigen. Mice fed 
25mg OVA prior to immunisation showed some degree of tolerance for virtually their entire 
life-span, with impaired DTH responses in vivo and suppressed OVA-specific IL3, IL5 and 
IL10 production in vitro when challenged for up to 18 months after feeding. In contrast, 
feeding 2mg OVA induced a less persistent form of oral tolerance, which was no longer 
detectable when mice were challenged beyond 3 months after feeding. Taken together with a 
recent report that the persistence of IgG and IgE tolerance is dependent on the dose of fed 
protein [151], these results imply that, like other forms of peripheral tolerance, oral tolerance 
requires the continued presence of antigen to be maintained [263]. The ability of a fed 
antigen to withstand degradation will probably depend on the initial dose administered, such 
that high antigen doses may persist for longer than lower doses. Although it may be 
impossible to confirm this issue directly due to difficulties in locating and quantifying the 
amount of antigen remaining in vivo at different times after feeding, it would be important to 
determine if oral tolerance required the continued presence of antigen, perhaps by "parking" 
T cells from an orally tolerised mouse for different times in a naive recipient before assessing 
antigen-specific immune responsiveness.
I also found that individual effector responses recovered at different times after 
feeding. This was particularly apparent in comparisons of cellular and humoral immunity, 
where DTH responses remained inhibited for at least 9 months, whereas serum IgG 
antibodies recovered to control levels after only 3 months. This is consistent with previous 
reports [120] and supports my earlier findings that individual immune responses differ in 
their sensitivity to be modulated by different doses of fed antigen. As in my dose response 
study, individual responses recovered from tolerance without a clear pattern. Contrary to 
expectation, the recovery in production of IFNy did not correlate with that of DTH or serum
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IgG2a responses. The reasons for this are unclear, but are consistent with my own previous 
findings that DTH and IFNy responses are not always related. However, since IFNy is 
important for a switch to IgG2a production [338], my finding that only low levels of IgG2a 
antibodies were produced in mice primed for IFNy production in vitro is confusing. If 
confirmed, these findings could mean that IFNy production in vitro does not correlate with 
that in vivo. Alternatively, the cytokine may be produced in vivo but fails to reach the 
environment of the germinal centres, where immunoglobulin class switching occurs. This 
might be predicted if orally tolerised T cells behaved in a manner similar to peripherally 
tolerised T cells, which are unable to enter germinal centres [362]. It would be interesting to 
investigate this by direct examination of IFNy production in vivo, using in situ hybridisation 
techniques.
Some evidence was obtained that the maintenance of the tolerant state was 
accompanied by upregulation of IFNy production. This occurred 6 months after feeding, 
but only in mice receiving 25mg OVA. Oral tolerance could no longer be detected in mice 
fed 2mg OVA at this time. As I had shown previously that IFNy production is particularly 
sensitive to oral tolerance and can even be reduced by low antigen doses, the enhanced 
release of this cytokine in the presence of tolerance of other responses, was surprising and 
and could imply a late role for IFNy-mediated active regulation. This requires confirmation 
by examining the longevity of oral tolerance in IFNyR/_ mice. As IFNy is known to mediate 
Th2 cell crossregulation [319], the absence of upregulated IFNy production might explain 
why tolerance waned quickly in mice fed 2mg OVA, with an associated skewing towards 
Th2-dependent functions, including OVA-specific ELIO and EL5 production.
In summary, my results highlight the long-lasting effects of oral tolerance and show 
that this affects individual immune functions differently and in a dose-dependent manner. 
Moreover, they suggest that different mechanisms may come into play at different times 
during the expression of unresponsiveness, highlighting that oral tolerance is a dynamic 
phenomenon, even after a single dose of fed antigen.
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Mechanisitic Review of Oral Tolerance
The oral administration of soluble protein antigen normally results in a profound 
immunological tolerance. Contrary to popular belief, I found that, in my hands, this did not 
involve active regulatory mechanisms and was probably mediated by clonal inactivation 
mechanisms such as anergy or deletion. As anergy results from TcR engagement in the 
absence of costimulation [254, 255, 257], my findings support the view that oral tolerance 
occurs because fed protein associates with "non-professional" APC, which are capable of 
processing and presenting antigen in the context of class II MHC molecules but cannot 
provide the costimulation necessary for complete T cell activation [375]. Consistent with 
this possibility is the finding that oral tolerance can be circumvented if the fed protein is 
administered along with inflammatory adjuvants, such as cholera toxin [376], muramyl 
dipeptide [166] or ISCOMS [377], which are likely to upregulate costimulatory molecules 
[378]. However, a number of important questions about the role of antigen processing and 
presentation remain, including the location of antigen presentation, the cells responsible and 
whether tolerance is induced locally in the gut or systemically. A role for entirely local 
presentation in oral tolerance is supported by the findings that lamina propria APC can 
present antigen in a manner that results in T cell unresponsiveness [35]. In order for 
intestinal APC to mediate the induction of systemic tolerance, these cells, which are as yet 
unidentified, would probably have to migrate from the intestine to peripheral tissues, since 
the only alternative would be that all antigen-specific T cells would have to pass through the 
gut to be tolerised and this is incompatible with the current understanding of lymphocyte 
recirculation [379]. Although gut-associated dendritic cells isolated from the thoracic duct of 
rats fed OVA carry immunologically relevant antigen [171, 172], these cells are thought of 
as professional APC and indeed were found to prime T cells when transferred into naive 
recipients [172]. However, the possibility remains that the dendritic cells were activated 
during the isolation procedure and might have been contributing to the induction of oral 
tolerance in vivo. Alternatively, fed antigen might associate with other APC, such as resting 
B cells, unactivated macrophages or epithelial cells, either locally or peripherally, to be 
presented to T cells in the absence of costimulation thereby inducing anergy.
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A further property of adjuvants is their ability to promote slow and persistent release 
of antigen [380] and recent studies show that rapid access to APC may prevent sustained 
presentation of peptide-class IIMHC complexes [381], which normally have a half-life of 6 
hours in vivo [382]. That transient T cell stimulation might induce functional 
unresponsiveness is consistent with the fact that anergy results when T cells receive TCR 
signals but do not proliferate extensively [383]. Thus oral tolerance could reflect the fact that 
fed antigen gains access to the systemic circulation very rapidly [138] and this is supported 
by previous studies correlating oral tolerance with the clearance of antigen from the 
circulation [384].
A critical role for anergy as a mechanism of oral tolerance would be consistent with a 
number of my in vitro findings, including the ability of antigen to rescue tolerised cells from 
apoptosis and to induce the partial persistence of some cytokines, but not IL2. Furthermore, 
the differential effects of different feeding doses on Thl and Th2 cell functions may reflect 
the fact that Th2 cells may be more resistant to anergy than Thl cells [254].
The dose-dependent effects of oral tolerance could also reflect differences in the 
extent of TcR ligation. Recent studies of T cell activation show that the ability of different 
doses of systemic antigen to prime Thl/Th2 cells correlates wtih the affinity of the resulting 
TcR-MHC-antigen interaction [173, 174]. This is believed to act by stimulating different 
levels of cytokine gene transcription, with high antigen doses resulting in high affinity 
interactions which induce Thl cell priming, whereas low doses were presented with a lower 
affinity which was optimal for priming Th2 cells. Thus, I would suggest that low doses of 
fed antigen may result in low ligand density antigen presentation in the absence of 
costimulation. This might be anticipated to favour Th2 cell activation and/or anergy. At the 
other end of the spectrum, high doses of fed antigen may swamp the immune system to be 
presented by many different types of APC at a high ligand density. If all T cells were of 
high affinity, this might lead to clonal exhaustion due to the synchronous activation of all 
specific T cells, as has been shown in TcR transgenic systems [229]. However, in normal 
mice, the TcR heterogeneity would result in both high and low affinity interactions 
producing a mixture of deletion and anergy. This would be consistent with my finding that
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oral tolerance induced by high doses was only partly reversed by IL2 treatment, whereas 
low doses completely reversed T cell unresponsiveness.
The capacity of very low antigen doses to induce oral priming rather than tolerance 
might reflect the limited availability of antigen, which would be presented in a more selective 
manner. This might favour antigen uptake by antigen-specific B cells which are the most 
potent APC at capturing antigen by virtue of their surface Igs [385] and can induce priming 
of naive T cells [386]. In addition, T cells with the highest affinity TcR would outcompete 
with others to interact with the peptide-class IIMHC complexes. During these high affinity 
interactions, it would be anticipated that Thl responses might be preferentially augmented 
[173, 174] and this is consistent with my own findings.
Overall, my hypothesis above provides a theoretical basis to explore factors such as 
APC type, ligand density and TcR-MHC-peptide affinity in oral tolerance induced by 
different antigen doses. This might be achieved by using combinations of mice deficient in 
particular APC populations and transgenic for T cells with different TcR affinities for 
antigen.
Oral Tolerance as a Therapeutic Strategy
The results I have presented in this thesis have a number of implications for the 
potential role of oral tolerance as a therapy for immunopathological disorders. As noted 
earlier, an effective therapy of this type should possess at least 3 important properties: it 
must be able to effectively inhibit all aspects of the immune response which would normally 
be involved in a particular disorder; it should be able to target these pathological immune 
functions without influencing other protective responses generated against unrelated 
antigens; and it must be able to mediate its effects for long enough to provide long-term 
therapy. Although, my results show that the regulatory factors governing oral tolerance can 
be manipulated to fulfill these factors, they also highlight a number of possible problems.
A highly beneficial characteristic of oral tolerance is that it can modulate a wide 
range of CD4-dependent effector functions in a dose-dependent manner. My results showed 
that different doses of fed antigen allowed Thl cell activity to be suppressed alone or in
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conjunction with Th2-dependent immune functions. In this way, both Thl-dependent 
autoimmunity and Th2-dependent allergic reactions might be treated by oral tolerance 
induction. However, the main feature of my results was the variability of individual effector 
functions, implying that it will be difficult to find a single regime with readily predictable 
effects for a range of different antigens.
The evidence that T cell anergy was induced by single doses of fed antigen would 
predict that oral tolerance should be antigen-specific and therefore superior to the other forms 
of immunosuppression currently used in immunopathological disorders. However, 
tolerance due to anergy carries the risk that the residual lymphocytes could be reactivated in 
the presence of inflammation, which would provide an environment rich in IL2 and other 
costimulatory cytokines. This potential complication would not arise if oral tolerance was 
mediated by active suppression, where further exposure to antigen would reactivate the 
regulatory T cells to maintain tolerance.
Another theoretical concern over anergy induction in therapeutic strategies for 
autoimmunity would be the potential hazard that thymic emigrants would not be tolerised 
unless the antigen was administered repeatedly. Thus, autoreactive T cells would 
accumulate and the autoimmune disorder might recur in susceptible individuals. However, 
my findings indicate that this problem need not arise, since oral tolerance could be 
demonstrated for the entire life-span of mice fed a high antigen dose. The persistence of 
unresponsiveness appeared to be associated with a switch to upregulation of IFNy 
production, which might have prevented the activation of naive OVA-specific T cells via its 
cytostatic properties [293, 319]. Regulation by IFNy might even have allowed bystander 
suppression to develop in oral tolerance induced by a single high dose feed, but this feature 
was not investigated.
In summary, my results have highlighted that oral tolerance has several advantages 
over the existing forms of immunosuppressive therapy. It induces a long-lasting effect 
without toxicity and can inhibit a wide range of systemic immune responses in an antigen- 
specific manner, allowing protective responses against unrelated antigens to be generated if 
and when required. The unresponsiveness induced by feeding can be manipulated, by
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altering the dose of antigen, to target particular aspects of the immune response and 
therefore, oral tolerance may form the basis of future therapies designed for the treatment of 
a variety of immunopathological disorders. However, it is important to point out the need to 
examine individual functions for each dose of each antigen, as very low doses may induce 
priming rather than tolerance and therefore exacerbate immunopathology. In addition, the 
results from this study were of naive T cell tolerance and previous findings in primed 
animals suggest that oral tolerance is more difficult to induce in the presence of antigen- 
experienced T cells [177]. This is consistent with other models of peripheral tolerance [175] 
and, as the principal application of oral tolerance would be for the treatment of patients with 
ongoing immunological disorders, my findings now need to be extended to tolerance of 
primed animals.
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